var title_f41_11_42160="Extensive pulmonary TB";
var content_f41_11_42160=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F77006&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F77006&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Extensive pulmonary tuberculosis in a pre-adolescent child",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 372px; height: 396px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Extensive pulmonary tuberculosis in a pre-adolescent child. There is advanced disease in the left lung, with disease in the righ lung occurring, perhaps, via lymphatic spread.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Jeffrey R Starke, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_11_42160=[""].join("\n");
var outline_f41_11_42160=null;
var title_f41_11_42161="Chronic fatigue syndrome";
var content_f41_11_42161=[" <h1 id=\"patTopicTitle\">",
"  Patient information: Chronic fatigue syndrome (Beyond the Basics)",
" </h1>",
" <div id=\"patTopicContributors\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <table>",
"    <tr>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"mobipreview.htm?41/11/42161/contributors\">",
"       Author",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/11/42161/contributors\" id=\"au4374\">",
"       Stephen J Gluckman, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"mobipreview.htm?41/11/42161/contributors\">",
"       Section Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/11/42161/contributors\" id=\"se6247\">",
"       Peter F Weller, MD, FACP",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"mobipreview.htm?41/11/42161/contributors\">",
"       Deputy Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/11/42161/contributors\" id=\"de1919\">",
"       Anna R Thorner, MD",
"      </a>",
"     </td>",
"    </tr>",
"   </table>",
"  </div>",
"  <div class=\"rcBottom\">",
"   <div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"patTopicTool\" id=\"patTopicToolTop\">",
"  <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"   Find",
"  </a>",
"  <a class=\"toolbutton printicon\" href=\"mobipreview.htm?41/11/42161?view=print\" title=\"Print This Topic\">",
"   Print",
"  </a>",
"  <script src=\"file://w.sharethis.com/button/sharethis.js#publisher=357881b8-c7e3-4c31-b7d2-242aeb1528e1&amp;type=website&amp;post_services=care2%2Cfacebook%2Ctwitter%2Cmyspace%2Cdigg%2Cdelicious%2Cfaves%2Creddit%2Cxanga%2Cstumbleupon%2Cblinklist%2Csimpy%2Cyigg%2Ctechnorati%2Cmeneame%2Corkut%2Cmixx%2Cfunp%2Cfresqui%2Cmister_wong%2Cfriendster%2Cfriendfeed%2Clinkedin%2Coknotizie%2Cgoogle_bmarks%2Cyahoo_bmarks%2Cfark%2Cnewsvine%2Clivejournal%2Ctypepad%2Cbus_exchange%2Cpropeller%2Cwordpress%2Cblogger%2Cblogmarks%2Cwindows_live%2Cfurl%2Cybuzz%2Cdiigo\" type=\"text/javascript\">",
"  </script>",
" </div>",
" <div id=\"patTopicMiddle\">",
"  <div id=\"topicContent\">",
"   <div id=\"topicText\">",
"    <p class=\"headingAnchor\" id=\"H1\">",
"     <span class=\"h1\">",
"      OVERVIEW",
"     </span>",
"    </p>",
"    <p>",
"     Chronic fatigue syndrome (CFS) is a disorder that causes unexplained, persistent, and sometimes debilitating fatigue.",
"    </p>",
"    <p>",
"     Living with chronic fatigue syndrome can be frustrating because most people, including healthcare providers, have a limited understanding of why or how CFS develops. In addition, there are limited treatment options. Although CFS is not likely to shorten your life, it can have a profound effect on your quality of life.",
"    </p>",
"    <p>",
"     More detailed information about chronic fatigue syndrome is available by subscription. (See",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/6/30825?source=see_link\">",
"      \"Clinical features and diagnosis of chronic fatigue syndrome\"",
"     </a>",
"     and",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/21/4440?source=see_link\">",
"      \"Treatment of chronic fatigue syndrome\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H2\">",
"     <span class=\"h1\">",
"      SYMPTOMS",
"     </span>",
"    </p>",
"    <p>",
"     Persistent fatigue is the hallmark of chronic fatigue syndrome.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Typically, the fatigue develops suddenly, often following an infection such as upper respiratory infection or mononucleosis. (See",
"       <a class=\"medical medical_patient\" href=\"mobipreview.htm?0/11/176?source=see_link\">",
"        \"Patient information: Infectious mononucleosis (mono) in adults and adolescents (Beyond the Basics)\"",
"       </a>",
"       .)",
"      </li>",
"      <li>",
"       After the initial illness gets better, you are left with overwhelming fatigue and a number of additional symptoms.",
"      </li>",
"      <li>",
"       Physical activity makes the symptoms worse.",
"      </li>",
"      <li>",
"       Typically, people who develop CFS were functioning at a high level previously. You do not have a history of worrying excessively about being ill. You do not have multiple physical complaints, such as chronic back ache, chronic headache, and so on.",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     Many, if not most, people with CFS have physical symptoms for which no cause can be found with an examination",
"     <span class=\"nowrap\">",
"      and/or",
"     </span>",
"     testing. In addition to the fatigue, you may have one or more of the following:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Sore throat",
"      </li>",
"      <li>",
"       Memory and concentration problems",
"      </li>",
"      <li>",
"       Generalized pain",
"      </li>",
"      <li>",
"       Headaches",
"      </li>",
"      <li>",
"       Difficulty sleeping",
"      </li>",
"      <li>",
"       Tender lymph nodes (glands) in the neck",
"       <span class=\"nowrap\">",
"        and/or",
"       </span>",
"       armpits",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     The bodywide nature of symptoms and lack of an identifiable cause can make coping with this disease difficult. People may suspect that you are making up the symptoms, and you may wonder if there is really anything wrong with you. Consequently, feelings of anger, frustration, and depression are common with CFS.",
"    </p>",
"    <p>",
"     The signs and symptoms of CFS can also occur with other medical conditions. Thus, it is essential to see a healthcare provider and have other potential causes ruled out. However, CFS can also occur at the same time as other illnesses.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H3\">",
"     <span class=\"h1\">",
"      POSSIBLE CAUSES",
"     </span>",
"    </p>",
"    <p>",
"     The cause of CFS is not known. Past explanations for CFS have included chronic Epstein Barr virus infection, Lyme disease, total allergy syndrome, multiple chemical sensitivity syndrome, bodywide yeast infection, and viruses called xenotropic murine leukemia virus-related virus (XMRV) and murine leukemia virus. However, in carefully done research studies, none of these conditions has been proven to cause CFS. (See",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/6/30825?source=see_link\">",
"      \"Clinical features and diagnosis of chronic fatigue syndrome\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     Several other potential causes of CFS are being studied. There is some evidence suggesting that CFS is an immune disorder, causing the body's defense system to function abnormally. This does not mean that the immune system is weakened, however.",
"    </p>",
"    <p>",
"     Another line of research has focused on chronic hypotension (low blood pressure) caused by a problem in the nervous system.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H4\">",
"     <span class=\"h1\">",
"      RISK FACTORS",
"     </span>",
"    </p>",
"    <p>",
"     There are some groups of people who seem to be at higher risk for developing chronic fatigue syndrome.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       CFS is diagnosed more often in young and middle-aged adults than in children or older adults.",
"      </li>",
"      <li>",
"       CFS is diagnosed about twice as often in women as in men, and is also more likely to be diagnosed in white (non-Hispanic) people compared with other ethnic groups.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H5\">",
"     <span class=\"h1\">",
"      DIAGNOSIS",
"     </span>",
"    </p>",
"    <p>",
"     Chronic fatigue syndrome is usually diagnosed based upon a medical history and physical examination. Blood or urine testing may be done to rule out other conditions, but are not needed to diagnose CFS.",
"    </p>",
"    <p>",
"     In order to be diagnosed with CFS, you must have unexplained, persistent, or relapsing fatigue, plus a number of the additional problems listed above. (See",
"     <a class=\"local\" href=\"#H2\">",
"      'Symptoms'",
"     </a>",
"     above.)",
"    </p>",
"    <p>",
"     If you have unexplained chronic fatigue but few, if any, of these additional symptoms, you may have unexplained chronic fatigue. This is considered to be a different problem and is managed differently than CFS.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H6\">",
"     <span class=\"h1\">",
"      TREATMENT",
"     </span>",
"    </p>",
"    <p>",
"     There is no cure for chronic fatigue syndrome; the goal of treatment is to reduce symptoms of fatigue and help you to cope. Many therapies have been tried in CFS but none has been consistently successful. Cognitive behavioral therapy and graded exercise appear to be the most effective treatments. (See",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/21/4440?source=see_link\">",
"      \"Treatment of chronic fatigue syndrome\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H7\">",
"     <span class=\"h2\">",
"      Cognitive behavioral therapy",
"     </span>",
"     &nbsp;&mdash;&nbsp;Cognitive behavioral therapy (CBT) is a type of therapy that can help to reduce symptoms of chronic fatigue syndrome. It typically involves a series of one-hour sessions with a psychotherapist or counselor. The sessions focus on discussing beliefs and behaviors that can interfere with your recovery. CBT will not cure CFS, but it can help you to cope better with your fatigue.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H8\">",
"     <span class=\"h2\">",
"      Graded exercise",
"     </span>",
"     &nbsp;&mdash;&nbsp;Although exercise can sometimes make chronic fatigue syndrome symptoms worse, a prolonged lack of exercise can also worsen CFS. Experts recommend beginning with gentle exercises and slowly increasing the intensity. Working with a professional trainer who is familiar with CFS may be of benefit.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H9\">",
"     <span class=\"h2\">",
"      Antibiotics",
"     </span>",
"     &nbsp;&mdash;&nbsp;You or your clinician may be tempted to try a course of antibiotics, especially if you happen to have a positive blood test for Lyme disease. A positive Lyme test, however, merely indicates that you have been exposed to the bacteria that causes Lyme disease. It does not mean that your symptoms are related to Lyme disease. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?31/17/32022?source=see_link\">",
"      \"Patient information: Lyme disease symptoms and diagnosis (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     There is no role for antibiotics in the treatment of CFS, and there is the potential for serious side effects from prolonged use of antibiotics.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H10\">",
"     <span class=\"h2\">",
"      Treatment for fibromyalgia",
"     </span>",
"     &nbsp;&mdash;&nbsp;Fibromyalgia is a condition that causes muscle and joint pain without an identifiable cause. Given the similarity between chronic fatigue syndrome and fibromyalgia, many physicians believe that they are the same disease with different primary symptoms. Some clinicians treat both illnesses, beginning with education and one or more medications. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?24/17/24854?source=see_link\">",
"      \"Patient information: Fibromyalgia (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H11\">",
"     <span class=\"h2\">",
"      Unproven treatments",
"     </span>",
"     &nbsp;&mdash;&nbsp;Treatments that are",
"     <strong>",
"      not",
"     </strong>",
"     proven to improve symptoms of chronic fatigue syndrome include the following:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Medications &mdash; This includes antidepressant medications, antibiotics, and antiviral drugs, including doxycycline, amantadine, and acyclovir, medications that affect the immune system, glucocorticoids (also called steroids), and cimetidine or ranitidine (antihistamines used to treat heartburn)",
"      </li>",
"      <li>",
"       Vitamin, mineral, or herbal supplements &mdash; These include magnesium, evening primrose oil, vitamin B12, and bovine (cow) or porcine (pig) liver extract",
"      </li>",
"      <li>",
"       Exclusion diets, in which certain foods are eliminated or minimized",
"      </li>",
"      <li>",
"       Removal of dental fillings",
"      </li>",
"      <li>",
"       Medications used to treat human immunodeficiency virus",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H12\">",
"     <span class=\"h1\">",
"      LIVING WITH CHRONIC FATIGUE SYNDROME",
"     </span>",
"    </p>",
"    <p>",
"     Although no specific treatment for CFS has been established, it is important to understand that CFS is not a new disease, and that there is considerable knowledge and experience with CFS. Some points to remember include:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       The severity of CFS is variable, but the symptoms are real and the condition can be completely incapacitating. The symptoms are not made up. Because there are no laboratory or other tests to prove the existence of CFS, many people struggle with the validity of their disease (as do their healthcare providers, family members, friends, and employers).",
"      </li>",
"      <li>",
"       There is no point to debating whether symptoms of CFS originate in your mind or are the result of a not-yet identified abnormality. If the cause is in your mind, the symptoms are no less real (a difficult concept for some patients",
"       <span class=\"nowrap\">",
"        and/or",
"       </span>",
"       their families). If the cause is an abnormality in your body, it is not yet known how to find it or treat it.",
"      </li>",
"      <li>",
"       Most people with CFS have some degree of depression. Depression can be successfully treated, and treatment can help people with CFS to cope better. (See",
"       <a class=\"medical medical_patient\" href=\"mobipreview.htm?21/24/21894?source=see_link\">",
"        \"Patient information: Depression treatment options for adults (Beyond the Basics)\"",
"       </a>",
"       .)",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     Research into the long-term course of CFS has yielded somewhat conflicting results. Some patients have an improvement in their symptoms over time while others worsen. Regardless of the long term prognosis, CFS does not result in organ failure or death.",
"    </p>",
"    <p>",
"     The most important factor in your ability to successfully cope with CFS is establishing a strong relationship with an experienced healthcare provider. This should include trust on both sides and a willingness to believe that CFS is both real and disabling.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H13\">",
"     <span class=\"h1\">",
"      WHERE TO GET MORE INFORMATION",
"     </span>",
"    </p>",
"    <p>",
"     Your healthcare provider is the best source of information for questions and concerns related to your medical problem.",
"    </p>",
"    <p>",
"     This article will be updated as needed on our web site (",
"     <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"      www.uptodate.com/patients",
"     </a>",
"     ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H3498570619\">",
"     <span class=\"h2\">",
"      Patient level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H5511622\">",
"     <span class=\"h3\">",
"      The Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?42/20/43329?source=see_link\">",
"      Patient information: Fibromyalgia (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?4/47/4850?source=see_link\">",
"      Patient information: Chronic fatigue syndrome (The Basics)",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H5511648\">",
"     <span class=\"h3\">",
"      Beyond the Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?0/11/176?source=see_link\">",
"      Patient information: Infectious mononucleosis (mono) in adults and adolescents (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?31/17/32022?source=see_link\">",
"      Patient information: Lyme disease symptoms and diagnosis (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?24/17/24854?source=see_link\">",
"      Patient information: Fibromyalgia (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?21/24/21894?source=see_link\">",
"      Patient information: Depression treatment options for adults (Beyond the Basics)",
"     </a>",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H14\">",
"     <span class=\"h2\">",
"      Professional level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/36/23111?source=see_link\">",
"      Approach to the adult patient with fatigue",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/6/30825?source=see_link\">",
"      Clinical features and diagnosis of chronic fatigue syndrome",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/30/29159?source=see_link\">",
"      Postural tachycardia syndrome",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/21/4440?source=see_link\">",
"      Treatment of chronic fatigue syndrome",
"     </a>",
"     <br/>",
"     <br/>",
"     The following organizations also provide reliable health information.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Library of Medicine",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.nlm.nih.gov/medlineplus/chronicfatiguesyndrome.html\">",
"      www.nlm.nih.gov/medlineplus/chronicfatiguesyndrome.html",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Centers for Disease Control and Prevention",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;404-639-1388 or 1-888-232-3228",
"     <br/>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.cdc.gov/cfs\">",
"      www.cdc.gov/cfs",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National CFS and Fibromyalgia Association",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; Telephone: 816-737-1343",
"     <br/>",
"     &nbsp; &nbsp; (",
"     <a class=\"external\" href=\"file://www.ncfsfa.org/\">",
"      www.ncfsfa.org",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Chronic Fatigue and Immune Dysfunction Syndrome Association of America",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.cfids.org/\">",
"      www.cfids.org",
"     </a>",
"     )",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H15\">",
"     <span class=\"h2\">",
"      Patient Support",
"     </span>",
"     &nbsp;&mdash;&nbsp;There are a number of online forums where patients can find information and support from other people with similar conditions.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       <a class=\"external\" href=\"file://about.com/\">",
"        About.com",
"       </a>",
"       Fibromyalgia and Chronic Fatigue Syndrome Forum",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://chronicfatigue.about.com/forum\">",
"      file://chronicfatigue.about.com/forum",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     [",
"     <a class=\"abstract\" href=\"mobipreview.htm?41/11/42161/abstract/1-4\">",
"      1-4",
"     </a>",
"     ]",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 22, 2012.",
"  </div>",
"  <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"   <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"    Find",
"   </a>",
"   <a class=\"toolbutton printicon\" href=\"mobipreview.htm?41/11/42161?view=print\" title=\"Print This Topic\">",
"    Print",
"   </a>",
"  </div>",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <div id=\"patTopicRefHeader\">",
"    <div id=\"patTopicRefHeaderHeader\">",
"     References",
"    </div>",
"    <div id=\"patTopicRefHeaderTop\">",
"     <a href=\"#top\">",
"      <img alt=\"\" src=\"./../images/top_arrow.myextg\">",
"       Top",
"      </img>",
"     </a>",
"    </div>",
"   </div>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42161/abstract/1\">",
"      Whiting P, Bagnall AM, Sowden AJ, et al. Interventions for the treatment and management of chronic fatigue syndrome: a systematic review. JAMA 2001; 286:1360.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42161/abstract/2\">",
"      Straus SE. Pharmacotherapy of chronic fatigue syndrome: another gallant attempt. JAMA 2004; 292:1234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42161/abstract/3\">",
"      Prins JB, van der Meer JW, Bleijenberg G. Chronic fatigue syndrome. Lancet 2006; 367:346.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42161/abstract/4\">",
"      Wessely S. Chronic fatigue: symptom and syndrome. Ann Intern Med 2001; 134:838.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
" </div>",
" <!-- patTopicMiddle -->",
"</div>"].join("\n");
var script_f41_11_42161=[""].join("\n");
var outline_f41_11_42161=[" <div class=\"patTopicFancyTop\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <p>",
"    Contents of this article",
"   </p>",
"  </div>",
" </div>",
" <div class=\"patTopicFancySpacer\">",
" </div>",
" <div class=\"patTopicOutline\">",
"  <div class=\"rcbBottom\">",
"   <div class=\"rcbLeft\">",
"    <div class=\"rcbRight\">",
"     <div class=\"rcbBottomLeft\">",
"      <div class=\"rcbBottomRight rcbBottomRightBottomOnly\">",
"       <div id=\"outline\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          <a href=\"#H1\">",
"           OVERVIEW",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H2\">",
"           SYMPTOMS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H3\">",
"           POSSIBLE CAUSES",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H4\">",
"           RISK FACTORS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H5\">",
"           DIAGNOSIS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H6\">",
"           TREATMENT",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H12\">",
"           LIVING WITH CHRONIC FATIGUE SYNDROME",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H13\">",
"           WHERE TO GET MORE INFORMATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#references\">",
"           REFERENCES",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"  </div>",
" </div>"].join("\n");
var title_f41_11_42162="Concentric hamstring strength testing";
var content_f41_11_42162=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F74953&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F74953&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 568px\">",
"   <div class=\"ttl\">",
"    Concentric hamstring strength testing",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 548px; height: 264px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Both concentric and eccentric strength should be part of the hamstring examination. Concentric strength testing begins with the knee bent at 90 degrees.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Karl Fields, MD; Spencer Copland, MD; and John Tipton, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_11_42162=[""].join("\n");
var outline_f41_11_42162=null;
var title_f41_11_42163="ANLL FAB M1";
var content_f41_11_42163=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F59431&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F59431&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Acute myeloid leukemia (AML FAB M1)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 364px; height: 252px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Bone marrow aspirate smear from a patient with AML of the M! type. The blasts are large, with a moderate amount of grayish blue cytoplasm, distinct nucleoli, and no cytoplasmic granules. (Wright-Giemsa).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of David S Rosenthal, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_11_42163=[""].join("\n");
var outline_f41_11_42163=null;
var title_f41_11_42164="Femoral nerve anatomy";
var content_f41_11_42164=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F66562&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F66562&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 504px\">",
"   <div class=\"ttl\">",
"    Femoral nerve anatomy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 484px; height: 655px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The femoral nerve (L2-L4) emerges at the lower border between the psoas and iliacus muscles, and passes beneath the inguinal ligament. The femoral nerve provides motor branches to thigh extensors, sensation to the anterior thigh, femur, knee joint, and medial leg. The saphenous nerve is the extension of the femoral nerve below the knee and is purely sensory.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_11_42164=[""].join("\n");
var outline_f41_11_42164=null;
var title_f41_11_42165="HeartMate XVE";
var content_f41_11_42165=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F86141&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F86141&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 530px\">",
"   <div class=\"ttl\">",
"    The HeartMate XVE pulsatile left ventricular assist device",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 510px; height: 572px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reprinted with the permission of Thoratec Corporation.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_11_42165=[""].join("\n");
var outline_f41_11_42165=null;
var title_f41_11_42166="Appendectomy open";
var content_f41_11_42166=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F53185&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F53185&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 555px\">",
"   <div class=\"ttl\">",
"    Open appendectomy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 535px; height: 716px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_11_42166=[""].join("\n");
var outline_f41_11_42166=null;
var title_f41_11_42167="Primidone: Pediatric drug information";
var content_f41_11_42167=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Primidone: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"mobipreview.htm?30/14/30952?source=see_link\">",
"    see \"Primidone: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?15/5/15445?source=see_link\">",
"    see \"Primidone: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F213318\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Mysoline&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F213319\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Primidone&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1055084\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Anticonvulsant, Barbiturate",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Barbiturate",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block don drugH1Div\" id=\"F11444852\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Neonatal",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral: Seizure disorder: 12-20 mg/kg/day in 2-4 divided doses; start with lower dosage and titrate upward",
"    </p>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1055078\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?30/14/30952?source=see_link\">",
"      see \"Primidone: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral: Seizure disorder:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children &lt;8 years: Initial: 50-125 mg/day given at bedtime; increase by 50-125 mg/day increments every 3-7 days; usual dose: 10-25 mg/kg/day in 3-4 divided doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children &ge;8 years and Adults: Initial: 125-250 mg/day at bedtime; increase by 125-250 mg/day every 3-7 days; usual dose: 750-1500 mg/day in 3-4 divided doses with maximum dosage of 2 g/day",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F213291\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: 50 mg, 250 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Mysoline&reg;: 50 mg, 250 mg [scored]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F213276\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F10523384\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product information and at",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/UCM222370.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/UCM222370.pdf",
"     </a>",
"     , must be dispensed with this medication.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1055089\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral: Administer with food to decrease GI upset",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1055088\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Management of generalized tonic-clonic (grand mal), complex partial and simple partial (focal) seizures",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F213368\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Primidone may be confused with predniSONE, primaquine, pyridoxine",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F213366\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Ataxia, drowsiness, emotional disturbances, fatigue, hyperirritability, suicidal ideation, vertigo",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Morbilliform skin eruptions",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Anorexia, nausea, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Impotence",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Agranulocytosis, granulocytopenia, megaloblastic anemia (idiosyncratic), red cell aplasia/hypoplasia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Diplopia, nystagmus",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1055092\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to primidone or any component; porphyria",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1055077\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients with renal or hepatic impairment. Abrupt discontinuation may precipitate status epilepticus",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1055076\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Antiepileptic drugs (AEDs) increase the risk of suicidal behavior and ideation in patients receiving these medications for any indication. Pooled analyses of placebo-controlled trials involving 11 different AEDs (regardless of indication) showed a twofold increased risk of suicidal thoughts or behavior (estimated incidence rate: 0.43% in AED treated patients compared to 0.24% of patients receiving placebo); increased risk was observed as early as 1 week after initiation of AED and continued through duration of trials (most trials &le;24 weeks); risk did not vary significantly by age (age range: 5&ndash;100 years). Consider risks and benefits of AEDs before prescribing. Monitor all patients receiving an AED for emergence of suicidal thoughts or behavior, thoughts of self-harm, any unusual changes in behavior or mood, or the emergence or worsening of depressive symptoms; notify healthcare provider immediately if symptoms or concerning behavior occur.",
"     <b>",
"      Note:",
"     </b>",
"     The FDA is requiring that a Medication Guide be developed for all antiepileptic drugs informing patients of this risk.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Generic tablet may contain sodium benzoate; benzoic acid (benzoate) is a metabolite of benzyl alcohol; large amounts of benzyl alcohol (&ge;99 mg/kg/day) have been associated with a potentially fatal toxicity (&ldquo;gasping syndrome&rdquo;) in neonates; the &ldquo;gasping syndrome&rdquo; consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension and cardiovascular collapse; avoid use of primidone products containing sodium benzoate in neonates;",
"     <i>",
"      in vitro",
"     </i>",
"     and animal studies have shown that benzoate displaces bilirubin from protein binding sites",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F213356\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Induces",
"     </b>",
"     CYP1A2 (strong), CYP2B6 (strong), CYP2C8 (strong), CYP2C9 (strong), CYP3A4 (strong)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F213285\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Apixaban: CYP3A4 Inducers (Strong) may decrease the serum concentration of Apixaban.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inducers may decrease the serum concentration of ARIPiprazole.  Management: Double the oral aripiprazole dose and closely monitor clinical response.  Reduce the oral aripiprazole dose to 10-15 mg/day if the inducer is discontinued. Avoid use of CYP3A4 inducers for more than 14 days with extended-release injectable aripiprazole.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Axitinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Axitinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Azelastine (Nasal): CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Barbiturates: Primidone may enhance the adverse/toxic effect of Barbiturates. Primidone is converted to phenobarbital, and thus becomes additive with existing barbiturate therapy.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bedaquiline: CYP3A4 Inducers (Strong) may decrease the serum concentration of Bedaquiline.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bendamustine: CYP1A2 Inducers (Strong) may decrease the serum concentration of Bendamustine. Concentrations of active metabolites may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Boceprevir: Primidone may decrease the serum concentration of Boceprevir.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bortezomib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Bortezomib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bosutinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Bosutinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Brentuximab Vedotin: CYP3A4 Inducers (Strong) may decrease the serum concentration of Brentuximab Vedotin. Specifically, concentrations of the active monomethyl auristatin E (MMAE) component may be decreased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Buprenorphine: CNS Depressants may enhance the CNS depressant effect of Buprenorphine.  Management: Consider reduced doses of CNS depressants used in combination with buprenorphine.  Consider avoiding other CNS depressants in patients thought to be at high risk of buprenorphine overuse or self-injection.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cabozantinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Cabozantinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Canagliflozin: Primidone may decrease the serum concentration of Canagliflozin.  Management: Consider increasing canagliflozin dose to 300 mg/day in patients with estimated GFR &gt;60 mL/min/1.73 m2 who tolerate canagliflozin 100 mg/day and require greater glycemic control. Consider alternatives in patients with estimated GFR 45-60 mL/min/1.73 m2.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Carbonic Anhydrase Inhibitors: May enhance the adverse/toxic effect of Anticonvulsants (Barbiturate). Specifically, osteomalacia and rickets.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Brinzolamide; Dorzolamide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Carbonic Anhydrase Inhibitors: May enhance the adverse/toxic effect of Primidone. Specifically, osteomalacia and rickets. Carbonic Anhydrase Inhibitors may decrease the serum concentration of Primidone.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Brinzolamide; Dorzolamide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Clarithromycin: CYP3A4 Inducers (Strong) may increase serum concentrations of the active metabolite(s) of Clarithromycin. Clarithromycin may increase the serum concentration of CYP3A4 Inducers (Strong). CYP3A4 Inducers (Strong) may decrease the serum concentration of Clarithromycin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Systemic): Primidone may decrease the serum concentration of Corticosteroids (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cosyntropin: May enhance the hepatotoxic effect of Primidone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Crizotinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Crizotinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP1A2 Substrates: CYP1A2 Inducers (Strong) may increase the metabolism of CYP1A2 Substrates.  Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2B6 Substrates: CYP2B6 Inducers (Strong) may increase the metabolism of CYP2B6 Substrates.  Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C8 Substrates: CYP2C8 Inducers (Strong) may increase the metabolism of CYP2C8 Substrates.  Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C9 Substrates: CYP2C9 Inducers (Strong) may increase the metabolism of CYP2C9 Substrates.  Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Substrates: CYP3A4 Inducers (Strong) may increase the metabolism of CYP3A4 Substrates.  Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Dasatinib.  Management: Avoid when possible. If such a combination cannot be avoided, consider increasing dasatinib dose and monitor clinical response and toxicity closely.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dexmethylphenidate: May increase serum concentrations of the active metabolite(s) of Primidone. Specifically, phenobarbital concentrations could become elevated. Dexmethylphenidate may increase the serum concentration of Primidone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Diclofenac (Systemic): CYP2C9 Inducers (Strong) may decrease the serum concentration of Diclofenac (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dienogest: CYP3A4 Inducers (Strong) may decrease the serum concentration of Dienogest.  Management: Avoid use of dienogest for contraception when using medications that induce CYP3A4 and for at least 28 days after discontinuation of a CYP3A4 inducer.  An alternative form of contraception should be used during this time.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Divalproex: May decrease the metabolism of Primidone. Primidone may decrease the serum concentration of Divalproex.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dronedarone: CYP3A4 Inducers (Strong) may decrease the serum concentration of Dronedarone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Droperidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (e.g., opioids, barbiturates) with concomitant use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Enzalutamide: CYP2C8 Inducers (Strong) may decrease the serum concentration of Enzalutamide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Enzalutamide: CYP3A4 Inducers (Strong) may decrease the serum concentration of Enzalutamide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Etravirine: Primidone may decrease the serum concentration of Etravirine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Everolimus: CYP3A4 Inducers (Strong) may decrease the serum concentration of Everolimus.  Management: Avoid concurrent use of strong CYP3A4 inducers, but if strong CYP3A4 inducers cannot be avoided, consider gradually (in 5 mg increments) increasing the everolimus dose from 10 mg/day to 20 mg/day (adult doses).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Exemestane: CYP3A4 Inducers (Strong) may decrease the serum concentration of Exemestane.  Management: Exemestane U.S. product labeling recommends using an increased dose (50 mg/day) in patients receiving concurrent strong CYP3A4 inducers. The Canadian product labeling does not recommend a dose adjustment  with concurrent use of strong CYP3A4 inducers.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Felbamate: May increase serum concentrations of the active metabolite(s) of Primidone. Specifically, phenobarbital concentrations may increase. Primidone may decrease the serum concentration of Felbamate. Management: In patients receiving primidone, initiate felbamate at 1200 mg/day in divided doses 3-4 times daily and reduce primidone dose by 20%. Monitor for increased phenobarbital concentrations/effects and decreased felbamate concentrations/effects.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Folic Acid: May decrease the serum concentration of Primidone. Additionally, folic acid may decrease concentrations of active metabolites of primidone (e.g., phenobarbital).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosphenytoin: May increase the metabolism of Primidone. The ratio of primidone:phenobarbital is thus changed.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Gefitinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Gefitinib.  Management: In the absence of severe adverse drug reactions, consider increasing gefitinib dose to 500 mg daily in patients receiving strong CYP3A4 inducers.  Carefully monitor clinical response and development of adverse reactions.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     GuanFACINE: CYP3A4 Inducers (Strong) may decrease the serum concentration of GuanFACINE.  Management: Consider increasing the guanfacine dose by 2-fold when adding a strong CYP3A4 inducer.  Titrate the guanfacine dose up to a max of 8 mg/day when starting guanfacine in a patient who is taking a strong CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ifosfamide: CYP3A4 Inducers (Strong) may increase serum concentrations of the active metabolite(s) of Ifosfamide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Imatinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Imatinib.  Management: Avoid concurrent use of imatinib with strong CYP3A4 inducers when possible.  If such a combination must be used, increase imatinib dose by at least 50% and monitor the patient's clinical response closely.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Itraconazole: CYP3A4 Inducers (Strong) may decrease the serum concentration of Itraconazole.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: CYP3A4 Inducers (Strong) may decrease the serum concentration of Ivacaftor.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ixabepilone: CYP3A4 Inducers (Strong) may decrease the serum concentration of Ixabepilone.  Management: Avoid this combination whenever possible.  If this combination must be used, a gradual increase in ixabepilone dose from 40 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     to 60 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     (given as a 4-hour infusion), as tolerated, should be considered.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ketorolac (Nasal): May diminish the therapeutic effect of Anticonvulsants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ketorolac (Systemic): May diminish the therapeutic effect of Anticonvulsants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     LamoTRIgine: Primidone may decrease the serum concentration of LamoTRIgine.  Management: Adjust dose per lamotrigine prescribing information guidelines during primidone treatment.  Monitor for decreased concentration/effect if primidone is initiated/dose increased or increased concentration/effect if primidone is discontinued/dose decreased.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lapatinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Lapatinib.  Management: If therapy overlap cannot be avoided, consider titrating lapatinib gradually from 1,250 mg/day up to 4,500 mg/day (HER2 positive metastatic breast cancer) or 1,500 mg/day up to 5,500 mg/day (hormone receptor/HER2 positive breast cancer) as tolerated.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Leucovorin Calcium-Levoleucovorin: May decrease the serum concentration of Primidone. Additionally, leucovorin/levoleucovorin may decrease concentrations of active metabolites of primidone (e.g., phenobarbital).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Levomefolate: May decrease serum concentrations of the active metabolite(s) of Primidone. Levomefolate may decrease the serum concentration of Primidone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Linagliptin: CYP3A4 Inducers (Strong) may decrease the serum concentration of Linagliptin.  Management: Strongly consider using an alternative to any strong CYP3A4 inducer in patients who are being treated with linagliptin. If this combination is used, monitor patients closely for evidence of reduced linagliptin effectiveness.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lurasidone: CYP3A4 Inducers (Strong) may decrease the serum concentration of Lurasidone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Maraviroc: CYP3A4 Inducers (Strong) may decrease the serum concentration of Maraviroc.  Management: Increase maraviroc adult dose to 600 mg twice daily when used with strong CYP3A4 inducers. This does not apply to patients also receiving strong CYP3A4 inhibitors. Do not use maraviroc with strong CYP3A4 inducers in patients with Clcr less than 30 mL/min.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mefloquine: May diminish the therapeutic effect of Anticonvulsants. Mefloquine may decrease the serum concentration of Anticonvulsants. Management: Mefloquine is contraindicated for malaria prophylaxis in persons with a history of convulsions.  Monitor anticonvulsant concentrations and treatment response closely with concurrent use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methotrimeprazine: CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants.  Management: Reduce adult dose of CNS depressant agents by 50% with initiation of concomitant methotrimeprazine therapy. Further CNS depressant dosage adjustments should be initiated only after clinically effective methotrimeprazine dose is established.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylfolate: May decrease the serum concentration of Primidone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylphenidate: May increase serum concentrations of the active metabolite(s) of Primidone. Specifically, phenobarbital concentrations could become elevated. Methylphenidate may increase the serum concentration of Primidone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metyrosine: CNS Depressants may enhance the sedative effect of Metyrosine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: CYP3A4 Inducers (Strong) may decrease the serum concentration of Mifepristone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mirtazapine: CNS Depressants may enhance the CNS depressant effect of Mirtazapine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     NIFEdipine: CYP3A4 Inducers (Strong) may decrease the serum concentration of NIFEdipine.  Management: Consider alternatives to nifedipine for patients who are using strong CYP3A4 inducers.  At least one specific brand of nifedipine (Adalat CC) lists this combination as contraindicated.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nilotinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Nilotinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nisoldipine: CYP3A4 Inducers (Strong) may decrease the serum concentration of Nisoldipine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pazopanib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Pazopanib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Perampanel: CYP3A4 Inducers (Strong) may decrease the serum concentration of Perampanel.  Management: Avoid use of perampanel with strong CYP3A inducers other than enzyme-inducing antiepileptic drugs (EIAEDs).  Increase perampanel starting dose to 4 mg/day when used with EIAEDs such as phenytoin, carbamazepine, or oxcarbazepine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Perampanel: May enhance the CNS depressant effect of CNS Depressants. Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they have experience using the combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phenytoin: May increase the metabolism of Primidone. The ratio of primidone:phenobarbital is thus changed.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pirfenidone: CYP1A2 Inducers (Strong) may decrease the serum concentration of Pirfenidone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pomalidomide: CYP1A2 Inducers (Strong) may decrease the serum concentration of Pomalidomide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pomalidomide: CYP3A4 Inducers (Strong) may decrease the serum concentration of Pomalidomide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ponatinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Ponatinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Praziquantel: CYP3A4 Inducers (Strong) may decrease the serum concentration of Praziquantel.  Management: Avoid concomitant use of praziquantel with strong CYP3A4 inducers. Discontinue rifampin 4 weeks prior to initiation of praziquantel therapy. Rifampin may be resumed the day following praziquantel completion.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QuiNIDine: Primidone may decrease the serum concentration of QuiNIDine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ranolazine: CYP3A4 Inducers (Strong) may decrease the serum concentration of Ranolazine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Regorafenib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Regorafenib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rilpivirine: Primidone may decrease the serum concentration of Rilpivirine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rivaroxaban: CYP3A4 Inducers (Strong) may decrease the serum concentration of Rivaroxaban.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Roflumilast: CYP3A4 Inducers (Strong) may decrease the serum concentration of Roflumilast.  Management: Roflumilast U.S. prescribing information recommends against combining strong CYP3A4 inducers with roflumilast.  The Canadian product monograph makes no such recommendation but notes that such agents may reduce roflumilast therapeutic effects.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     RomiDEPsin: CYP3A4 Inducers (Strong) may decrease the serum concentration of RomiDEPsin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rufinamide: Primidone may decrease the serum concentration of Rufinamide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Saxagliptin: CYP3A4 Inducers may decrease the serum concentration of Saxagliptin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: CNS Depressants may enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors. Specifically, the risk of psychomotor impairment may be enhanced.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Oxybate: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to combined use. When combined use is needed, consider minimizing doses of one or more drugs. Use of sodium oxybate with alcohol or sedative hypnotics is contraindicated.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     SORAfenib: CYP3A4 Inducers (Strong) may decrease the serum concentration of SORAfenib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     SUNItinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of SUNItinib.  Management: Avoid when possible. If such a combination cannot be avoided, consider increasing sunitinib dose and monitor clinical response and toxicity closely.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tadalafil: CYP3A4 Inducers (Strong) may decrease the serum concentration of Tadalafil.  Management: Erectile dysfunction: monitor for decreased effectiveness - no standard dose adjustments recommended.  Avoid use of tadalafil for pulmonary arterial hypertension in patients receiving a strong CYP3A4 inducer.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ticagrelor: CYP3A4 Inducers (Strong) may decrease serum concentrations of the active metabolite(s) of Ticagrelor. CYP3A4 Inducers (Strong) may decrease the serum concentration of Ticagrelor.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tofacitinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Tofacitinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tolvaptan: CYP3A4 Inducers (Strong) may decrease the serum concentration of Tolvaptan.  Management: If concurrent use is necessary, increased doses of tolvaptan (with close monitoring for toxicity and clinical response) may be needed.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Toremifene: CYP3A4 Inducers (Strong) may decrease the serum concentration of Toremifene.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Treprostinil: CYP2C8 Inducers (Strong) may decrease the serum concentration of Treprostinil.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ulipristal: CYP3A4 Inducers (Strong) may decrease the serum concentration of Ulipristal.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Valproic Acid: May decrease the metabolism of Primidone. More specifically, the metabolism of phenobarbital, primidone's primary active metabolite, would be decreased. Primidone may decrease the serum concentration of Valproic Acid.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vandetanib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Vandetanib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vemurafenib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Vemurafenib.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     VinCRIStine (Liposomal): CYP3A4 Inducers (Strong) may decrease the serum concentration of VinCRIStine (Liposomal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem dose to 1.75 mg for men who are also receiving other CNS depressants.  No such dose change is recommended for women.  Avoid use with other CNS depressants at bedtime; avoid use with alcohol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zuclopenthixol: CYP3A4 Inducers (Strong) may decrease the serum concentration of Zuclopenthixol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F1055094\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Food Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May increase the metabolism of vitamins D and K; dietary requirements of vitamins D, K, B",
"     <sub>",
"      12",
"     </sub>",
"     , folate, and calcium may be increased with long-term use",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F213301\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Primidone and its metabolites (PEMA, phenobarbital, and p-hydroxyphenobarbital) cross the placenta; neonatal serum concentrations at birth are similar to those in the mother. Withdrawal symptoms may occur in the neonate and may be delayed due to the long half-life of primidone and its metabolites. Use may be associated with birth defects and adverse events; the use of folic acid throughout pregnancy and vitamin K during the last month of pregnancy is recommended. Epilepsy itself, number of medications, genetic factors, or a combination of these probably influence the teratogenicity of anticonvulsant therapy.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Patients exposed to primidone during pregnancy are encouraged to enroll themselves into the NAAED Pregnancy Registry by calling 1-888-233-2334. Additional information is available at www.aedpregnancyregistry.org.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1055083\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Serum primidone and phenobarbital concentrations; CBC with differential; neurological status, seizure frequency, duration, severity; signs and symptoms of suicidality (eg, anxiety, depression, behavior changes)",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F1055087\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Monitor both primidone and phenobarbital concentrations.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Primidone:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Therapeutic: 5-12 mcg/mL (SI: 23-55 micromoles/L)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Toxic effects rarely present with levels &lt;10 mcg/mL (SI: 46 micromoles/L) if phenobarbital concentrations are low",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Toxic: &gt;15 mcg/mL (SI: &gt;69 micromoles/L)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phenobarbital:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Therapeutic: 15-40 mcg/mL (SI: 65-172 micromoles/L)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Potentially toxic: &gt;40 mcg/mL (SI: &gt;172 micromoles/L)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Coma: &gt;50 mcg/mL (SI: &gt;215 micromoles/L)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Potentially lethal: &gt;80 mcg/mL (SI: &gt;344 micromoles/L)",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1055075\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Decreases neuron excitability, raises seizure threshold similar to phenobarbital",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1055091\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : Adults: 2-3 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein-binding: 99%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: In the liver to phenobarbital (active) and phenylethylmalonamide (PEMA)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: 60% to 80%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Primidone: 10-12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     PEMA: 16 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Phenobarbital: 52-118 hours (age-dependent)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak serum concentration: Oral: Within 4 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: Urinary excretion of both active metabolites and unchanged primidone (15% to 25%)",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1055082\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?15/5/15445?source=see_link\">",
"      see \"Primidone: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Avoid alcohol; limit caffeine. May cause drowsiness and impair ability to perform activities requiring mental alertness or physical coordination. Do not abruptly discontinue (an increase in seizure activity may occur) or change dose without physician approval. Antiepileptic agents may increase the risk of suicidal thoughts and behavior; notify physician if you feel more depressed or have thoughts of suicide or self-harm. Report behavioral or CNS changes (increased sedation, lethargy); worsening of seizure activity or loss of seizure control.",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F1055093\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Mysoline&reg; suspension was discontinued in February 2001",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12727 Version 44.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-183.166.191.243-285D26EE14-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_11_42167=[""].join("\n");
var outline_f41_11_42167=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F213318\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F213319\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1055084\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11444852\">",
"      Dosing: Neonatal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1055078\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F213291\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F213276\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10523384\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1055089\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1055088\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F213368\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F213366\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1055092\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1055077\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1055076\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F213356\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F213285\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1055094\">",
"      Food Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F213301\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1055083\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1055087\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1055075\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1055091\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1055082\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1055093\">",
"      Additional Information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12727\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12727|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?30/14/30952?source=related_link\">",
"      Primidone: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?15/5/15445?source=related_link\">",
"      Primidone: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f41_11_42168="Selective IgM deficiency";
var content_f41_11_42168=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Selective IgM deficiency",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?41/11/42168/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/11/42168/contributors\">",
"     David S Chi, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/11/42168/contributors\">",
"     Guha Krishnaswamy, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?41/11/42168/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/11/42168/contributors\">",
"     E Richard Stiehm, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?41/11/42168/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/11/42168/contributors\">",
"     Anna M Feldweg, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?41/11/42168/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 18, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Selective deficiency of immunoglobulin M (SIgMD) is a rare immune disorder that has been reported in association with serious infections, such as bacteremia. The disorder can occur in infants, children, and adults. Cumulatively, there have been fewer than 300 cases reported in the literature, and understanding of this condition is therefore preliminary. This topic review discusses the normal immunophysiology of IgM, theories of pathogenesis, and the clinical features, diagnosis, and treatment of selective IgM deficiency. More general discussions of antibody deficiency are found separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/48/24326?source=see_link\">",
"     \"Primary humoral immune deficiencies: An overview\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6106648\">",
"    <span class=\"h1\">",
"     DEFINITION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Selective IgM deficiency (SIgMD) is characterized by the following clinical and laboratory features:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Isolated absence or deficiency of IgM",
"     </li>",
"     <li>",
"      Normal levels of other immunoglobulins (notably IgG and IgA)",
"     </li>",
"     <li>",
"      Recurrent infections from infancy onwards, associated with susceptibility to Staphylococcus aureus, encapsulated pathogens (Streptococcus pneumoniae, Hemophilus influenza), and viral infections",
"     </li>",
"     <li>",
"      The disorder may be associated with autoimmune or malignant conditions, but these are not prerequisites for the diagnosis",
"     </li>",
"     <li>",
"      Normal T cell numbers and function",
"     </li>",
"     <li>",
"      No other identifiable immunodeficiency",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     NORMAL IMMUNOPHYSIOLOGY OF IgM",
"    </span>",
"    &nbsp;&mdash;&nbsp;The five classes or isotypes of immunoglobulins (Ig) that contribute to humoral immunity are IgG, IgM, IgA, IgD, and IgE. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/9/7318?source=see_link\">",
"     \"Structure of immunoglobulins\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/53/40792?source=see_link\">",
"     \"Function and clinical applications of immunoglobulins\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Naive B lymphocytes express both IgM and IgD, and these are the only immunoglobulin isotypes produced by B lymphocytes prior to contact with antigen. Membrane bound monomeric IgM, complexed with additional proteins such as Ig&alpha; and Ig&beta;, constitute the B cell receptor for antigen. Naive B lymphocytes use alternative mRNA splicing to make both IgM and IgD. The &micro; and &delta; constant region (C) genes, which code for the M and D heavy chains respectively, are those nearest to the assembled VDJ sequence (",
"    <a class=\"graphic graphic_figure graphicRef75596 \" href=\"mobipreview.htm?22/43/23230\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Following binding of antigen by the B lymphocyte receptor, signaling occurs through immunoreceptor tyrosine-based activation motifs (ITAMs), leading to activation of intracellular pathways, which ultimately culminate in changes in B lymphocyte gene expression. In the presence of appropriate activation (costimulators, cytokines, etc), B lymphocytes rearrange their immunoglobulin genes to switch from IgM to IgG, IgA, or IgE (",
"    <a class=\"graphic graphic_figure graphicRef77742 \" href=\"mobipreview.htm?11/50/12078\">",
"     figure 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/11/42168/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Immunoglobulin gene rearrangement is presented in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/52/37702?source=see_link\">",
"     \"Immunoglobulin genetics\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Secreted IgM exists as a pentamer and has a half-life of about 10 days (",
"    <a class=\"graphic graphic_figure graphicRef79613 \" href=\"mobipreview.htm?12/11/12464\">",
"     figure 3",
"    </a>",
"    ). Because of its pentameric structure, IgM is referred to as \"macroglobulin.\" Pentameric IgM, which has 10 antigen binding sites, readily forms antigen-antibody complexes and has high avidity, despite the fact that each individual binding site has relatively low affinity for antigen. Because of this, IgM is an exceptionally potent activator of the classical complement pathway. IgM does not activate the alternative pathway of complement, nor does it undergo transplacental transfer. The majority of IgM is intravascular in location, and accordingly, SIgMD is often associated with systemic infections and bacteremia. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/53/40792?source=see_link\">",
"     \"Function and clinical applications of immunoglobulins\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The majority of natural antibodies and autoantibodies are of the IgM class. These antibodies are polyspecific and of low affinity, and appear to play an important role in removal of self antigens and clearing of dead cells (house-keeping), homeostasis, and protection against microbes (especially microbes with polysaccharide components) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/11/42168/abstract/3-5\">",
"     3-5",
"    </a>",
"    ]. IgM may regulate the selection of B lymphocyte subsets [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/11/42168/abstract/6\">",
"     6",
"    </a>",
"    ]. The functions of natural antibodies are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/53/40792?source=see_link&amp;anchor=H1550679#H1550679\">",
"     \"Function and clinical applications of immunoglobulins\", section on 'Natural antibodies'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    IgM is the first antibody to be produced during an immune response, and most of the primary humoral immune response is mediated by IgM. The IgM response wanes as other subtypes are produced. Examples of specific disorders in which IgM responses are used in diagnosis include isohemagglutinins (which are mostly IgM but also IgG), cold agglutinins, rheumatoid factor, and the heterophile antibody [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/11/42168/abstract/7\">",
"     7",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/62/27624?source=see_link&amp;anchor=H22#H22\">",
"     \"The humoral immune response\", section on 'Primary immune response'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The normal concentration of IgM in the serum is approximately 50 to 400",
"    <span class=\"nowrap\">",
"     mg/dL.",
"    </span>",
"    By definition, this range includes 95 percent of the population and 2.5 percent will fall below that range. However, some of these individuals will have low levels of other immunoglobulins, in addition to IgM. Estimates of the prevalence of",
"    <strong>",
"     isolated",
"    </strong>",
"    low serum IgM levels depend upon the population examined:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Isolated low levels of IgM in the general population were identified in one person in a study of approximately 3000 individuals [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/11/42168/abstract/8\">",
"       8",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In series of hospitalized patients, prevalence ranged from 0.1 to 2 percent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/11/42168/abstract/9,10\">",
"       9,10",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a study of approximately 14,000 adults being treated in an allergy and immunology practice, 36 individuals were identified, for a prevalence of approximately 1:385 in this selected population [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/11/42168/abstract/11\">",
"       11",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There have been a small number of familial cases of SIgMD reported [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/11/42168/abstract/12-15\">",
"     12-15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with SIgMD may present with repeated infections or with an associated condition or they may be asymptomatic [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/11/42168/abstract/13,16\">",
"     13,16",
"    </a>",
"    ]. Clinical presentations of symptomatic IgM deficiency that have been reported in the published literature are summarized in the table (",
"    <a class=\"graphic graphic_table graphicRef67168 \" href=\"mobipreview.htm?20/34/21035\">",
"     table 1",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one study of 89 hospitalized patients, associated conditions included infections (60 percent), septicemia (36 percent), atopy (22 percent), splenomegaly (11 percent), neoplasia (7 percent), and autoimmunity (3 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/11/42168/abstract/10\">",
"       10",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In the series of 36 adult patients evaluated in an",
"      <span class=\"nowrap\">",
"       allergy/immunology",
"      </span>",
"      clinic, patients presented with recurrent upper respiratory tract infections (77 percent), allergic and nonallergic rhinitis (49 percent), asthma (47 percent), angioedema (14 percent) and anaphylaxis (11 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/11/42168/abstract/11\">",
"       11",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In another series of 15 patients presenting to an immunology clinic, disorders included infectious diseases (80 percent), atopic manifestations (33 percent), fibromyalgia-like symptoms (28 percent), and autoimmune disease (20 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/11/42168/abstract/17\">",
"       17",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Repeated infections",
"    </span>",
"    &nbsp;&mdash;&nbsp;Based on the available studies, between 60 and 80 percent of patients with SIgMD suffer from repeated infections with both bacterial and viral pathogens. More common presentations include recurrent otitis media, bronchitis, chronic rhinosinusitis, pneumonia, and sepsis (",
"    <a class=\"graphic graphic_table graphicRef68510 \" href=\"mobipreview.htm?10/55/11132\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/11/42168/abstract/11,18\">",
"     11,18",
"    </a>",
"    ]. Failure to thrive, stunted growth, and malnutrition may be observed in severely affected children with persistent infection. There have been case reports of meningococcal septicemia, pseudomonas nasopharyngitis, recurrent staphylococcal skin infections or pyoderma, recurrent hordeola, bronchiectasis, and Brucella infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/11/42168/abstract/11-13,17,19-22\">",
"     11-13,17,19-22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Viral infections reported in patients with SIgMD include occupationally-acquired smallpox, generalized non-progressive vaccinia, disseminated molluscum contagiosum, and Epidermodysplasia verruciformis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/11/42168/abstract/23-27\">",
"     23-27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Associated conditions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Subnormal levels of IgM may be identified in the context of another disease process (",
"    <a class=\"graphic graphic_table graphicRef68510 \" href=\"mobipreview.htm?10/55/11132\">",
"     table 2",
"    </a>",
"    ). In this setting, IgM deficiency is usually less profound and may reverse with improvement of underlying disease, although this is not noted in all reports.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Malignant and hematologic disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;Malignancies and hematological diseases that have been reported in association with IgM deficiency include multiple myeloma and paraproteinemias, clear cell sarcoma, Bloom's syndrome, lymphomatoid papulosis, immune thrombocytopenia (ITP), and lymphocytic leukemias [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/11/42168/abstract/19,28-33\">",
"     19,28-33",
"    </a>",
"    ]. One patient had acquired C1 inhibitor deficiency and later developed a B-cell lymphoma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/11/42168/abstract/17\">",
"     17",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/12/26824?source=see_link\">",
"     \"Acquired C1 inhibitor deficiency: Clinical manifestations, epidemiology, pathogenesis, and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Many immunodeficiency disorders demonstrate an increased prevalence of malignancy. This may result from dysregulation of immune surveillance, infection with transforming viruses, or other poorly defined mechanisms.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Autoimmune disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rheumatologic and autoimmune disorders are reported in association with selective IgM deficiency, although the cause and effect relationship is unclear. It is also unknown whether selective IgM deficiency includes deficiency of natural",
"    <span class=\"nowrap\">",
"     antibodies/autoantibodies,",
"    </span>",
"    which could predispose to pathologic autoantibody formation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/11/42168/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Normal immunophysiology of IgM'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Associated disorders include systemic lupus erythematosus, Hashimoto's thyroiditis, immune thrombocytopenia (ITP), autoimmune glomerulonephritis, and rheumatoid arthritis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/11/42168/abstract/17,19,34-37\">",
"     17,19,34-37",
"    </a>",
"    ]. In one review of the literature, 14 percent of individuals with SIgMD originally presented with autoimmune diseases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/11/42168/abstract/11\">",
"     11",
"    </a>",
"    ]. In the series of 36 patients with SIgMD followed in an outpatient",
"    <span class=\"nowrap\">",
"     allergy/immunology",
"    </span>",
"    clinic, 13 percent had low titers of antinuclear antibodies (ANA) of uncertain clinical significance [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/11/42168/abstract/11\">",
"     11",
"    </a>",
"    ]. Whether this predicts the future development of autoimmune disorders is unknown.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Atopy",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is likely that an increased incidence of atopy occurs in these individuals, as has been described with IgA deficiency. Allergic rhinitis, asthma, and eczema may be presenting features in some patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/11/42168/abstract/11\">",
"     11",
"    </a>",
"    ]. Allergic disease may also represent the effects of immune dysregulation.",
"   </p>",
"   <p>",
"    A high prevalence of idiopathic anaphylaxis and idiopathic angioedema was noted in the series of 36 outpatients gathered from an",
"    <span class=\"nowrap\">",
"     allergy/immunology",
"    </span>",
"    practice [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/11/42168/abstract/11\">",
"     11",
"    </a>",
"    ]. This is a newly proposed association that has not been observed in earlier reported cases.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Miscellaneous conditions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other conditions that have been described in association with SIgMD include Crohn's disease, gastroesophageal reflux disease, interstitial lung disease, massive splenomegaly, inflammatory multifocal osteomyelitis, and inability to train in athletes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/11/42168/abstract/11,38-42\">",
"     11,38-42",
"    </a>",
"    ]. IgM deficiency may also be found in celiac disease, although it may be secondary to intestinal malabsorption in this setting, as IgM levels sometimes rise with a gluten free diet [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/11/42168/abstract/11,43-45\">",
"     11,43-45",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Isolated IgM deficiency has been associated with serious bacterial infection and the other complications listed earlier, although it is unlikely that low or absent serum IgM, by itself, leads to increased susceptibility to infection. Rather, SIgMD is probably a manifestation of immune dysregulation, and the associated immunologic dysfunction (such as poor antibody response or other defects described below) is what results in increased infections.",
"   </p>",
"   <p>",
"    The pathogenesis of SIgMD is unclear, although several mechanisms have been proposed, including B cells defects, disordered T cell help, and possibly chromosomal defects. There are likely multiple mechanisms that can result in isolated low serum IgM:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      B lymphocyte defects: Studies have consistently found that surface levels of IgM on circulating B lymphocytes are normal in patients with SIgMD [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/11/42168/abstract/9,46,47\">",
"       9,46,47",
"      </a>",
"      ]. Single studies have shown normal production of messenger RNA for IgM, and a lack of mutations in the IgM heavy chain gene [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/11/42168/abstract/36,48\">",
"       36,48",
"      </a>",
"      ], although possible defects in IgM production by B cells were identified in other studies [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/11/42168/abstract/36,47\">",
"       36,47",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      T lymphocyte dysfunction: Although no well-defined T cell abnormalities have been consistently identified, inadequate T cell help, excessive T cell suppressive activity, abnormal",
"      <span class=\"nowrap\">",
"       CD4/CD8",
"      </span>",
"      ratios, and inhibitory factors have all been demonstrated in some patients with SIgMD [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/11/42168/abstract/9,21,46,49,50\">",
"       9,21,46,49,50",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Chromosomal disorders: In a small number of case reports, sIgM deficiency has been identified in patients with chromosome 22q11.2 deletion syndrome, although chromosome 22q11.2 deletions are relatively common, occurring in approximately 1 in 4000 to 6000 live births [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/11/42168/abstract/51,52\">",
"       51,52",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?31/37/32343?source=see_link\">",
"       \"DiGeorge syndrome: Epidemiology and pathogenesis\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     EVALUATION AND DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Selective IgM deficiency is usually identified when evaluating a patient for recurrent or serious infections. It is a diagnosis of exclusion and formal diagnostic criteria have not been established. The minimal diagnostic evaluation required for the diagnosis includes the demonstration of an isolated deficiency of serum IgM and no other classifiable immunodeficiency or secondary cause of low IgM. Characteristic laboratory findings are described in the table and discussed in this section (",
"    <a class=\"graphic graphic_table graphicRef80591 \" href=\"mobipreview.htm?37/37/38491\">",
"     table 3",
"    </a>",
"    ). The clinical history should be explored for the presence of associated conditions, as these may ultimately explain the low levels of IgM. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Associated conditions'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Initial immunologic testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Any individual with recurrent infections, especially those with sepsis or other serious sequelae of infection, should be evaluated for immunodeficiency. Initial tests to evaluate for immunodeficiency include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Complete blood count with differential to look for abnormally high or low cell populations and low platelets (see",
"      <a class=\"local\" href=\"#H7\">",
"       'Malignant and hematologic disorders'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Quantitative serum immunoglobulin levels (IgG, IgM, IgA, and IgE)",
"     </li>",
"     <li>",
"      A measure of total hemolytic complement (CH50) to screen for complement deficiency",
"     </li>",
"     <li>",
"      Testing for human immunodeficiency virus (HIV) if the patient has any risk factors",
"     </li>",
"     <li>",
"      Flow cytometric lymphocyte analysis to quantitate B cells, T cells, and NK cells",
"     </li>",
"     <li>",
"      Antinuclear antibodies as a initial screen for autoimmunity in patients with concerning symptoms, with the recognition that a negative test does not exclude the possibility of autoimmune disease (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?27/54/28520?source=see_link\">",
"       \"Measurement and clinical significance of antinuclear antibodies\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The above studies are normal or only mildly abnormal in patients with selective IgM deficiency (SIgMD), as shown in the table (",
"    <a class=\"graphic graphic_table graphicRef80591 \" href=\"mobipreview.htm?37/37/38491\">",
"     table 3",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H889929\">",
"    <span class=\"h3\">",
"     Low or absent serum IgM levels",
"    </span>",
"    &nbsp;&mdash;&nbsp;The normal serum concentration of IgM is between 50 and 400",
"    <span class=\"nowrap\">",
"     mg/dL.",
"    </span>",
"    Although there are no strict numeric cutoff values for defining IgM deficiency, a level of IgM less than 2 standard deviations from the mean, or less than 10 percent from the mean for age, is generally accepted as deficient [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/11/42168/abstract/16\">",
"     16",
"    </a>",
"    ]. Thus, IgM levels less than 10 to 15",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    in infants and children and less than 20 to 30",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    in adults are compatible with IgM deficiency. Immunoglobulin levels should be measured on a least two separate occasions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H890030\">",
"    <span class=\"h3\">",
"     Lymphocyte analysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Numbers of circulating B cells are normal in SIgMD. T cell numbers are usually normal, although CD4+ T cells may be low, and CD8+ may be high. For some complicated patients, referral to a specialty center for further study of B lymphocyte biology and function may be indicated (",
"    <a class=\"graphic graphic_table graphicRef52719 \" href=\"mobipreview.htm?35/29/36315\">",
"     table 4",
"    </a>",
"    ). Flow cytometry to assess lymphocyte subsets is reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/58/43945?source=see_link&amp;anchor=H4#H4\">",
"     \"Laboratory evaluation of the immune system\", section on 'Flow cytometry'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H890089\">",
"    <span class=\"h3\">",
"     Vaccine response",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vaccine responses are variable in SIgMD, although they should be assessed to exclude other immune deficiency disorders, and to determine if the patient is a candidate for prophylactic treatment to prevent infections. (See",
"    <a class=\"local\" href=\"#H6107188\">",
"     'Measures to prevent infections'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Titers for protective IgG against tetanus and diphtheria can be measured to assess response to protein antigens in vaccinated individuals.",
"     </li>",
"     <li>",
"      Titers for the serotype-specific IgG to the carbohydrate antigens in the polysaccharide pneumococcal vaccine (usually a commercially-available panel of 14 to 23 serotypes) can be measured in children and adults over the age of two years.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    If titers are low to either",
"    <span class=\"nowrap\">",
"     tetanus/diphtheria",
"    </span>",
"    or to pneumococcus and the patient was not vaccinated within the past three to five years, then a dose of an age-appropriate vaccine should be given and titers repeated one month later. The interpretation of a patient&rsquo;s immune response to vaccination is reviewed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/48/24328?source=see_link\">",
"     \"Assessing the immunologic response to vaccination\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Vaccine responses to protein and polysaccharide antigens have not been systematically studied in patients with SIgMD. Case reports and small series suggest that they may be normal or impaired. Depressed IgG responses to diphtheria-tetanus were reported in two of six patients with SIgMD in one series, despite normal levels of total IgG [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/11/42168/abstract/44\">",
"     44",
"    </a>",
"    ]. Impaired responses to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/8/12422?source=see_link\">",
"     pneumococcal polysaccharide vaccine",
"    </a>",
"    were reported in five of eight patients in another series [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/11/42168/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H889956\">",
"    <span class=\"h3\">",
"     Evaluation of infections",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients presenting with acute infections during the diagnostic evaluation, attempts should be made to document the infection, as well as the responsible organism, whenever possible. This may involve radiological evaluation for sinusitis and pneumonia, lumbar puncture for meningitis, serologies, and",
"    <span class=\"nowrap\">",
"     tissue/secretion",
"    </span>",
"    cultures, as indicated by the clinical presentation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H890366\">",
"    <span class=\"h2\">",
"     Further laboratory evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Once an isolated deficiency of serum IgM has been identified, further evaluation may be considered, although these studies are not needed for the diagnosis (",
"    <a class=\"graphic graphic_table graphicRef52719 \" href=\"mobipreview.htm?35/29/36315\">",
"     table 4",
"    </a>",
"    ). Rather, they are included here to relay what is known about this disorder. Not all of the studies discussed below are readily available and some are only performed at speciality centers or research laboratories.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H890785\">",
"    <span class=\"h3\">",
"     Other antibody studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;IgG subclasses may be measured for the purpose of fully assessing the patient&rsquo;s immune system, although the clinical significance of a concomitant IgG subclass deficiency is unclear, as management of IgG subclass deficiency and SIgMD are similar. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/16/35078?source=see_link\">",
"     \"IgG subclasses: Physical properties, genetics, and biologic functions\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/25/10647?source=see_link\">",
"     \"Overview and clinical assessment of the complement system\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Isohemagglutinins, which are comprised of both IgM and IgG, have been variably reported in patients with SIgMD [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/11/42168/abstract/11,44\">",
"       11,44",
"      </a>",
"      ]. The largest available series reported isohemagglutinins in 33 patients, and found a mean titer of anti-A of 1:50 &plusmn; 92 and a mean titer of anti-B of 1:12 &plusmn; 13 (normal controls were &ge;1:64 for both) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/11/42168/abstract/11\">",
"       11",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Vaccination with neoantigens may be helpful in uncommon instances where pneumococcal vaccination is either contraindicated (such as an earlier adverse reaction) or ineffective. Neoantigens are only available in some research laboratories.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Additional lymphocyte testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Immunophenotyping of B cells and in vitro stimulation studies of B and T lymphocytes are commercially available and also performed by specialty centers (",
"    <a class=\"graphic graphic_table graphicRef52719 \" href=\"mobipreview.htm?35/29/36315\">",
"     table 4",
"    </a>",
"    ). B lymphocytes display normal levels of surface IgM, although this measurement is not commercially available.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H890167\">",
"    <span class=\"h2\">",
"     Evaluation for associated conditions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with SIgMD should be evaluated for the conditions that have been reported in association with it, if indicated by a careful history and physical examination. In some cases (although not all), the IgM deficiency may be secondary to the other condition, and improve as the primary condition is treated (",
"    <a class=\"graphic graphic_table graphicRef67168 \" href=\"mobipreview.htm?20/34/21035\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Other immunodeficiencies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Subnormal serum levels of IgM (although not",
"    <strong>",
"     isolated",
"    </strong>",
"    IgM deficiency) may be seen in other immune deficiency disorders, including:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Common variable immune deficiency (CVID) (in association with low IgG levels and impaired vaccine response &plusmn; low IgA). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?17/28/17866?source=see_link\">",
"       \"Clinical manifestations, epidemiology, and diagnosis of common variable immunodeficiency in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Other antibody deficiency syndromes, although other isotypes should be affected as well. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?23/48/24326?source=see_link\">",
"       \"Primary humoral immune deficiencies: An overview\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Wiskott-Aldrich syndrome (characterized by eczema, thrombocytopenia, and an associated elevation of IgA and IgE). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?35/29/36313?source=see_link\">",
"       \"Wiskott-Aldrich syndrome\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Similarly, severe combined immune deficiency (SCID) syndromes, which are associated with both cellular and humoral defects, may also demonstrate IgM hypogammaglobulinemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/11/42168/abstract/53\">",
"     53",
"    </a>",
"    ]. In all of these conditions, IgM deficiency is accompanied by either abnormal levels of other immunoglobulin classes or by reduced T cell numbers. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/58/40873?source=see_link\">",
"     \"Combined immunodeficiencies\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/30/42471?source=see_link\">",
"     \"Severe combined immunodeficiency (SCID): An overview\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Drug-induced hypogammaglobulinemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Subnormal immunoglobulin levels have been reported with medications such as gold and d-penicillamine, although IgA deficiency or deficiency of multiple immunoglobulin classes is more typical. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/0/29706?source=see_link&amp;anchor=H18#H18\">",
"     \"Secondary immune deficiency induced by drugs and biologics\", section on 'Medications that cause hypogammaglobulinemia'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     TREATMENT AND MONITORING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with selective IgM deficiency and recurrent infections are managed similarly to individuals with other humoral immune defects, although there are no studies to evaluate the effectiveness of these interventions specifically in patients with SIgMD. Our approach to managing these patients is described here.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4746774\">",
"    <span class=\"h2\">",
"     Patient education",
"    </span>",
"    &nbsp;&mdash;&nbsp;We explain to patients that information about selective IgM deficiency is limited, and that although some patients appear to have no specific problems related to the lack of IgM, others are at increased risk for serious infections. We advise patients to seek medical care promptly for fevers or infections that seem to be worsening. We provide them with a letter signed by the evaluating clinician, which states that the patient has selective IgM deficiency, a disorder that is sometimes associated with serious infections, such as bacteremia and sepsis. We do this to encourage a thorough evaluation in urgent care and emergency department settings, and to increase the likelihood that providers will err on the side of caution when treating these individuals. We counsel patients in this manner even if they are asymptomatic.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6107180\">",
"    <span class=\"h2\">",
"     Prompt evaluation and treatment of infections",
"    </span>",
"    &nbsp;&mdash;&nbsp;If infection is suspected, we evaluate patients promptly, obtain cultures when possible, and have a low threshold for initiating antimicrobials. We follow these individuals closely to assure the infections are fully cleared before terminating treatment. Patients with immunodeficiencies are less likely to clear minor infections without antimicrobials, and more likely to require prolonged courses of treatment to eradicate established infections. We provide patients with an informational handout about seeking prompt evaluation for infections (",
"    <a class=\"graphic graphic_table graphicRef62481 \" href=\"mobipreview.htm?9/5/9308\">",
"     table 5",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6107188\">",
"    <span class=\"h2\">",
"     Measures to prevent infections",
"    </span>",
"    &nbsp;&mdash;&nbsp;Measures to prevent recurrent infections include vaccinations, aggressive management of allergic respiratory disease, and in some cases, prophylactic antibiotics or immune globulin therapy.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients who respond immunologically to vaccination, even if the response is partial, should be fully vaccinated. We administer",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?12/8/12422?source=see_link\">",
"       pneumococcal polysaccharide vaccine",
"      </a>",
"      during the immune evaluation, and administer meningococcal vaccine subsequently if there is adequate polysaccharide responsiveness. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?8/27/8633?source=see_link&amp;anchor=H15#H15\">",
"       \"Medical management of immune deficiency\", section on 'Vaccination'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?22/32/23050?source=see_link&amp;anchor=H18#H18\">",
"       \"Meningococcal vaccines\", section on 'Country-specific vaccination guidelines'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Aggressive management of atopic diseases, such as asthma and allergic rhinitis, may be helpful in reducing the incidence of complicating sinopulmonary infections. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?8/37/8794?source=see_link\">",
"       \"An overview of asthma management\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?36/60/37834?source=see_link\">",
"       \"Pharmacotherapy of allergic rhinitis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Prophylactic antibiotics can be administered to those patients who continue to have frequent infections despite the above measures. Specific regimens are discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?8/27/8633?source=see_link&amp;anchor=H18#H18\">",
"       \"Medical management of immune deficiency\", section on 'Prophylactic antibiotics'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Therapeutic preparations of immunoglobulins contain very little IgM, and serum levels of IgM are not reconstituted with immune globulin. However, the propensity of patients with SIgMD to get infections is likely not simply related to low serum IgM. Accordingly, one report described five patients with frequent infections despite preventative measures who were treated with intravenous immunoglobulin and had an excellent clinical response [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/11/42168/abstract/17\">",
"       17",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?13/48/14087?source=see_link\">",
"       \"Immune globulin therapy in primary immunodeficiency\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6107318\">",
"    <span class=\"h2\">",
"     Monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;We monitor patients for changes in clinical status. New signs or symptoms should be evaluated for evidence of associated conditions. Periodic measurements of IgM, IgG, and IgA may be performed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19655759\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;In some infants, SIgMD may be transient [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/11/42168/abstract/54\">",
"     54",
"    </a>",
"    ]. Beyond this, there is insufficient information to allow generalizations about the prognosis of patients with SIgMD, as the numbers of patients are small and prospective studies are lacking.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h1\">",
"     RESOURCES FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;General information for patients with immune deficiency disorders is available from several sources:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The Immune Deficiency Foundation (",
"      <a class=\"external\" href=\"file://www.primaryimmune.org/\">",
"       file://www.primaryimmune.org",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      International Patient Organization for Primary Immunodeficiencies (",
"      <a class=\"external\" href=\"file://www.ipopi.org/\">",
"       file://www.ipopi.org",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      The National Institutes of Health (",
"      <a class=\"external\" href=\"file://www.nichd.nih.gov/publications/pubs/primary_immuno.cfm\">",
"       file://www.nichd.nih.gov/publications/pubs/primary_immuno.cfm",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      The Mayo Clinic (",
"      <a class=\"external\" href=\"file://www.mayoclinic.com/health/primary-immunodeficiency/DS01006\">",
"       file://www.mayoclinic.com/health/primary-immunodeficiency/DS01006",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Selective deficiency of immunoglobulin M (SIgMD) is a rare immune disorder that has been reported in association with bacteremia and other serious infections. There have been fewer than 200 to 300 cases reported to date. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with IgM deficiency may be asymptomatic, have repeated infections,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      present with associated conditions, such as atopic diseases, autoimmune disorders, or malignant and hematologic disorders (",
"      <a class=\"graphic graphic_table graphicRef67168 \" href=\"mobipreview.htm?20/34/21035\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Clinical features'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      IgM deficiency is defined in terms of standard deviations from a population mean, which correlates to levels less than 10 to 15",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      in infants and children and less than 20 to 30",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      in adults. (See",
"      <a class=\"local\" href=\"#H889929\">",
"       'Low or absent serum IgM levels'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      SIgMD is characterized by deficiency of serum IgM, in association with infection and with normal levels of other immunoglobulin isotypes. Vaccine response may be normal or impaired (",
"      <a class=\"graphic graphic_table graphicRef80591 \" href=\"mobipreview.htm?37/37/38491\">",
"       table 3",
"      </a>",
"      ). SIgMD is a diagnosis of exclusion and other immunologic disorders should be excluded. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Evaluation and diagnosis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H24\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with SIgMD should be evaluated for associated conditions if these are suggested by the history and physical examination. In some cases, the IgM deficiency may improve as the other condition is treated (",
"      <a class=\"graphic graphic_table graphicRef67168 \" href=\"mobipreview.htm?20/34/21035\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H890167\">",
"       'Evaluation for associated conditions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with SIgMD and recurrent infections are managed similarly to individuals with other antibody defects and deficiencies, although there are no studies to evaluate the effectiveness of these interventions specifically in patients with SIgMD. (See",
"      <a class=\"local\" href=\"#H27\">",
"       'Treatment and monitoring'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      Several measures are used to reduce the frequency of infections in patients with SIgMD:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      For patients who are shown to be either partially or fully vaccine-responsive during immune evaluation, we suggest vaccination with pneumococcal and meningococcal vaccines to provide protection against these organisms (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      We suggest administration of prophylactic antibiotics to patients who continue to experience recurrent infections (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      For patients with impaired vaccine response and severe or refractory recurrent infections despite antibiotic prophylaxis, we suggest immune globulin replacement therapy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42168/abstract/1\">",
"      Stavnezer J, Amemiya CT. Evolution of isotype switching. Semin Immunol 2004; 16:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42168/abstract/2\">",
"      Diamant E, Melamed D. Class switch recombination in B lymphopoiesis: a potential pathway for B cell autoimmunity. Autoimmun Rev 2004; 3:464.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42168/abstract/3\">",
"      Manson JJ, Mauri C, Ehrenstein MR. Natural serum IgM maintains immunological homeostasis and prevents autoimmunity. Springer Semin Immunopathol 2005; 26:425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42168/abstract/4\">",
"      Ehrenstein MR, Cook HT, Neuberger MS. Deficiency in serum immunoglobulin (Ig)M predisposes to development of IgG autoantibodies. J Exp Med 2000; 191:1253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42168/abstract/5\">",
"      Quartier P, Potter PK, Ehrenstein MR, et al. Predominant role of IgM-dependent activation of the classical pathway in the clearance of dying cells by murine bone marrow-derived macrophages in vitro. Eur J Immunol 2005; 35:252.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42168/abstract/6\">",
"      Baker N, Ehrenstein MR. Cutting edge: selection of B lymphocyte subsets is regulated by natural IgM. J Immunol 2002; 169:6686.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42168/abstract/7\">",
"      GILBERT C, HONG R. QUALITATIVE AND QUANTITATIVE IMMUNOGLOBULIN DEFICIENCY. Am J Med 1964; 37:602.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42168/abstract/8\">",
"      Cassidy JT, Nordby GL. Human serum immunoglobulin concentrations: prevalence of immunoglobulin deficiencies. J Allergy Clin Immunol 1975; 55:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42168/abstract/9\">",
"      Inoue T, Okumura Y, Shirama M, et al. Selective partial IgM deficiency: functional assessment of T and B lymphocytes in vitro. J Clin Immunol 1986; 6:130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42168/abstract/10\">",
"      Hobbs JR. IgM deficiency. Birth Defects Orig Artic Ser 1975; 11:112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42168/abstract/11\">",
"      Goldstein MF, Goldstein AL, Dunsky EH, et al. Selective IgM immunodeficiency: retrospective analysis of 36 adult patients with review of the literature. Ann Allergy Asthma Immunol 2006; 97:717.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42168/abstract/12\">",
"      Yocum MW, Strong DM, Chusid MJ, Lakin JD. Selective immunoglobulin M (IgM) deficiency in two immunodeficient adults with recurrent staphylococcal pyoderma. Am J Med 1976; 60:486.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42168/abstract/13\">",
"      Faulk WP, Kiyasu WS, Cooper MD, Fudenberg HH. Deficiency of IgM. Pediatrics 1971; 47:399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42168/abstract/14\">",
"      Jones DM, Tobin BM, Butterworth A. Three cases of meningococcal infection in a family, associated with a deficient immune response. Arch Dis Child 1973; 48:742.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42168/abstract/15\">",
"      Silver HK, Shuster J, Gold P, Freedman SO. Leukopenia, leukoagglutinins, and low IgM in a family with severe febrile illnesses. Clin Immunol Immunopathol 1973; 1:220.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42168/abstract/16\">",
"      Thong YH, Maxwell GM. Primary selective deficiency of immunoglobulin M. Aust N Z J Med 1978; 8:436.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42168/abstract/17\">",
"      Yel L, Ramanuja S, Gupta S. Clinical and immunological features in IgM deficiency. Int Arch Allergy Immunol 2009; 150:291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42168/abstract/18\">",
"      Hong R, Gupta S. Selective immunoglobulin M deficiency in an adult with Streptococcus pneumoniae sepsis and invasive aspergillosis. J Investig Allergol Clin Immunol 2008; 18:214.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42168/abstract/19\">",
"      Sugita K, Eguchi M. Chronic idiopathic thrombocytic purpura in a young male patient with isolated IgM deficiency. Int J Hematol 2001; 73:532.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42168/abstract/20\">",
"      Kiratli HK, Akar Y. Multiple recurrent hordeola associated with selective IgM deficiency. J AAPOS 2001; 5:60.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42168/abstract/21\">",
"      Raziuddin S, Bilal N, Benjamin B. Transient T-cell abnormality in a selective IgM-immunodeficient patient with Brucella infection. Clin Immunol Immunopathol 1988; 46:360.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42168/abstract/22\">",
"      Belgemen T, Suskan E, Dogu F, Ikinciogullari A. Selective immunoglobulin M deficiency presenting with recurrent impetigo: a case report and review of the literature. Int Arch Allergy Immunol 2009; 149:283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42168/abstract/23\">",
"      Brilliant LB, Nakano JH, Kitamura T, et al. Occupationally-acquired smallpox in an IgM-deficient health worker. Bull World Health Organ 1981; 59:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42168/abstract/24\">",
"      Chandra RK, Kaveramma B, Soothill JF. Generalised non-progressive vaccinia associated with IgM deficiency. Lancet 1969; 1:687.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42168/abstract/25\">",
"      Mayumi M, Yamaoka K, Tsutsui T, et al. Selective immunoglobulin M deficiency associated with disseminated molluscum contagiosum. Eur J Pediatr 1986; 145:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42168/abstract/26\">",
"      Iraji F, Faghihi G. Epidermodysplasia verruciformis: association with isolated IgM deficiency and response to treatment with acitretin. Clin Exp Dermatol 2000; 25:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42168/abstract/27\">",
"      Gul U, Soylu S, Yavuzer R. Epidermodysplasia verruciformis associated with isolated IgM deficiency. Indian J Dermatol Venereol Leprol 2007; 73:420.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42168/abstract/28\">",
"      Vogelzang NJ, Corwin H, Finlay JL, et al. Clear cell sarcoma and selective IgM deficiency: a case report. Cancer 1982; 49:234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42168/abstract/29\">",
"      Kondo N, Ozawa T, Kato Y, et al. Reduced secreted mu mRNA synthesis in selective IgM deficiency of Bloom's syndrome. Clin Exp Immunol 1992; 88:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42168/abstract/30\">",
"      Takenaka T, Nakamine H, Nishihara T, et al. Prolymphocytic leukemia with IgM hypogammaglobulinemia. Am J Clin Pathol 1983; 80:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42168/abstract/31\">",
"      Ozawa T, Kondo N, Motoyoshi F, et al. Preferential damage to IgM production by ultraviolet B in the cells of patients with Bloom's syndrome. Scand J Immunol 1993; 38:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42168/abstract/32\">",
"      Saini S, Dettore AJ, Bhambhani KJ, et al. Selective IgM deficiency in CD30+ cutaneous lymphoproliferative disorder. J Pediatr Hematol Oncol 2011; 33:e156.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42168/abstract/33\">",
"      Karakantza M, Mouzaki A, Theodoropoulou M, et al. Th1 and Th2 cytokines in a patient with Evans' syndrome and profound lymphopenia. Br J Haematol 2000; 110:968.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42168/abstract/34\">",
"      Saiki O, Saeki Y, Tanaka T, et al. Development of selective IgM deficiency in systemic lupus erythematosus patients with disease of long duration. Arthritis Rheum 1987; 30:1289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42168/abstract/35\">",
"      Kimura S, Tanigawa M, Nakahashi Y, et al. Selective IgM deficiency in a patient with Hashimoto's disease. Intern Med 1993; 32:302.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42168/abstract/36\">",
"      Takeuchi T, Nakagawa T, Maeda Y, et al. Functional defect of B lymphocytes in a patient with selective IgM deficiency associated with systemic lupus erythematosus. Autoimmunity 2001; 34:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42168/abstract/37\">",
"      Antar M, Lamarche J, Peguero A, et al. A case of selective immunoglobulin M deficiency and autoimmune glomerulonephritis. Clin Exp Nephrol 2008; 12:300.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42168/abstract/38\">",
"      Morita M, Saibara T, Nakazawa Y, et al. [A case of Crohn's disease associated with selective IgM deficiency]. Nihon Shokakibyo Gakkai Zasshi 1984; 81:1070.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42168/abstract/39\">",
"      Popa V, Colby TV, Reich SB. Pulmonary interstitial disease in Ig deficiency. Chest 2002; 122:1594.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42168/abstract/40\">",
"      Bedu-Addo G, Sheldon J, Bates I. Massive splenomegaly in tropical West Africa. Postgrad Med J 2000; 76:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42168/abstract/41\">",
"      Fallon KE. Inability to train, recurrent infection, and selective IgM deficiency. Clin J Sport Med 2004; 14:357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42168/abstract/42\">",
"      Makay B, Unsal E, Anal O, et al. Chronic recurrent multifocal osteomyelitis in a patient with selective immunoglobulin M deficiency. Rheumatol Int 2009; 29:811.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42168/abstract/43\">",
"      Ross IN, Thompson RA. Severe selective IgM deficiency. J Clin Pathol 1976; 29:773.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42168/abstract/44\">",
"      Guill MF, Brown DA, Ochs HD, et al. IgM deficiency: clinical spectrum and immunologic assessment. Ann Allergy 1989; 62:547.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42168/abstract/45\">",
"      Hobbs JR. Immunoflobulins and malabsorption. Proc R Soc Med 1969; 62:982.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42168/abstract/46\">",
"      Ohno T, Inaba M, Kuribayashi K, et al. Selective IgM deficiency in adults: phenotypically and functionally altered profiles of peripheral blood lymphocytes. Clin Exp Immunol 1987; 68:630.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42168/abstract/47\">",
"      Yamasaki T. Selective IgM deficiency: functional assessment of peripheral blood lymphocytes in vitro. Intern Med 1992; 31:866.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42168/abstract/48\">",
"      Boes M, Schmidt T, Linkemann K, et al. Accelerated development of IgG autoantibodies and autoimmune disease in the absence of secreted IgM. Proc Natl Acad Sci U S A 2000; 97:1184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42168/abstract/49\">",
"      Moffitt JE, Guill MF, Wray BB, et al. Effect of interleukin-2 and mitogen on in vitro immunoglobulin production by peripheral blood lymphocytes from patients with selective IgM deficiency. Ann Allergy 1988; 61:424.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42168/abstract/50\">",
"      De la Concha EG, Garcia-Rodriguez MC, Zabay JM, et al. Functional assessment of T and B lymphocytes in patients with selective IgM deficiency. Clin Exp Immunol 1982; 49:670.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42168/abstract/51\">",
"      Al-Herz W, McGeady SJ, Gripp KW. 22q11.2 deletion syndrome and selective IgM deficiency: an association of a common chromosomal abnormality with a rare immunodeficiency. Am J Med Genet A 2004; 127A:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42168/abstract/52\">",
"      Kung SJ, Gripp KW, Stephan MJ, et al. Selective IgM deficiency and 22q11.2 deletion syndrome. Ann Allergy Asthma Immunol 2007; 99:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42168/abstract/53\">",
"      Fischer A. Human primary immunodeficiency diseases: a perspective. Nat Immunol 2004; 5:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42168/abstract/54\">",
"      Ozen A, Baris S, Karakoc-Aydiner E, et al. Outcome of hypogammaglobulinemia in children: immunoglobulin levels as predictors. Clin Immunol 2010; 137:374.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3921 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-60.18.131.125-92069A6D88-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_11_42168=[""].join("\n");
var outline_f41_11_42168=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H30\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6106648\">",
"      DEFINITION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      NORMAL IMMUNOPHYSIOLOGY OF IgM",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Repeated infections",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Associated conditions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Malignant and hematologic disorders",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Autoimmune disorders",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Atopy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Miscellaneous conditions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      EVALUATION AND DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Initial immunologic testing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H889929\">",
"      - Low or absent serum IgM levels",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H890030\">",
"      - Lymphocyte analysis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H890089\">",
"      - Vaccine response",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H889956\">",
"      - Evaluation of infections",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H890366\">",
"      Further laboratory evaluation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H890785\">",
"      - Other antibody studies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Additional lymphocyte testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H890167\">",
"      Evaluation for associated conditions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Other immunodeficiencies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Drug-induced hypogammaglobulinemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      TREATMENT AND MONITORING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4746774\">",
"      Patient education",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6107180\">",
"      Prompt evaluation and treatment of infections",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6107188\">",
"      Measures to prevent infections",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6107318\">",
"      Monitoring",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19655759\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      RESOURCES FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ALLRG/3921\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/3921|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?22/43/23230\" title=\"figure 1\">",
"      Immunoglobulin genes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?11/50/12078\" title=\"figure 2\">",
"      Development human B cells",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?12/11/12464\" title=\"figure 3\">",
"      Pentameric IgM structure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/3921|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?20/34/21035\" title=\"table 1\">",
"      Clinical features sIgMD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?10/55/11132\" title=\"table 2\">",
"      Diseases IgM deficiency",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?37/37/38491\" title=\"table 3\">",
"      Laboratories features of selective IgM deficiency",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?35/29/36315\" title=\"table 4\">",
"      Tests to be considered in patients with selective IgM deficiency",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?9/5/9308\" title=\"table 5\">",
"      Selective IgM deficiency patient instructions re infections",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/12/26824?source=related_link\">",
"      Acquired C1 inhibitor deficiency: Clinical manifestations, epidemiology, pathogenesis, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/37/8794?source=related_link\">",
"      An overview of asthma management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/48/24328?source=related_link\">",
"      Assessing the immunologic response to vaccination",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/28/17866?source=related_link\">",
"      Clinical manifestations, epidemiology, and diagnosis of common variable immunodeficiency in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/58/40873?source=related_link\">",
"      Combined immunodeficiencies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/37/32343?source=related_link\">",
"      DiGeorge syndrome: Epidemiology and pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/53/40792?source=related_link\">",
"      Function and clinical applications of immunoglobulins",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/16/35078?source=related_link\">",
"      IgG subclasses: Physical properties, genetics, and biologic functions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/48/14087?source=related_link\">",
"      Immune globulin therapy in primary immunodeficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/52/37702?source=related_link\">",
"      Immunoglobulin genetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/58/43945?source=related_link\">",
"      Laboratory evaluation of the immune system",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/54/28520?source=related_link\">",
"      Measurement and clinical significance of antinuclear antibodies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/27/8633?source=related_link\">",
"      Medical management of immune deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/32/23050?source=related_link\">",
"      Meningococcal vaccines",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/25/10647?source=related_link\">",
"      Overview and clinical assessment of the complement system",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/60/37834?source=related_link\">",
"      Pharmacotherapy of allergic rhinitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/48/24326?source=related_link\">",
"      Primary humoral immune deficiencies: An overview",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/0/29706?source=related_link\">",
"      Secondary immune deficiency induced by drugs and biologics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/30/42471?source=related_link\">",
"      Severe combined immunodeficiency (SCID): An overview",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/9/7318?source=related_link\">",
"      Structure of immunoglobulins",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/62/27624?source=related_link\">",
"      The humoral immune response",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/29/36313?source=related_link\">",
"      Wiskott-Aldrich syndrome",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f41_11_42169="Congenital diaphragmatic hernia: Prenatal diagnosis and management";
var content_f41_11_42169=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Congenital diaphragmatic hernia: Prenatal diagnosis and management",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?41/11/42169/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/11/42169/contributors\">",
"     Holly L Hedrick, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/11/42169/contributors\">",
"     N Scott Adzick, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?41/11/42169/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/11/42169/contributors\">",
"     Louise Wilkins-Haug, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?41/11/42169/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/11/42169/contributors\">",
"     Vanessa A Barss, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?41/11/42169/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 11, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Congenital diaphragmatic hernia (CDH) is a developmental discontinuity of the diaphragm that allows abdominal viscera to herniate into the chest, resulting in pulmonary hypoplasia and pulmonary hypertension, which are often fatal.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EMBRYOLOGY AND PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Visceral herniation into the thoracic cavity occurs during the critical period of lung development when the bronchi and pulmonary arteries are undergoing branching, from just after the third week postfertilization through the 16th week of gestation. Interference with normal lung development at this time results in decreased bronchiolar branching and loss of pulmonary mass (pulmonary hypoplasia) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/11/42169/abstract/1\">",
"     1",
"    </a>",
"    ], as well as truncation and over-muscularization of the pulmonary arterial tree [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/11/42169/abstract/2\">",
"     2",
"    </a>",
"    ]. Abnormal development of the lung also results in a dysfunctional surfactant system late in gestation and after birth [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/11/42169/abstract/3-6\">",
"     3-6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The pathogenesis of CDH has not been established definitively. The leading theories are that it is due to failure of normal closure of the pleuroperitoneal folds during the 4th to 10th weeks postfertilization or to genetic or environmental triggers that disrupt differentiation of mesenchymal cells during formation of the diaphragm and other somatic structures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/11/42169/abstract/7-9\">",
"     7-9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Familial cases involving autosomal recessive, autosomal dominant, and X-linked inheritance patterns have been reported [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/11/42169/abstract/10-13\">",
"     10-13",
"    </a>",
"    ]. However, the vast majority of CDH occurs sporadically, with no identifiable familial link. Even among monozygotic twin pairs, concordance for CDH is rare: in a large CDH registry, there were no concordant cases among the five monozygotic twin pairs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/11/42169/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Many different chromosomal anomalies (eg, deletions, duplications, translocations) and gene mutations have been identified among sporadic cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/11/42169/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. These cases may represent de novo mutational events in genes for normal diaphragmatic development or reflect polygenic or multifactorial inheritance, or both.",
"   </p>",
"   <p>",
"    The possibility of an environmental trigger is supported by cases of CDH as a manifestation of vitamin A deficiency [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/11/42169/abstract/17-22\">",
"     17-22",
"    </a>",
"    ] and after exposure to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/62/29673?source=see_link\">",
"     thalidomide",
"    </a>",
"    , anticonvulsants, and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/46/15080?source=see_link\">",
"     quinine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/11/42169/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     ANATOMICAL FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diaphragmatic defect is usually posterolateral (Bochdalek hernia), but may be anterior retrosternal or peristernal (Morgagni hernia), or rarely central.",
"   </p>",
"   <p>",
"    Herniation usually occurs on the left (80 to 85 percent); right-sided diaphragmatic hernias occur in only 10 to 15 percent of cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/11/42169/abstract/24,25\">",
"     24,25",
"    </a>",
"    ]. Bilateral herniation is rare. With left sided herniation, the stomach is often involved, while the liver is often involved when the hernia is on the right; however, the liver may herniate even with left sided CDH. Both right and left sided hernias involve bowel. A sac may cover the herniated abdominal contents.",
"   </p>",
"   <p>",
"    Pulmonary changes are most severe on the ipsilateral side, but can also occur on the contralateral side. The contralateral side is almost always affected in CDH. Differing degrees of bilateral pulmonary hypoplasia may explain the variation in severity among neonates presenting with respiratory distress and CDH.",
"   </p>",
"   <p>",
"    Abnormal pulmonary vascular development and function occur on both sides. The size of the pulmonary vascular bed is decreased in the hypoplastic lungs, and the adventitia and media of the pulmonary arterial walls are thickened [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/11/42169/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Diaphragmatic eventration",
"      </strong>",
"      &mdash; Diaphragmatic eventration refers to elevation of a portion of the diaphragm that is intact, but thinned because of incomplete muscularization [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/11/42169/abstract/27\">",
"       27",
"      </a>",
"      ]. The thin and redundant membranous diaphragm resulting from an eventration defect may form a \"sac\" that contains abdominal contents and is displaced into the thorax. It is likely that eventration and \"sac type\" CDH diagnoses are often used interchangeably, making it difficult to estimate the frequency of these entities. Although severe diaphragmatic eventration can be associated with pulmonary hypoplasia and respiratory distress during infancy, the presence of a sac is generally associated with a better prognosis than classical CDH [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/11/42169/abstract/28,29\">",
"       28,29",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Milder degrees of diaphragmatic eventration",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      CDH with sac can present later in life with gastrointestinal or mild respiratory symptoms, or without symptoms so that the diagnosis is made incidentally on chest x-ray. In a study to analyze patterns of delayed presentation of CDH, 6 of 15 patients diagnosed after 2 months of age had a hernia sac [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/11/42169/abstract/30\">",
"       30",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Diaphragmatic agenesis",
"      </strong>",
"      &mdash; Anatomically, diaphragmatic agenesis is the most extreme form of CDH. In 1959, Bingham described absence of the hemidiaphragm (diaphragmatic agenesis) as distinct from the usual posterolateral Bochdalek defect [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/11/42169/abstract/31\">",
"       31",
"      </a>",
"      ]. A study of 48 patients noted significant differences in long-term survival for patients with diaphragmatic agenesis versus classical CDH (survival 29 versus 70 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/11/42169/abstract/32\">",
"       32",
"      </a>",
"      ]. Patients with absence of the diaphragm also had lower mean Apgar scores, longer period of preoperative stabilization and postoperative respiratory support, and a 100 percent rate of complications.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     INCIDENCE AND EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;CDH occurs in approximately 1 in 2200 live births [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/11/42169/abstract/33\">",
"     33",
"    </a>",
"    ]. Most series have not observed a gender association, although some reported a slightly higher incidence in males.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     PRENATAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is a wide range in reported sensitivity of ultrasound in detection of CDH. Sensitivity is higher when there are associated abnormalities, with advancing gestation, and when experienced fetal ultrasonographers are performing the examination [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/11/42169/abstract/34\">",
"     34",
"    </a>",
"    ]. The mean gestational age at diagnosis is about 24 weeks.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Ultrasound findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prenatal diagnosis is based upon ultrasound examination [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/11/42169/abstract/35\">",
"     35",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    Left sided CDH is characterized by the presence of a heterogeneous mass in the chest that often results in right mediastinal shift. The fluid filled stomach may be identified in the chest cavity next to or just behind the heart, and noted to be absent in the abdomen, but the stomach is not always displaced into the chest. Peristalsis of bowel in the chest helps to distinguish CDH from an intrathoracic mass, such as cystic adenomatoid malformation (see",
"    <a class=\"local\" href=\"#H10\">",
"     'Differential diagnosis'",
"    </a>",
"    below). Fluid in the small bowel also helps to distinguish bowel from lung or other thoracic neoplasm. The liver may be herniated, as well; it appears as a homogeneous mass in the chest at the level of the heart and continuous with the intraabdominal liver. The gallbladder and hepatic or umbilical veins may be abnormally located within the abdomen, which can be scaphoid.",
"   </p>",
"   <p>",
"    Right sided CDH is characterized by the presence of a homogeneous mass (liver) in the right chest that often results in left mediastinal shift. Pleural fluid is often present, and bowel may herniate, as well. The left shift of the heart is a key finding since sonographically the liver is similar in appearance to fetal lung, and bowel peristalsis may not be observed. Identifying the gallbladder in the chest is also diagnostic of right sided CDH.",
"   </p>",
"   <p>",
"    Color Doppler ultrasound can be used to document the location of the liver by demonstrating the course of the intrahepatic vessels.",
"   </p>",
"   <p>",
"    Polyhydramnios may be present due to esophageal compression. Hydrops fetalis can occur from mediastinal shift and compression of the great vessels.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Associated anomalies",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Isolated CDH",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approximately 50 to 60 percent of cases of CDH are isolated ('isolated CDH'). The presence of anomalies such as pulmonary hypoplasia, intestinal malrotation and cardiac dextroposition is due to the hemodynamic or mechanical consequences of CDH, thus they are usually considered part of the CDH sequence and their presence does not negate the designation 'isolated CDH.'",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Complex, nonisolated or syndromic CDH (CDH+)",
"    </span>",
"    &nbsp;&mdash;&nbsp;The other 40 to 50 percent of cases are called 'complex,' 'nonisolated' or 'syndromic' CDH (CDH+) because they are associated with additional abnormalities, including major structural malformations, chromosomal abnormalities,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    single gene disorders. Malformations occur in all major organ systems, with no specific pattern.",
"   </p>",
"   <p>",
"    Chromosomal anomalies are identified in 10 to 20 percent of prenatally identified cases; the most common diagnoses include trisomies 18, 13, and 21 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/11/42169/abstract/14,35,36\">",
"     14,35,36",
"    </a>",
"    ]. Other karyotype abnormalities, such as monosomy X, tetrasomy 12 p (isochromosome 12p), partial trisomy 5, partial trisomy 20, and polyploidies, have also been reported [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/11/42169/abstract/34,37\">",
"     34,37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An underlying syndrome is present in approximately 10 percent of CDH cases occurring with associated anomalies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/11/42169/abstract/23\">",
"     23",
"    </a>",
"    ]. CDH is a prominent finding in the Fryns phenotype; facial dysmorphology, distal digital hypoplasia, and",
"    <span class=\"nowrap\">",
"     cardiac/renal/brain",
"    </span>",
"    anomalies can also occur. CDH and diaphragmatic eventration are also an occasional component of many other syndromes, including Apert,",
"    <span class=\"nowrap\">",
"     Killian/Teschler-Nicola",
"    </span>",
"    (Pallister-Killian), CHARGE, Coffin-Siris, Goltz, Perlman, Swyer, Brachmann-Cornelia De Lange, Goldenhar sequence, Beckwith Wiedemann, Simpson-Golabi-Behmel, Donnai-Barrow, Mathew-Wood, Jarcho-Levin, and others [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/11/42169/abstract/34,37\">",
"     34,37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Associated anomalies are most common with bilateral CDH and in stillborn infants with CDH, where the prevalence is as high as 95 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/11/42169/abstract/36,38,39\">",
"     36,38,39",
"    </a>",
"    ]. Anomalies in stillborn infants with CDH primarily consist of neural tube defects (anencephaly, myelomeningocele, hydrocephalus, and encephaloceles) and cardiac defects (ventriculoseptal defects, vascular rings, and coarctation of the aorta) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/11/42169/abstract/40\">",
"     40",
"    </a>",
"    ]. Other midline developmental anomalies have also been reported, and include esophageal atresia, omphalocele, and cleft palate.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Differential diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other thoracic lesions which should be considered in differential diagnosis include congenital cystic adenomatoid malformation (CCAM), bronchopulmonary sequestration (BPS), bronchopulmonary foregut malformation, bronchogenic cysts, bronchial atresia, enteric cysts, and teratomas [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/11/42169/abstract/34\">",
"     34",
"    </a>",
"    ]. (Please see the individual topic reviews on these conditions).",
"   </p>",
"   <p>",
"    As discussed above, the definitive sonographic diagnosis of fetal CDH relies on the visualization of abdominal organs in the fetal chest (see",
"    <a class=\"local\" href=\"#H6\">",
"     'Ultrasound findings'",
"    </a>",
"    above). The sonographic hallmark of a left CDH is a fluid-filled stomach just behind the left atrium and ventricle in the lower thorax as seen on a transverse view. Other sonographic features that imply the presence of left CDH include the absence of the stomach below the diaphragm, mediastinal shift to the right and a small abdominal circumference. Right CDH is more frequently missed or misdiagnosed because the herniated viscera consists predominantly of the right lobe of the liver, which may have similar echogenicity to the lung, or be confused with a solid mass in the chest such as a CCAM or BPS.",
"   </p>",
"   <p>",
"    Cystic lesions in the chest are more likely to be CCAM or foregut duplication cysts than CDH. The presence of a systemic feeding vessel to a cystic or solid mass is consistent with a hybrid lesion or BPS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/11/42169/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In few instances, BPS and CDH are both present. Magnetic resonance imaging (MRI) delineates liver position, and helps in distinguishing the relationship of the diaphragm to other potential fetal chest lesions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/11/42169/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    CDH should also be distinguished from diaphragmatic eventration (displacement of abdominal contents into the thorax as a result of a congenitally thin, hypoplastic but intact diaphragm). Diaphragmatic eventration is a component of several syndromes (eg, trisomy 18). It is rare and usually has less severe effects on lung development and function than CDH [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/11/42169/abstract/28,29\">",
"     28,29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     PROGNOSTIC FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prognosis for survival of affected infants depends on a number of prenatally assessable factors. Prognosis is worse in the setting of an abnormal karyotype, severe associated anomalies, right-sided defect, liver herniation, and lower fetal lung volume [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/11/42169/abstract/43\">",
"     43",
"    </a>",
"    ]. The lung area to head circumference ratio (LHR) is more predictive of morbidity than mortality. A large defect is more likely to result in pulmonary hypoplasia and death than a small defect. The size of the defect is not measurable prenatally, so the presence of liver herniation and fetal lung volume measurements serves as a proxy for defect size.",
"   </p>",
"   <p>",
"    Several other clinical features initially thought to be related to low likelihood of survival have not been confirmed as consistently reliable prognostic indicators. These features include early gestational age at diagnosis, severe mediastinal shift, polyhydramnios, a small lung-thorax transverse area ratio, left",
"    <span class=\"nowrap\">",
"     ventricle/right",
"    </span>",
"    ventricle index, left heart hypoplasia, and the presence of stomach in the chest [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/11/42169/abstract/44-48\">",
"     44-48",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Liver herniation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most reliable prenatal predictor of postnatal survival is absence of liver herniation. A systematic review of studies that used ultrasound or MRI to evaluate outcome of fetuses with liver herniation included 710 fetuses and reported significantly higher survival rate in fetuses without herniation (74 percent versus 45 percent with herniation) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/11/42169/abstract/49\">",
"     49",
"    </a>",
"    ]. These results were limited by wide variability among studies in the definition of liver herniation and mortality (prenatal versus postnatal) and the use of either ultrasound or MR since ultrasound is more likely than MR to miss small herniations.",
"   </p>",
"   <p>",
"    Ultrafast fetal MRI using rapid HASTE technique is the most powerful tool to accurately demonstrate liver herniation (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef82186 \" href=\"mobipreview.htm?9/13/9426\">",
"     image 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/11/42169/abstract/42,50-52\">",
"     42,50-52",
"    </a>",
"    ]. Ultrasound can be useful (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef56002 \" href=\"mobipreview.htm?27/19/27956\">",
"     image 2",
"    </a>",
"    ); in particular, color flow Doppler can visualize bowing of the ductus venosus to the left of the midline or coursing of the portal branches or hepatic veins to the lateral segment of the left lobe above the diaphragm; however, ultrasound has not always accurately demonstrated liver herniation in the fetus with left-sided CDH.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Fetal lung volume",
"    </span>",
"    &nbsp;&mdash;&nbsp;Absolute or relative fetal lung volume appears to be useful for predicting survival, but the optimum equation has not been determined [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/11/42169/abstract/53\">",
"     53",
"    </a>",
"    ]. Several small studies have suggested that postnatal survival is poor when fetal lung volume measured by MRI is less than about 30 percent of expected lung volume [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/11/42169/abstract/47,54-58\">",
"     47,54-58",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Lung volume can also be assessed using 3-D sonography, but MRI may be more reliable. In comparative studies, 3-D ultrasound either underestimated the volume measured with MRI [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/11/42169/abstract/59,60\">",
"     59,60",
"    </a>",
"    ] or provided good agreement [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/11/42169/abstract/61\">",
"     61",
"    </a>",
"    ]. The volume of the ipsilateral lung is difficult to measure with either technique and there are no comparative studies correlating method of lung volume assessment with outcome.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Right versus left sided lesion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Disease severity in patients with right-sided lesions appears to be as or more severe than those with left-sided lesions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/11/42169/abstract/62,63\">",
"     62,63",
"    </a>",
"    ]. In a series of 267 infants with CDH who underwent surgical repair from 1990 to 2006, the 40 infants with right-sided CDH had a lower survival rate than those with left-sided lesions (50 versus 75 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/11/42169/abstract/63\">",
"     63",
"    </a>",
"    ]. A greater proportion of infants with right-sided lesions required ECMO (40 versus 15 percent with left-sided lesions) and a diaphragmatic patch (76 versus 41 percent with left-sided lesions) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/11/42169/abstract/63\">",
"     63",
"    </a>",
"    ]. However, in another series of 199 patients, 27 patients with right CDH had an ECMO rate of 52 percent, patch rate of 66 percent, and an overall survival rate of 83 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/11/42169/abstract/62\">",
"     62",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Lung area to head circumference ratio",
"    </span>",
"    &nbsp;&mdash;&nbsp;The lung area to head circumference ratio (LHR) is an estimate of contralateral lung size and mediastinal shift at the level of the atria on transverse scan of the fetal thorax. Although there is a significant correlation between LHR and survival [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/11/42169/abstract/46,64-72\">",
"     46,64-72",
"    </a>",
"    ], the lower limit of LHR compatible with survival is dropping, so the test is less predictive than in the past [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/11/42169/abstract/73\">",
"     73",
"    </a>",
"    ]. In our experience, LHR is now more indicative of morbidity than mortality.",
"   </p>",
"   <p>",
"    In left CDH, the LHR is calculated using a two-dimensional perpendicular linear measurement of right lung area (in square millimeters) divided by the head circumference (in millimeters) to minimize lung size differences owing to gestational age (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef73330 \" href=\"mobipreview.htm?20/63/21488\">",
"     image 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/11/42169/abstract/64\">",
"     64",
"    </a>",
"    ]. Measurement of fetal lung volume is much more useful than LHR in fetuses without liver herniation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/11/42169/abstract/66\">",
"     66",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     OBSTETRICAL MANAGEMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Work-up",
"    </span>",
"    &nbsp;&mdash;&nbsp;When CDH is suspected on prenatal ultrasound examination, we suggest:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Ultrafast fetal MRI to look for associated abnormalities and liver herniation, and to estimate lung volumes [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/11/42169/abstract/74,75\">",
"       74,75",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Fetal echocardiography",
"     </li>",
"     <li>",
"      Fetal karyotype",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Referral to a genetic counselor can be useful for thorough genetic evaluation and counseling. Microarray-based comparative genomic hybridization (aCGH) is a powerful tool for detection of submicroscopic chromosomal abnormalities. We perform aCGH in all of our patients.",
"   </p>",
"   <p>",
"    Amniocentesis rather than fetal blood sampling is recommended for genetic studies since Pallister-Killian syndrome is characterized by a tissue-specific mosaic distribution of an additional isochromosome 12p, which can be detected in preparations made from chorionic villi, amniocytes, and skin fibroblasts, but not reliably from fetal lymphocytes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Monitoring and intervention",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no data from well-designed studies on which to base recommendations for antepartum obstetrical management. The intrauterine risk of fetal demise is 3 to 8 percent, but higher when other anomalies are present [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/11/42169/abstract/33,76\">",
"     33,76",
"    </a>",
"    ]. For this reason, we monitor fetuses closely.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We begin twice weekly nonstress testing or biophysical profile testing at 33 to 34 weeks.",
"     </li>",
"     <li>",
"      We suggest ultrasound examinations at 28, 30, 32, and 34 to 35 weeks of gestation to assess fetal growth and amniotic fluid volume. Polyhydramnios may develop at 28 to 32 weeks if fetal swallowing is impaired, and oligohydramnios may develop if the fetus is compromised later in gestation. We also look for signs of secondary complications, such as particulate meconium in fluid, dilated stomach in chest, effusions, or ascites. These signs of secondary complications may lead us to deliver the fetus.",
"     </li>",
"     <li>",
"      If nonreassuring signs are present, such as fetal growth restriction or oligohydramnios, the baby is delivered early. A course of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?43/5/44120?source=see_link\">",
"       betamethasone",
"      </a>",
"      is given prior to delivery if the gestational age is less than 34 weeks.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Lung maturity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Studies for assessing lung maturity are not usually needed. In an experimental lamb model, there was no significant difference between CDH and normal control lambs in amniotic fluid",
"    <span class=\"nowrap\">",
"     lecithin/sphingomyelin",
"    </span>",
"    <span class=\"nowrap\">",
"     (L/S)",
"    </span>",
"    ratios and phosphatidylglycerol (PG) status, but bronchoalveolar lavage of CDH lambs revealed significant surfactant deficiency [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/11/42169/abstract/6\">",
"     6",
"    </a>",
"    ]. However, a chronological study of surfactant content (concentration of disaturated phosphatidylcholine and surfactant proteins) in human fetuses with CDH compared to age-matched fetuses with nonpulmonary diseases showed no significant impairment in surfactant storage in human fetuses [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/11/42169/abstract/77\">",
"     77",
"    </a>",
"    ]. CDH lungs exhibited no trend toward a decrease in contents, or a delay in developmental changes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Antenatal glucocorticoids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antenatal glucocorticoids are given, if appropriate, for threatened preterm delivery. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/55/31610?source=see_link\">",
"     \"Antenatal corticosteroid therapy for reduction of neonatal morbidity and mortality from preterm delivery\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There are inadequate data in humans to support use of these drugs for reasons other than this standard indication [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/11/42169/abstract/78\">",
"     78",
"    </a>",
"    ]. However, pilot studies in which prenatal glucocorticoids were given to fetal sheep that underwent prolonged tracheal occlusion therapy for severe diaphragmatic hernia reported this therapy improved gas exchange, ventilation efficiency, and lung morphology, and decreased medial hypertrophy of pulmonary arterioles [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/11/42169/abstract/79-81\">",
"     79-81",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Timing and mode of delivery",
"    </span>",
"    &nbsp;&mdash;&nbsp;The optimal mode and gestational age for delivery of an infant diagnosed prenatally with CDH is uncertain. We suggest a planned induction of labor between 38 and 39 weeks of gestation so that the fetus is monitored from the earliest stage of labor and so pediatric surgery and neonatology services are prepared to care for the infant. We do not assess fetal lung maturity prior to delivery.",
"   </p>",
"   <p>",
"    In our experience, up to 50 percent of cases require extracorporeal membrane oxygenation (ECMO); therefore, we recommend delivery at a tertiary center with ECMO capability [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/11/42169/abstract/82\">",
"     82",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Cesarean delivery is performed for standard obstetrical indications; there is no evidence that routine cesarean delivery is beneficial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/11/42169/abstract/83\">",
"     83",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Because the severity of pulmonary hypoplasia and pulmonary hypertension may increase with increasing gestational age, some investigators have suggested that slightly early delivery at 37 to 38 weeks of gestation rather than at 39 to 41 weeks of gestation may improve survival in infants with CDH. Data from a retrospective report from the CDHSG of 628 term infants with prenatal diagnosis of CDH and no other major anomaly appear to support this hypothesis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/11/42169/abstract/84\">",
"     84",
"    </a>",
"    ]. Infants delivered early term compared to those born late term showed a trend towards a better survival rate (73 versus 67 percent), but there was no difference in the use of ECMO. In a subgroup analysis of infants delivered by scheduled cesarean delivery, early term infants had less use of ECMO (22 versus 36 percent) and also trended to a higher survival rate (75 versus 66 percent).",
"   </p>",
"   <p>",
"    However, clinicians should be careful about acting upon this retrospective data. The two groups were not comparable, as the early term delivery group was more likely to have conditions associated with a better outcome (proportionately fewer males and black infants, and more cesarean deliveries). In addition, the mode of delivery was known in only 51 percent of the deliveries, which is an unaccounted confounding variable that could have had a significant impact on the results. As noted by the authors, because of these limitations and other potential unrecognized confounding variables, a randomized controlled trial is needed before elective early term delivery can be recommended.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     In utero therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;In utero therapy is an investigational procedure with limited geographic availability.",
"   </p>",
"   <p>",
"    The rationale for prenatal therapy in severe CDH is to prevent or reverse pulmonary hypoplasia, and restore adequate lung growth for neonatal survival [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/11/42169/abstract/46,85\">",
"     46,85",
"    </a>",
"    ]. This hypothesis was supported by work in sheep, which showed that if the space occupying abdominal viscera were reduced from the chest cavity, then the lungs would grow and develop normally [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/11/42169/abstract/86\">",
"     86",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The initial approach to in utero repair was patch closure of the diaphragmatic defect [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/11/42169/abstract/87\">",
"     87",
"    </a>",
"    ]. In all cases of liver herniation into the chest, the fetuses could not be salvaged due to kinking of the umbilical vein and subsequent fetal demise. The open approach to fetal repair of CDH was abandoned when a clinical trial showed no survival advantage, even in fetuses without liver herniation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/11/42169/abstract/88\">",
"     88",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Fetal tracheal occlusion (TO) is an alternative prenatal therapy which avoids kinking of the umbilical vein, and, more importantly, reverses lung hypoplasia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/11/42169/abstract/69,89\">",
"     69,89",
"    </a>",
"    ]. The rationale for this approach is that the dynamics of fetal lung fluid can dramatically affect lung growth [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/11/42169/abstract/90-92\">",
"     90-92",
"    </a>",
"    ]. Under normal circumstances, the lungs are net producers of amniotic fluid with lung liquid volume and intratracheal pressure maintained at constant values by fetal laryngeal mechanisms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/11/42169/abstract/93\">",
"     93",
"    </a>",
"    ]. Increasing the egress of lung fluid by fetal tracheostomy, induced oligohydramnios, or recurrent laryngeal nerve or cord transection results in pulmonary hypoplasia. Conversely, prenatal TO obstructs the normal egress of lung fluid during pulmonary development, increasing transpulmonic pressure and resulting in large fluid-filled lungs (",
"    <a class=\"graphic graphic_figure graphicRef74750 \" href=\"mobipreview.htm?14/63/15347\">",
"     figure 1",
"    </a>",
"    ). This hypothesis was supported by multiple studies in animal models that showed prenatal TO accelerated parenchymal lung growth in normal and hypoplastic lungs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/11/42169/abstract/94-96\">",
"     94-96",
"    </a>",
"    ]. Lack of lung expansion two and seven days after TO is a poor prognostic sign and may indicate that the occlusion is inadequate [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/11/42169/abstract/97\">",
"     97",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the first human",
"    <span class=\"nowrap\">",
"     CDH/TO",
"    </span>",
"    study, exposure of the fetal head and neck via a hysterotomy was performed to occlude the fetal trachea; this procedure was associated with a 13 percent survival rate [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/11/42169/abstract/98\">",
"     98",
"    </a>",
"    ]. Using a similar open-fetal surgical approach, a subsequent study reported a 33 percent postnatal survival rate [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/11/42169/abstract/69\">",
"     69",
"    </a>",
"    ]. In both studies, predicted mortality approached 100 percent; therefore, surgery improved the predicted outcome. However, lung growth was variable (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef63970 \" href=\"mobipreview.htm?20/2/20513\">",
"     image 4",
"    </a>",
"    ), postnatal respiratory function was marginal, and infants often required long-term, aggressive ventilatory support. This appears to be due to a diminished number of alveolar epithelial type-II cells after prolonged periods of TO, leading to decreased levels of pulmonary surfactant gene and protein expression [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/11/42169/abstract/99-102\">",
"     99-102",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Techniques to achieve minimally invasive fetoscopic reversible fetal TO have been developed to decrease the risks of preterm labor and restore surfactant deficiency [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/11/42169/abstract/89,103,104\">",
"     89,103,104",
"    </a>",
"    ]. In a study using fetoscopic balloon TO for severe isolated CDH, survival was higher in the 35 fetuses that underwent the intervention than in the 37 fetuses that did not (54.3 versus 5.4 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/11/42169/abstract/105\">",
"     105",
"    </a>",
"    ]. Smaller and fewer trocars were utilized in this study, resulting in a lower rate of preterm rupture of membranes and preterm delivery than was seen in a NIH sponsored trial of fetoscopic TO for fetuses with liver herniation and LHR &lt;1.4. This NIH trial was halted after enrollment of 24 patients demonstrated no survival advantage and an increased rate of prematurity (mean gestational age at delivery 31 weeks versus 37 weeks for standard postnatal care) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/11/42169/abstract/106\">",
"     106",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Important factors in offering prenatal therapy continue to be, first and foremost, determining which fetuses have a poor prognosis. The optimal timing, duration, and release of occlusion in humans are not known. The Eurofetus group has had early success with fetoscopic reversible TO in fetuses with liver herniation and LHR less than 1.0, and these studies are ongoing [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/11/42169/abstract/107\">",
"     107",
"    </a>",
"    ]. In their report of TO in 24 poor prognosis fetuses (LHR &lt;1.0 and liver herniation) in whom occlusion was performed at 26 to 28 weeks and the balloon was retrieved at 34 weeks, mean gestational age at delivery was 33.5 weeks and survival to discharge was 12 of 24 (50 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/11/42169/abstract/108\">",
"     108",
"    </a>",
"    ]. A randomized trial of standard postnatal therapy and fetoscopic TO in the severest of CDH (liver herniation, LHR &lt;1) is needed to examine the utility of TO in CDH.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     NEONATAL MANAGEMENT AND OUTCOME",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neonatal management and outcome are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/23/28026?source=see_link\">",
"     \"Congenital diaphragmatic hernia in the neonate\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     RECURRENCE RISK",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients should be referred to a genetic counselor for a genetic work-up and counseling. The recurrence risk of specific chromosomal abnormalities and syndromes may be known. No data are available to guide counseling of recurrence risk in CDH+ when multiple malformations are present, but a specific chromosomal abnormality or genetic syndrome cannot be identified. The recurrence risk for multiple congenital anomalies of unknown etiology is considered to be &lt;5 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/11/42169/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the absence of a family history of CDH, the risk of isolated CDH in future siblings is 1 to 2 percent after one affected child [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/11/42169/abstract/14,109,110\">",
"     14,109,110",
"    </a>",
"    ]. Although low, this risk is 20- to 40-fold higher than the baseline population risk of about 1 in 2000.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?2/6/2146?source=see_link\">",
"       \"Patient information: Congenital hernia of the diaphragm (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Congenital diaphragmatic hernia is a developmental defect in the diaphragm that allows abdominal viscera to herniate into the chest, thereby interfering with normal lung development. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Prenatal diagnosis is based upon ultrasound examination. The principal findings include a chest mass (which may exhibit peristalsis) and mediastinal shift, in the setting of malposition of the stomach",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      liver. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Prenatal diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Chromosomal abnormalities and structural malformations in other major organ systems (eg, congenital heart disease, neural tube defects) are often associated with congenital diaphragmatic hernia. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Associated anomalies'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The most reliable prenatal predictor of postnatal outcome is liver herniation, which is a poor prognostic finding. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Liver herniation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The prenatal assessment of patients with suspected congenital diaphragmatic hernia should include: fetal karyotype, ultrafast fetal magnetic resonance imaging to look for liver herniation, echocardiography, serial ultrasound examinations, and antepartum fetal testing. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Obstetrical management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest planned induction of labor between 38 and 39 weeks of gestation (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Obstetrical management'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42169/abstract/1\">",
"      DiFiore JW, Fauza DO, Slavin R, Wilson JM. Experimental fetal tracheal ligation and congenital diaphragmatic hernia: a pulmonary vascular morphometric analysis. J Pediatr Surg 1995; 30:917.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42169/abstract/2\">",
"      Bloss RS, Aranda JV, Beardmore HE. Congenital diaphragmatic hernia: pathophysiology and pharmacologic support. Surgery 1981; 89:518.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42169/abstract/3\">",
"      Lotze A, Knight GR, Anderson KD, et al. Surfactant (beractant) therapy for infants with congenital diaphragmatic hernia on ECMO: evidence of persistent surfactant deficiency. J Pediatr Surg 1994; 29:407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42169/abstract/4\">",
"      Wilcox DT, Glick PL, Karamanoukian HL, Holm BA. Pathophysiology of congenital diaphragmatic hernia. IX: Correlation of surfactant maturation with fetal cortisol and triiodothyronine concentration. J Pediatr Surg 1994; 29:825.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42169/abstract/5\">",
"      Wilcox DT, Glick PL, Karamanoukian HL, et al. Pathophysiology of congenital diaphragmatic hernia. XII: Amniotic fluid lecithin/sphingomyelin ratio and phosphatidylglycerol concentrations do not predict surfactant status in congenital diaphragmatic hernia. J Pediatr Surg 1995; 30:410.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42169/abstract/6\">",
"      Karamanoukian HL, Glick PL, Wilcox DT, et al. Pathophysiology of congenital diaphragmatic hernia. X: Localization of nitric oxide synthase in the intima of pulmonary artery trunks of lambs with surgically created congenital diaphragmatic hernia. J Pediatr Surg 1995; 30:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42169/abstract/7\">",
"      Slavotinek AM. The genetics of congenital diaphragmatic hernia. Semin Perinatol 2005; 29:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42169/abstract/8\">",
"      Clugston RD, Klattig J, Englert C, et al. Teratogen-induced, dietary and genetic models of congenital diaphragmatic hernia share a common mechanism of pathogenesis. Am J Pathol 2006; 169:1541.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42169/abstract/9\">",
"      Bielinska M, Jay PY, Erlich JM, et al. Molecular genetics of congenital diaphragmatic defects. Ann Med 2007; 39:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42169/abstract/10\">",
"      Tazuke Y, Kawahara H, Soh H, et al. Congenital diaphragmatic hernia in identical twins. Pediatr Surg Int 2000; 16:512.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42169/abstract/11\">",
"      Gibbs DL, Rice HE, Farrell JA, et al. Familial diaphragmatic agenesis: an autosomal-recessive syndrome with a poor prognosis. J Pediatr Surg 1997; 32:366.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42169/abstract/12\">",
"      Narayan H, De Chazal R, Barrow M, et al. Familial congenital diaphragmatic hernia: prenatal diagnosis, management, and outcome. Prenat Diagn 1993; 13:893.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42169/abstract/13\">",
"      Mishalany H, Gordo J. Congenital diaphragmatic hernia in monozygotic twins. J Pediatr Surg 1986; 21:372.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42169/abstract/14\">",
"      Pober BR, Lin A, Russell M, et al. Infants with Bochdalek diaphragmatic hernia: sibling precurrence and monozygotic twin discordance in a hospital-based malformation surveillance program. Am J Med Genet A 2005; 138A:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42169/abstract/15\">",
"      Holder AM, Klaassens M, Tibboel D, et al. Genetic factors in congenital diaphragmatic hernia. Am J Hum Genet 2007; 80:825.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42169/abstract/16\">",
"      Lurie IW. Where to look for the genes related to diaphragmatic hernia? Genet Couns 2003; 14:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42169/abstract/17\">",
"      Kling DE, Schnitzer JJ. Vitamin A deficiency (VAD), teratogenic, and surgical models of congenital diaphragmatic hernia (CDH). Am J Med Genet C Semin Med Genet 2007; 145C:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42169/abstract/18\">",
"      Major D, Cadenas M, Fournier L, et al. Retinol status of newborn infants with congenital diaphragmatic hernia. Pediatr Surg Int 1998; 13:547.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42169/abstract/19\">",
"      Yang W, Shaw GM, Carmichael SL, et al. Nutrient intakes in women and congenital diaphragmatic hernia in their offspring. Birth Defects Res A Clin Mol Teratol 2008; 82:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42169/abstract/20\">",
"      Gallot D, Marceau G, Coste K, et al. Congenital diaphragmatic hernia: a retinoid-signaling pathway disruption during lung development? Birth Defects Res A Clin Mol Teratol 2005; 73:523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42169/abstract/21\">",
"      Beurskens LW, Schrijver LH, Tibboel D, et al. Dietary vitamin A intake below the recommended daily intake during pregnancy and the risk of congenital diaphragmatic hernia in the offspring. Birth Defects Res A Clin Mol Teratol 2013; 97:60.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42169/abstract/22\">",
"      See AW, Kaiser ME, White JC, Clagett-Dame M. A nutritional model of late embryonic vitamin A deficiency produces defects in organogenesis at a high penetrance and reveals new roles for the vitamin in skeletal development. Dev Biol 2008; 316:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42169/abstract/23\">",
"      Enns GM, Cox VA, Goldstein RB, et al. Congenital diaphragmatic defects and associated syndromes, malformations, and chromosome anomalies: a retrospective study of 60 patients and literature review. Am J Med Genet 1998; 79:215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42169/abstract/24\">",
"      Dott MM, Wong LY, Rasmussen SA. Population-based study of congenital diaphragmatic hernia: risk factors and survival in Metropolitan Atlanta, 1968-1999. Birth Defects Res A Clin Mol Teratol 2003; 67:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42169/abstract/25\">",
"      Torfs CP, Curry CJ, Bateson TF, Honor&eacute; LH. A population-based study of congenital diaphragmatic hernia. Teratology 1992; 46:555.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42169/abstract/26\">",
"      Yamataka T, Puri P. Pulmonary artery structural changes in pulmonary hypertension complicating congenital diaphragmatic hernia. J Pediatr Surg 1997; 32:387.",
"     </a>",
"    </li>",
"    <li>",
"     Pober, BR, Russell, MK, Ackerman, KG. Congenital diaphragmatic hernia overview. GenerReviews 2006. available at www.ncbi.nlm.nih.gov/bookshelf/br.fcgi?book=gene&amp;part=cdh-ov (accessed February 2, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42169/abstract/28\">",
"      Eren S, Ceviz N, Alper F. Congenital diaphragmatic eventration as a cause of anterior mediastinal mass in the children: imaging modalities and literature review. Eur J Radiol 2004; 51:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42169/abstract/29\">",
"      Yazici M, Karaca I, Arikan A, et al. Congenital eventration of the diaphragm in children: 25 years' experience in three pediatric surgery centers. Eur J Pediatr Surg 2003; 13:298.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42169/abstract/30\">",
"      Elhalaby EA, Abo Sikeena MH. Delayed presentation of congenital diaphragmatic hernia. Pediatr Surg Int 2002; 18:480.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42169/abstract/31\">",
"      BINGHAM JA. Herniation through congenital diaphragmatic defects. Br J Surg 1959; 47:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42169/abstract/32\">",
"      Tsang TM, Tam PK, Dudley NE, Stevens J. Diaphragmatic agenesis as a distinct clinical entity. J Pediatr Surg 1995; 30:16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42169/abstract/33\">",
"      Harrison MR, Bjordal RI, Langmark F, Knutrud O. Congenital diaphragmatic hernia: the hidden mortality. J Pediatr Surg 1978; 13:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42169/abstract/34\">",
"      Graham G, Devine PC. Antenatal diagnosis of congenital diaphragmatic hernia. Semin Perinatol 2005; 29:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42169/abstract/35\">",
"      Taylor GA, Atalabi OM, Estroff JA. Imaging of congenital diaphragmatic hernias. Pediatr Radiol 2009; 39:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42169/abstract/36\">",
"      Crane JP. Familial congenital diaphragmatic hernia: prenatal diagnostic approach and analysis of twelve families. Clin Genet 1979; 16:244.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42169/abstract/37\">",
"      Pober BR. Genetic aspects of human congenital diaphragmatic hernia. Clin Genet 2008; 74:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42169/abstract/38\">",
"      Puri P, Gorman F. Lethal nonpulmonary anomalies associated with congenital diaphragmatic hernia: implications for early intrauterine surgery. J Pediatr Surg 1984; 19:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42169/abstract/39\">",
"      Witters I, Legius E, Moerman P, et al. Associated malformations and chromosomal anomalies in 42 cases of prenatally diagnosed diaphragmatic hernia. Am J Med Genet 2001; 103:278.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42169/abstract/40\">",
"      Sweed Y, Puri P. Congenital diaphragmatic hernia: influence of associated malformations on survival. Arch Dis Child 1993; 69:68.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42169/abstract/41\">",
"      Cass DL, Crombleholme TM, Howell LJ, et al. Cystic lung lesions with systemic arterial blood supply: a hybrid of congenital cystic adenomatoid malformation and bronchopulmonary sequestration. J Pediatr Surg 1997; 32:986.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42169/abstract/42\">",
"      Quinn TM, Hubbard AM, Adzick NS. Prenatal magnetic resonance imaging enhances fetal diagnosis. J Pediatr Surg 1998; 33:553.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42169/abstract/43\">",
"      Mayer S, Klaritsch P, Petersen S, et al. The correlation between lung volume and liver herniation measurements by fetal MRI in isolated congenital diaphragmatic hernia: a systematic review and meta-analysis of observational studies. Prenat Diagn 2011; 31:1086.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42169/abstract/44\">",
"      Newman KD, Anderson KD, Van Meurs K, et al. Extracorporeal membrane oxygenation and congenital diaphragmatic hernia: should any infant be excluded? J Pediatr Surg 1990; 25:1048.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42169/abstract/45\">",
"      O'Rourke PP. Congenital diaphragmatic hernia: are there reliable clinical predictors? Crit Care Med 1993; 21:S380.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42169/abstract/46\">",
"      Flake AW. Fetal surgery for congenital diaphragmatic hernia. Semin Pediatr Surg 1996; 5:266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42169/abstract/47\">",
"      Datin-Dorriere V, Rouzies S, Taupin P, et al. Prenatal prognosis in isolated congenital diaphragmatic hernia. Am J Obstet Gynecol 2008; 198:80.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42169/abstract/48\">",
"      Vogel M, McElhinney DB, Marcus E, et al. Significance and outcome of left heart hypoplasia in fetal congenital diaphragmatic hernia. Ultrasound Obstet Gynecol 2010; 35:310.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42169/abstract/49\">",
"      Mullassery D, Ba'ath ME, Jesudason EC, Losty PD. Value of liver herniation in prediction of outcome in fetal congenital diaphragmatic hernia: a systematic review and meta-analysis. Ultrasound Obstet Gynecol 2010; 35:609.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42169/abstract/50\">",
"      Worley KC, Dashe JS, Barber RG, et al. Fetal magnetic resonance imaging in isolated diaphragmatic hernia: volume of herniated liver and neonatal outcome. Am J Obstet Gynecol 2009; 200:318.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42169/abstract/51\">",
"      Hubbard AM, Crombleholme TM, Adzick NS, et al. Prenatal MRI evaluation of congenital diaphragmatic hernia. Am J Perinatol 1999; 16:407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42169/abstract/52\">",
"      Hubbard AM, Adzick NS, Crombleholme TM, Haselgrove JC. Left-sided congenital diaphragmatic hernia: value of prenatal MR imaging in preparation for fetal surgery. Radiology 1997; 203:636.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42169/abstract/53\">",
"      B&uuml;sing KA, Kilian AK, Schaible T, et al. MR relative fetal lung volume in congenital diaphragmatic hernia: survival and need for extracorporeal membrane oxygenation. Radiology 2008; 248:240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42169/abstract/54\">",
"      Paek BW, Coakley FV, Lu Y, et al. Congenital diaphragmatic hernia: prenatal evaluation with MR lung volumetry--preliminary experience. Radiology 2001; 220:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42169/abstract/55\">",
"      Mahieu-Caputo D, Sonigo P, Dommergues M, et al. Fetal lung volume measurement by magnetic resonance imaging in congenital diaphragmatic hernia. BJOG 2001; 108:863.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42169/abstract/56\">",
"      Gorincour G, Bouvenot J, Mourot MG, et al. Prenatal prognosis of congenital diaphragmatic hernia using magnetic resonance imaging measurement of fetal lung volume. Ultrasound Obstet Gynecol 2005; 26:738.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42169/abstract/57\">",
"      Bonfils M, Emeriaud G, Durand C, et al. Fetal lung volume in congenital diaphragmatic hernia. Arch Dis Child Fetal Neonatal Ed 2006; 91:F363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42169/abstract/58\">",
"      Victoria T, Bebbington MW, Danzer E, et al. Use of magnetic resonance imaging in prenatal prognosis of the fetus with isolated left congenital diaphragmatic hernia. Prenat Diagn 2012; 32:715.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42169/abstract/59\">",
"      Jani JC, Cannie M, Peralta CF, et al. Lung volumes in fetuses with congenital diaphragmatic hernia: comparison of 3D US and MR imaging assessments. Radiology 2007; 244:575.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42169/abstract/60\">",
"      Peralta CF, Kazan-Tannus JF, Bunduki V, et al. Evaluation of the agreement between 3-dimensional ultrasonography and magnetic resonance imaging for fetal lung volume measurement. J Ultrasound Med 2006; 25:461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42169/abstract/61\">",
"      Ruano R, Joubin L, Sonigo P, et al. Fetal lung volume estimated by 3-dimensional ultrasonography and magnetic resonance imaging in cases with isolated congenital diaphragmatic hernia. J Ultrasound Med 2004; 23:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42169/abstract/62\">",
"      Hedrick HL, Crombleholme TM, Flake AW, et al. Right congenital diaphragmatic hernia: Prenatal assessment and outcome. J Pediatr Surg 2004; 39:319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42169/abstract/63\">",
"      Fisher JC, Jefferson RA, Arkovitz MS, Stolar CJ. Redefining outcomes in right congenital diaphragmatic hernia. J Pediatr Surg 2008; 43:373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42169/abstract/64\">",
"      Metkus AP, Filly RA, Stringer MD, et al. Sonographic predictors of survival in fetal diaphragmatic hernia. J Pediatr Surg 1996; 31:148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42169/abstract/65\">",
"      Lipshutz GS, Albanese CT, Feldstein VA, et al. Prospective analysis of lung-to-head ratio predicts survival for patients with prenatally diagnosed congenital diaphragmatic hernia. J Pediatr Surg 1997; 32:1634.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42169/abstract/66\">",
"      Sbragia L, Paek BW, Filly RA, et al. Congenital diaphragmatic hernia without herniation of the liver: does the lung-to-head ratio predict survival? J Ultrasound Med 2000; 19:845.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42169/abstract/67\">",
"      Keller RL, Glidden DV, Paek BW, et al. The lung-to-head ratio and fetoscopic temporary tracheal occlusion: prediction of survival in severe left congenital diaphragmatic hernia. Ultrasound Obstet Gynecol 2003; 21:244.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42169/abstract/68\">",
"      Laudy JA, Van Gucht M, Van Dooren MF, et al. Congenital diaphragmatic hernia: an evaluation of the prognostic value of the lung-to-head ratio and other prenatal parameters. Prenat Diagn 2003; 23:634.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42169/abstract/69\">",
"      Flake AW, Crombleholme TM, Johnson MP, et al. Treatment of severe congenital diaphragmatic hernia by fetal tracheal occlusion: clinical experience with fifteen cases. Am J Obstet Gynecol 2000; 183:1059.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42169/abstract/70\">",
"      Jani JC, Nicolaides KH, Gratac&oacute;s E, et al. Fetal lung-to-head ratio in the prediction of survival in severe left-sided diaphragmatic hernia treated by fetal endoscopic tracheal occlusion (FETO). Am J Obstet Gynecol 2006; 195:1646.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42169/abstract/71\">",
"      Yang SH, Nobuhara KK, Keller RL, et al. Reliability of the lung-to-head ratio as a predictor of outcome in fetuses with isolated left congenital diaphragmatic hernia at gestation outside 24-26 weeks. Am J Obstet Gynecol 2007; 197:30.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42169/abstract/72\">",
"      Jani J, Nicolaides KH, Keller RL, et al. Observed to expected lung area to head circumference ratio in the prediction of survival in fetuses with isolated diaphragmatic hernia. Ultrasound Obstet Gynecol 2007; 30:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42169/abstract/73\">",
"      Harrison MR, Sydorak RM, Farrell JA, et al. Fetoscopic temporary tracheal occlusion for congenital diaphragmatic hernia: prelude to a randomized, controlled trial. J Pediatr Surg 2003; 38:1012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42169/abstract/74\">",
"      Levine D, Barnewolt CE, Mehta TS, et al. Fetal thoracic abnormalities: MR imaging. Radiology 2003; 228:379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42169/abstract/75\">",
"      B&uuml;sing KA, Kilian AK, Schaible T, et al. Reliability and validity of MR image lung volume measurement in fetuses with congenital diaphragmatic hernia and in vitro lung models. Radiology 2008; 246:553.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42169/abstract/76\">",
"      Harrison MR, Adzick NS, Estes JM, Howell LJ. A prospective study of the outcome for fetuses with diaphragmatic hernia. JAMA 1994; 271:382.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42169/abstract/77\">",
"      Boucherat O, Benachi A, Chailley-Heu B, et al. Surfactant maturation is not delayed in human fetuses with diaphragmatic hernia. PLoS Med 2007; 4:e237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42169/abstract/78\">",
"      Lally KP, Bagolan P, Hosie S, et al. Corticosteroids for fetuses with congenital diaphragmatic hernia: can we show benefit? J Pediatr Surg 2006; 41:668.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42169/abstract/79\">",
"      Davey M, Shegu S, Danzer E, et al. Pulmonary arteriole muscularization in lambs with diaphragmatic hernia after combined tracheal occlusion/glucocorticoid therapy. Am J Obstet Gynecol 2007; 197:381.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42169/abstract/80\">",
"      Davey MG, Danzer E, Schwarz U, et al. Prenatal glucocorticoids and exogenous surfactant therapy improve respiratory function in lambs with severe diaphragmatic hernia following fetal tracheal occlusion. Pediatr Res 2006; 60:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42169/abstract/81\">",
"      Davey MG, Danzer E, Schwarz U, et al. Prenatal glucocorticoids improve lung morphology and partially restores surfactant mRNA expression in lambs with diaphragmatic hernia undergoing fetal tracheal occlusion. Pediatr Pulmonol 2006; 41:1188.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42169/abstract/82\">",
"      Logan JW, Rice HE, Goldberg RN, Cotten CM. Congenital diaphragmatic hernia: a systematic review and summary of best-evidence practice strategies. J Perinatol 2007; 27:535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42169/abstract/83\">",
"      Frenckner BP, Lally PA, Hintz SR, et al. Prenatal diagnosis of congenital diaphragmatic hernia: how should the babies be delivered? J Pediatr Surg 2007; 42:1533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42169/abstract/84\">",
"      Stevens TP, van Wijngaarden E, Ackerman KG, et al. Timing of delivery and survival rates for infants with prenatal diagnoses of congenital diaphragmatic hernia. Pediatrics 2009; 123:494.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42169/abstract/85\">",
"      Doyle NM, Lally KP. The CDH Study Group and advances in the clinical care of the patient with congenital diaphragmatic hernia. Semin Perinatol 2004; 28:174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42169/abstract/86\">",
"      Harrison MR, Bressack MA, Churg AM, de Lorimier AA. Correction of congenital diaphragmatic hernia in utero. II. Simulated correction permits fetal lung growth with survival at birth. Surgery 1980; 88:260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42169/abstract/87\">",
"      Harrison MR, Adzick NS, Flake AW, Jennings RW. The CDH two-step: a dance of necessity. J Pediatr Surg 1993; 28:813.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42169/abstract/88\">",
"      Harrison MR, Adzick NS, Bullard KM, et al. Correction of congenital diaphragmatic hernia in utero VII: a prospective trial. J Pediatr Surg 1997; 32:1637.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42169/abstract/89\">",
"      Harrison MR, Mychaliska GB, Albanese CT, et al. Correction of congenital diaphragmatic hernia in utero IX: fetuses with poor prognosis (liver herniation and low lung-to-head ratio) can be saved by fetoscopic temporary tracheal occlusion. J Pediatr Surg 1998; 33:1017.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42169/abstract/90\">",
"      Fewell JE, Hislop AA, Kitterman JA, Johnson P. Effect of tracheostomy on lung development in fetal lambs. J Appl Physiol 1983; 55:1103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42169/abstract/91\">",
"      Alcorn D, Adamson TM, Lambert TF, et al. Morphological effects of chronic tracheal ligation and drainage in the fetal lamb lung. J Anat 1977; 123:649.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42169/abstract/92\">",
"      Adzick NS, Harrison MR, Glick PL, et al. Experimental pulmonary hypoplasia and oligohydramnios: relative contributions of lung fluid and fetal breathing movements. J Pediatr Surg 1984; 19:658.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42169/abstract/93\">",
"      Harding R, Bocking AD, Sigger JN. Influence of upper respiratory tract on liquid flow to and from fetal lungs. J Appl Physiol 1986; 61:68.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42169/abstract/94\">",
"      Wilson JM, DiFiore JW, Peters CA. Experimental fetal tracheal ligation prevents the pulmonary hypoplasia associated with fetal nephrectomy: possible application for congenital diaphragmatic hernia. J Pediatr Surg 1993; 28:1433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42169/abstract/95\">",
"      DiFiore JW, Fauza DO, Slavin R, et al. Experimental fetal tracheal ligation reverses the structural and physiological effects of pulmonary hypoplasia in congenital diaphragmatic hernia. J Pediatr Surg 1994; 29:248.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42169/abstract/96\">",
"      Hedrick MH, Estes JM, Sullivan KM, et al. Plug the lung until it grows (PLUG): a new method to treat congenital diaphragmatic hernia in utero. J Pediatr Surg 1994; 29:612.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42169/abstract/97\">",
"      Peralta CF, Jani JC, Van Schoubroeck D, et al. Fetal lung volume after endoscopic tracheal occlusion in the prediction of postnatal outcome. Am J Obstet Gynecol 2008; 198:60.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42169/abstract/98\">",
"      Harrison MR, Adzick NS, Flake AW, et al. Correction of congenital diaphragmatic hernia in utero VIII: Response of the hypoplastic lung to tracheal occlusion. J Pediatr Surg 1996; 31:1339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42169/abstract/99\">",
"      Benachi A, Chailley-Heu B, Delezoide AL, et al. Lung growth and maturation after tracheal occlusion in diaphragmatic hernia. Am J Respir Crit Care Med 1998; 157:921.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42169/abstract/100\">",
"      De Paepe ME, Johnson BD, Papadakis K, et al. Temporal pattern of accelerated lung growth after tracheal occlusion in the fetal rabbit. Am J Pathol 1998; 152:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42169/abstract/101\">",
"      Piedboeuf B, Laberge JM, Ghitulescu G, et al. Deleterious effect of tracheal obstruction on type II pneumocytes in fetal sheep. Pediatr Res 1997; 41:473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42169/abstract/102\">",
"      Davey MG, Hedrick HL, Bouchard S, et al. Temporary tracheal occlusion in fetal sheep with lung hypoplasia does not improve postnatal lung function. J Appl Physiol 2003; 94:1054.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42169/abstract/103\">",
"      VanderWall KJ, Bruch SW, Meuli M, et al. Fetal endoscopic ('Fetendo') tracheal clip. J Pediatr Surg 1996; 31:1101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42169/abstract/104\">",
"      VanderWall KJ, Skarsgard ED, Filly RA, et al. Fetendo-clip: a fetal endoscopic tracheal clip procedure in a human fetus. J Pediatr Surg 1997; 32:970.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42169/abstract/105\">",
"      Ruano R, da Silva MM, Campos JA, et al. Fetal pulmonary response after fetoscopic tracheal occlusion for severe isolated congenital diaphragmatic hernia. Obstet Gynecol 2012; 119:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42169/abstract/106\">",
"      Harrison MR, Keller RL, Hawgood SB, et al. A randomized trial of fetal endoscopic tracheal occlusion for severe fetal congenital diaphragmatic hernia. N Engl J Med 2003; 349:1916.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42169/abstract/107\">",
"      Deprest J, Gratacos E, Nicolaides KH, FETO Task Group. Fetoscopic tracheal occlusion (FETO) for severe congenital diaphragmatic hernia: evolution of a technique and preliminary results. Ultrasound Obstet Gynecol 2004; 24:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42169/abstract/108\">",
"      Deprest J, Jani J, Van Schoubroeck D, et al. Current consequences of prenatal diagnosis of congenital diaphragmatic hernia. J Pediatr Surg 2006; 41:423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42169/abstract/109\">",
"      Czeizel A, Kov&aacute;cs M. A family study of congenital diaphragmatic defects. Am J Med Genet 1985; 21:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42169/abstract/110\">",
"      David TJ, Illingworth CA. Diaphragmatic hernia in the south-west of England. J Med Genet 1976; 13:253.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6800 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-213.131.41.98-90976AC03E-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_11_42169=[""].join("\n");
var outline_f41_11_42169=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H25\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EMBRYOLOGY AND PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      ANATOMICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      INCIDENCE AND EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      PRENATAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Ultrasound findings",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Associated anomalies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Isolated CDH",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Complex, nonisolated or syndromic CDH (CDH+)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Differential diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      PROGNOSTIC FACTORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Liver herniation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Fetal lung volume",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Right versus left sided lesion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Lung area to head circumference ratio",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      OBSTETRICAL MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Work-up",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Monitoring and intervention",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Lung maturity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Antenatal glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Timing and mode of delivery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      In utero therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      NEONATAL MANAGEMENT AND OUTCOME",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      RECURRENCE RISK",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"OBGYN/6800\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/6800|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?9/13/9426\" title=\"diagnostic image 1\">",
"      MR fetal liver herniation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?27/19/27956\" title=\"diagnostic image 2\">",
"      U-S fetal liver herniation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?20/63/21488\" title=\"diagnostic image 3\">",
"      Lung area HC ratio",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?20/2/20513\" title=\"diagnostic image 4\">",
"      Tracheal occlusion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/6800|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?14/63/15347\" title=\"figure 1\">",
"      Tracheal occlusion for CDH",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/55/31610?source=related_link\">",
"      Antenatal corticosteroid therapy for reduction of neonatal morbidity and mortality from preterm delivery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/23/28026?source=related_link\">",
"      Congenital diaphragmatic hernia in the neonate",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?2/6/2146?source=related_link\">",
"      Patient information: Congenital hernia of the diaphragm (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f41_11_42170="Overview of the clinical manifestations of sickle cell disease";
var content_f41_11_42170=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"7\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Overview of the clinical manifestations of sickle cell disease",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?41/11/42170/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/11/42170/contributors\">",
"     Elliott P Vichinsky, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?41/11/42170/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/11/42170/contributors\">",
"     Stanley L Schrier, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?41/11/42170/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/11/42170/contributors\">",
"     Jennifer S Tirnauer, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?41/11/42170/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 16, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vaso-occlusive phenomena and hemolysis are the clinical hallmarks of sickle cell disease (SCD), an inherited disorder due to homozygosity for the abnormal hemoglobin, hemoglobin S (HbS). Vaso-occlusion results in recurrent painful episodes (previously called sickle cell crisis) and a variety of serious organ system complications that can lead to life-long disabilities",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    early death.",
"   </p>",
"   <p>",
"    Hemoglobin S (HbS), results from the substitution of a valine for glutamic acid as the sixth amino acid of the beta globin chain, which produces a hemoglobin tetramer",
"    <span class=\"nowrap\">",
"     (alpha2/beta",
"    </span>",
"    S2) that is poorly soluble when deoxygenated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/11/42170/abstract/1\">",
"     1",
"    </a>",
"    ]. The polymerization of deoxy HbS is essential to vaso-occlusive phenomena [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/11/42170/abstract/1\">",
"     1",
"    </a>",
"    ]. The polymer assumes the form of an elongated rope-like fiber, which usually aligns with other fibers, resulting in distortion into the classic crescent or sickle shape (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef77366 \" href=\"mobipreview.htm?43/18/44335\">",
"     image 1",
"    </a>",
"    ) and a marked decrease in red cell deformability. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/25/30104?source=see_link\">",
"     \"Sickle hemoglobin polymer: Structure and functional properties\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This polymerization process is altered by several factors. Fetal hemoglobin (HbF) is a major modulator of polymerization in that the higher the HbF levels, the more benign the clinical and hematologic features of sickle cell anemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/11/42170/abstract/2\">",
"     2",
"    </a>",
"    ]. However, polymerization alone does not account for the pathophysiology of SCD. Subsequent changes in red cell membrane structure and function, disordered cell volume control, and increased adherence to vascular endothelium also play an important role [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/11/42170/abstract/1,3\">",
"     1,3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An overview of the clinical manifestations of homozygous SCD will be presented here, with more complete discussions of the major clinical manifestations presented separately (eg, pulmonary, renal, bone and joint, cerebrovascular disease) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/11/42170/abstract/4\">",
"     4",
"    </a>",
"    ]. The diagnosis and treatment of SCD and the management of pregnancy in SCD are also discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/54/42856?source=see_link\">",
"     \"Diagnosis of sickle cell syndromes\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/0/39946?source=see_link\">",
"     \"Overview of the management of sickle cell disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/33/34330?source=see_link\">",
"     \"Specific therapies for sickle cell disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/62/20458?source=see_link\">",
"     \"Pregnancy in women with sickle cell disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     GENERAL OVERVIEW",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical manifestations of sickle cell disease vary markedly among the major genotypes. The following general principles apply to the major sickle cell subtypes. However, within each subtype, there can be a marked variability in disease severity. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/5/5209?source=see_link\">",
"     \"Variant sickle cell syndromes\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The term sickle cell disease (SCD) is generally used to describe all of the conditions associated with the phenomenon of sickling, whereas the term sickle cell anemia is generally used to describe homozygosity for hemoglobin S (ie, Hb SS).",
"     </li>",
"     <li>",
"      The disorder is most severe in patients with homozygosity for HbS, of intermediate severity in hemoglobin SC disease (HbSC, combined heterozygosity for hemoglobins S and C), and generally benign in those with sickle cell trait (heterozygosity for HbS). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?5/5/5209?source=see_link\">",
"       \"Variant sickle cell syndromes\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Among patients with sickle cell-beta thalassemia, the disease varies with the quantity of hemoglobin A, often being quite severe in patients with sickle cell-beta (0) thalassemia and less severe in patients with sickle cell-beta (+) thalassemia. This difference may not apply to cerebrovascular disease. In one series of 3647 patients from the Cooperative Study of Sickle Cell Disease, for example, the age-adjusted incidence of cerebrovascular accident per 100 patient years was 0.61 in SCD, 0.15 in HbSC disease, and 0.09 and 0.08 in sickle cell-beta (+) thalassemia and sickle cell-beta (0) thalassemia, respectively (",
"      <a class=\"graphic graphic_figure graphicRef61397 \" href=\"mobipreview.htm?40/31/41469\">",
"       figure 1",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/11/42170/abstract/5\">",
"       5",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Among patients with coexisting alpha thalassemia, the anemia is less severe (because of a lower cellular hemoglobin concentration) but the effects on the clinical manifestations are variable.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients with homozygous Hb S are typically anemic and often lead a life punctuated by recurrent painful vasoocclusive episodes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/11/42170/abstract/6\">",
"     6",
"    </a>",
"    ]. Clinical signs and symptoms typically develop at an early age. This was illustrated in a study of 305 children diagnosed at birth in whom the prevalence of symptoms according to age was as follows [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/11/42170/abstract/7\">",
"     7",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Six months of age &mdash; 6 percent",
"     </li>",
"     <li>",
"      Twelve months of age &mdash; 32 percent",
"     </li>",
"     <li>",
"      Two years of age &mdash; 61 percent",
"     </li>",
"     <li>",
"      Six years of age &mdash; 92 percent",
"     </li>",
"     <li>",
"      Eight years of age &mdash; 96 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Dactylitis (acute pain in the hands",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    feet) was the most common initial symptom, occurring in 40 percent overall and 50 percent of children who became symptomatic before age two. An acute episode of pain was the initial symptom in more than 25 percent and was the most frequent initial symptom after the age of two. The third major presenting symptom was splenic sequestration, occurring in 20 percent overall and one-third before age two. Over time, vaso-occlusion can occur in virtually every organ system, accounting for the characteristic acute and chronic multisystem failure associated with this disease. Progressive vaso-occlusion resulting in multiorgan dysfunction often occurs without any overt clinical manifestations.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Survival and prognosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Overall survival of patients with SCD is reduced, but has been improving steadily following institution of comprehensive care, immunizations, antibiotics,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/16/16648?source=see_link\">",
"     hydroxyurea",
"    </a>",
"    , and more rapid treatment of disease complications. In regions where comprehensive care is available, the disease has shifted from a fatal pediatric illness to a chronic disease associated with progressive deterioration in quality of life and organ function [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/11/42170/abstract/8\">",
"     8",
"    </a>",
"    ]. However, in many parts of the world, sickle cell disease is a major cause of death in young children, often due to infections and other complications [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/11/42170/abstract/9\">",
"     9",
"    </a>",
"    ], with a mortality rate under five years of age of at least 7 per 100 person-years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/11/42170/abstract/10\">",
"     10",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/0/39946?source=see_link&amp;anchor=H2#H2\">",
"     \"Overview of the management of sickle cell disease\", section on 'General principles'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The Center for Disease Control and Prevention's National Center for Health Statistics has analyzed trends in pediatric sickle cell disease-related mortality from 1983 through 2002 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/11/42170/abstract/11\">",
"     11",
"    </a>",
"    ]. There has been a 68 percent reduction in SCD mortality for ages zero to three years and a 39 percent decline for ages four through nine. In contrast, the mortality rate in the group older than 10 years was slightly higher. This lack of significant improvement in survival among older children was noted in a report on Medicaid-enrolled children from the state of Tennessee. They found SCD patients &gt;10 years had an eight-times greater mortality than matched non-SCD children.",
"   </p>",
"   <p>",
"    The largest prospective cohort of children followed for survival is the Dallas Newborn Cohort, which consists of 711 subjects born in Texas on or after November 1, 1983, identified by newborn screening to have SCD, and treated at a single comprehensive sickle cell center for up to 18 years. Results of the long-term follow-up of this cohort, as reported in 2004, include [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/11/42170/abstract/12\">",
"     12",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There were 25 deaths at a mean age of 5.6 years. Fifteen of the deaths were probably related to SCD, with infection (5 deaths) being the most common cause. The overall rate of death was 0.59 per 100 patient-years. The most common ages of death were from four to six years of age.",
"     </li>",
"     <li>",
"      Thirty children had at least one stroke, with an overall rate of 0.85 per 100 patient-years. The first clinical stroke occurred most frequently between two and eight years of age.",
"     </li>",
"     <li>",
"      No SCD-related deaths or strokes occurred in children with HbSC disease or sickle cell-beta(+) thalassemia. The estimated cumulative overall, SCD-related complication-free, and stroke-free survivals at 18 years were 85.6, 93.6, and 88.5 percent, respectively.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    As of a 2010 report, the Dallas Newborn Cohort now comprises 940 subjects with 8857 years of follow-up. The following observations were made [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/11/42170/abstract/13\">",
"     13",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The incidence of death among patients with HbSS and",
"      <span class=\"nowrap\">",
"       HbS/beta(0)",
"      </span>",
"      thalassemia has been decreasing steadily, with death rates (deaths per 100 patient-years) of 0.67, 0.37, and 0.15 for the eras 1983 to 1990, 1991 to 1999, and 2000 to 2007, respectively.",
"     </li>",
"     <li>",
"      The estimated overall survival at 18 years is now 94 percent for those with HbSS or",
"      <span class=\"nowrap\">",
"       HbS/beta(0)",
"      </span>",
"      thalassemia and 98 percent for those with HbSC or",
"      <span class=\"nowrap\">",
"       HbS/beta(+)",
"      </span>",
"      thalassemia. The highest incidence of death was in patients 15 years and older, which was at least 3 times the incidence in younger age groups.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The median age of death in the Dallas cohort has gradually changed from 3 years in 1983 to 17 years after 2001. Acute chest syndrome and multi-organ failure now replace bacterial sepsis as the leading causes of death. All of the seven deaths in this cohort since 2002 have been in subjects &ge;18 years of age; of these, six occurred after the patient was transferred from pediatric to adult medical care.",
"   </p>",
"   <p>",
"    In summary, mortality trends indicate that infants and young children with SCD are surviving because of the employment of comprehensive care, in large part because of decreased sepsis from early use of prophylactic antibiotics and bacterial vaccines. However, there is a disturbing increase in mortality of older children and adults that may reflect access to care and inadequate preventive measures for acute chest syndrome and organ failure.",
"   </p>",
"   <p>",
"    As an example of this phenomenon of death from late complications of SCD, plasma samples from 758 patients enrolled in the Cooperative Study of Sickle Cell Disease were analyzed for N-terminal-pro brain natriuretic peptide (NT-proBNP), a biomarker elevated in pulmonary arterial and venous hypertension, a major complication of SCD. Findings of this study included [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/11/42170/abstract/14\">",
"     14",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The incidence rate of the development of a high NT-proBNP level in subjects with a normal baseline level was",
"      <span class=\"nowrap\">",
"       1.03/100",
"      </span>",
"      person-years in the pediatric cohort and",
"      <span class=\"nowrap\">",
"       8.59/100",
"      </span>",
"      person-years in the adult cohort.",
"     </li>",
"     <li>",
"      A NT-proBNP level &ge;160",
"      <span class=\"nowrap\">",
"       ng/L",
"      </span>",
"      was present in 28 percent of adult patients with SCD and was an independent predictor of mortality (RR 6.24; 95% CI 2.9-13.3). High levels were also associated with markers of hemolytic anemia.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Early predictors of morbidity and mortality",
"    </span>",
"    &nbsp;&mdash;&nbsp;Attempts have been made to identify infants and children with SCD who will be at high risk for complications later in life [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/11/42170/abstract/15-17\">",
"     15-17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In one report from the Cooperative Study of Sickle Cell disease, 392 infants diagnosed with SCD or sickle cell-beta (0) thalassemia before the age of six months were followed with comprehensive clinical and laboratory data for a mean of 10 years; the results obtained before the age of two years were evaluated to determine whether they predicted the outcome later in life [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/11/42170/abstract/15\">",
"     15",
"    </a>",
"    ]. An adverse outcome, defined as stroke, frequent episodes of pain, recurrent acute chest syndrome, or death, occurred in 18 percent. Three significant predictors of an adverse outcome were identified:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Dactylitis before age one (relative risk [RR] 2.6)",
"     </li>",
"     <li>",
"      Hemoglobin concentration &lt;7",
"      <span class=\"nowrap\">",
"       g/dL",
"      </span>",
"      (RR 2.5)",
"     </li>",
"     <li>",
"      Leukocytosis in the absence of infection (RR 1.8)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A similar long-term study in 168 children from the Dallas Newborn Cohort who were followed for a mean of 7.1 years, was not able to confirm the utility of this model, with the possible exception of the leukocyte count [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/11/42170/abstract/17\">",
"     17",
"    </a>",
"    ]. Specifically, hospitalization in the first three years of life for painful events, dactylitis, or acute chest syndrome (ACS) did not predict for death or stroke after the third birthday [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/11/42170/abstract/16\">",
"     16",
"    </a>",
"    ]. However, early ACS significantly increased the odds of more frequent episodes of ACS during childhood (OR 2.5; 95% CI 1.7-3.9).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     LABORATORY FINDINGS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     CBC and routine laboratory testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;The chronic hemolysis of sickle cell disease is usually associated with a mild to moderate anemia (hematocrit 20 to 30 percent), reticulocytosis of 3 to 15 percent, unconjugated hyperbilirubinemia, elevated serum lactate dehydrogenase, and low serum haptoglobin. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/3/18489?source=see_link&amp;anchor=H16#H16\">",
"     \"Approach to the diagnosis of hemolytic anemia in the adult\", section on 'Diagnostic approach'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The peripheral blood smear may reveal sickled red cells, polychromasia indicative of reticulocytosis, and Howell-Jolly bodies reflecting hyposplenia secondary to repeated splenic infarctions (",
"    <a class=\"graphic graphic_picture graphicRef64449 \" href=\"mobipreview.htm?1/42/1703\">",
"     picture 1",
"    </a>",
"    ). The red cells are generally normocytic and normochromic unless there is coexistent alpha or beta thalassemia or iron deficiency, in which case microcytosis and hypochromia may be present. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/46/29418?source=see_link&amp;anchor=H22#H22\">",
"     \"Approach to the adult patient with anemia\", section on 'Microcytic anemia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Fetal hemoglobin (HbF) is usually slightly to moderately elevated and is a function of the number of reticulocytes that contain HbF, the extent of selective survival of HbF-containing reticulocytes to become mature HbF-containing erythrocytes, and the amount of HbF per red cell. Each variable is separately regulated and the expression of each shows interpatient variability [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/11/42170/abstract/18\">",
"     18",
"    </a>",
"    ]. In some patients with SCD alone, values are as high (1 to 4 percent) as the modest elevations seen in heterocellular hereditary persistence of fetal hemoglobin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/11/42170/abstract/18\">",
"     18",
"    </a>",
"    ]. Patients treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/16/16648?source=see_link\">",
"     hydroxyurea",
"    </a>",
"    may have levels of HbF of 15 percent or more. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/33/34330?source=see_link&amp;anchor=H5#H5\">",
"     \"Specific therapies for sickle cell disease\", section on 'Hydroxyurea'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition, certain beta globin haplotypes appear to be related to factors that regulate production of HbF. As examples, the Arab-Indian and Senegal haplotypes are associated with higher levels of HbF (over 20 percent in some cases), probably due to linkage with important gamma globin regulatory sequences in the locus control region [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/11/42170/abstract/19-21\">",
"     19-21",
"    </a>",
"    ]. In one study of Senegalese patients, the mean HbF was 8.2 percent, and approximately one-half of patients had a benign form of sickle cell anemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/11/42170/abstract/21\">",
"     21",
"    </a>",
"    ]. Genetic linkage and genome-wide association studies have identified single nucleotide polymorphisms that modulate fetal hemoglobin and the clinical phenotype of sickle cell disease. BCL11A, a regulator of gamma globin gene expression, is an important regulator that has been identified through these studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/11/42170/abstract/22\">",
"     22",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/32/39434?source=see_link&amp;anchor=H4#H4\">",
"     \"Clinical variability in sickle cell anemia\", section on 'Control of HbF expression'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/29/23001?source=see_link&amp;anchor=H15#H15\">",
"     \"Structure and function of normal human hemoglobins\", section on 'Fetal hemoglobin'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A comprehensive analysis of the clinical laboratory data collected from 2600 subjects with sickle cell disease found the following [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/11/42170/abstract/23\">",
"     23",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In patients with SCD, mean white blood cell (WBC) counts were higher than normal, particularly in those under the age of 10, and mean platelet counts were elevated, particularly in those under the age of 18. Mean WBC and platelet counts were not elevated in HbSC disease or sickle cell-beta (+) thalassemia. Elevated WBC is linked to the pathophysiology of sickle cell disease and increases the morbidity [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/11/42170/abstract/24\">",
"       24",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?13/63/14330?source=see_link&amp;anchor=H18#H18\">",
"       \"Vasoocclusion in sickle cell disease\", section on 'Leukocytes and inflammation'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Mean serum bilirubin concentrations were higher in SCD than in HbSC disease or sickle cell-beta (+) thalassemia due to the greater hemolytic rate. The serum bilirubin rose after the first decade, possibly due to chronic hepatobiliary dysfunction. Serum aminotransferase concentrations were often elevated, particularly in adults with SCD, but mean levels were normal. Serum alkaline phosphatase was elevated in all genotypes until puberty, which occurred later in males and in those with SCD.",
"     </li>",
"     <li>",
"      Serum creatinine concentrations were low in all genotypes until 18 years of age, due in part to an initial elevation in glomerular filtration rate, when males experienced a rise apparently related to increasing muscle mass. Serum creatinine increased with age in all genotypes due to declining renal function. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?6/3/6202?source=see_link\">",
"       \"Renal manifestations of sickle cell disease\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Hemoglobin electrophoresis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hemoglobin electrophoretic patterns in the various sickle cell disorders are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/54/42856?source=see_link&amp;anchor=H12#H12\">",
"     \"Diagnosis of sickle cell syndromes\", section on 'Findings in sickle cell disease'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/5/5209?source=see_link\">",
"     \"Variant sickle cell syndromes\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Anemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;The anemia of SCA is usually a chronic, reasonably well-compensated hemolytic anemia with an appropriate reticulocytosis. In one series, for example, the mean hemoglobin and hematocrit concentrations were 7.9",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    and 22.9 percent, respectively, with an absolute reticulocyte count of",
"    <span class=\"nowrap\">",
"     501,000/microL",
"    </span>",
"    (normal 25,000 to",
"    <span class=\"nowrap\">",
"     75,000/microL)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/11/42170/abstract/25\">",
"     25",
"    </a>",
"    ]. The erythrocytes in SCD are destroyed randomly, with a mean life span of 17 days (normal: 110 to 120 days) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/11/42170/abstract/23,26\">",
"     23,26",
"    </a>",
"    ]. Other SCD variants are less anemic with an appropriate compensated reticulocytosis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/30/36326?source=see_link\">",
"     \"Red blood cell survival: Normal values and measurement\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A number of factors other than chronic hemolysis can contribute to the anemia. These include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Inappropriately low serum erythropoietin (EPO) concentrations, which may result in deficient compensation for hemolysis (ie, chronic relative reticulocytopenia, chRR) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/11/42170/abstract/27\">",
"       27",
"      </a>",
"      ]. This effect is more pronounced in adults, possibly due to progressive renal disease [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/11/42170/abstract/23,27\">",
"       23,27",
"      </a>",
"      ]. However, in one study, chRR along with inappropriately low levels of EPO was found even in patients with normal serum creatinine, and was associated with a significantly increased risk of death (HR 3.60; 95% CI 2.05-6.33) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/11/42170/abstract/28\">",
"       28",
"      </a>",
"      ]. Increased plasma viscosity may play a contributory role [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/11/42170/abstract/29\">",
"       29",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?6/3/6202?source=see_link\">",
"       \"Renal manifestations of sickle cell disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Folate",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      iron deficiency resulting from increased utilization of folate [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/11/42170/abstract/30,31\">",
"       30,31",
"      </a>",
"      ] and enhanced urinary losses of iron. The net effect is that iron deficiency is present in approximately 20 percent of patients with sickle cell disease [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/11/42170/abstract/32,33\">",
"       32,33",
"      </a>",
"      ]. The diagnosis of iron deficiency may be obscured by the elevated serum iron concentration associated with chronic hemolysis and the normal to increased mean corpuscular volume. A serum ferritin &lt;25",
"      <span class=\"nowrap\">",
"       ng/mL",
"      </span>",
"      or an elevated serum transferrin should be used to make this diagnosis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/11/42170/abstract/33\">",
"       33",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?25/39/26234?source=see_link\">",
"       \"Causes and diagnosis of anemia due to iron deficiency\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Acute severe anemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are three settings in which an acute fall in hemoglobin concentration may be superimposed upon the chronic anemia: splenic sequestration crisis, aplastic crisis, and hyperhemolytic crisis. Affected patients with these complications usually present with pallor, weakness, and lethargy; fatalities are not uncommon.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Splenic sequestration crisis",
"    </span>",
"    &nbsp;&mdash;&nbsp;With splenic sequestration crisis, vaso-occlusion within the spleen and splenic pooling of red cells produce a marked fall in hemoglobin concentration accompanied by persistent reticulocytosis and a rapidly enlarging spleen [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/11/42170/abstract/7,34-36\">",
"     7,34-36",
"    </a>",
"    ]. There is a risk of hypovolemic shock, particularly in children. Although primarily associated with aplastic crisis, parvovirus B19 infection may also be a risk factor for splenic sequestration [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/11/42170/abstract/37\">",
"     37",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Aplastic crisis'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The subjects who are susceptible to this syndrome are those with SCD whose spleens have not yet undergone fibrosis secondary to multiple episodes of splenic infarction. Sequestration can occur as early as a few weeks of age and may cause death before sickle cell disease is diagnosed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/11/42170/abstract/38,39\">",
"     38,39",
"    </a>",
"    ]. Young children with SCD have as much as a 30 percent incidence of this complication [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/11/42170/abstract/35\">",
"     35",
"    </a>",
"    ] and, as noted above, it is the initial symptom in as many as 20 percent of patients overall and one-third before age two [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/11/42170/abstract/7\">",
"     7",
"    </a>",
"    ]. In comparison, patients with HbSC disease and sickle cell-thalassemia are at a much lower risk of early-onset functional asplenia because of the lesser incidence of splenic scarring and atrophy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/11/42170/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Infants with SC disease rarely have functional asplenia. However, after age four, functional asplenia increases and reaches 45 percent of patients over 12 years of age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/11/42170/abstract/40\">",
"     40",
"    </a>",
"    ]. While acute splenic sequestration crises occur in SC disease and S-Beta thalassemia, they are much less common. These patients more often develop chronic hypersplenism.",
"   </p>",
"   <p>",
"    Splenic sequestration crisis is associated with a 10 to 15 percent mortality rate, occurring before transfusions can be given [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/11/42170/abstract/34,35\">",
"     34,35",
"    </a>",
"    ]. Sequestration is recurrent in 50 percent of survivors; as a result, splenectomy is usually recommended after the first acute event [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/11/42170/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a report of 15 children who underwent elective open splenectomy for recurrent acute splenic sequestration crisis, the median age at splenectomy was 5 years (range: 13 months to 15 years) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/11/42170/abstract/41\">",
"     41",
"    </a>",
"    ]. No postsurgical complications were noted, and, at a median follow-up of 12 months, no child had developed bacterial infection. As had been noted by others, vasoocclusive events appeared to be more common post-splenectomy than before this procedure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/11/42170/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Aplastic crisis",
"    </span>",
"    &nbsp;&mdash;&nbsp;An aplastic crisis is characterized by the transient arrest of erythropoiesis, leading to abrupt reductions in hemoglobin concentration and red cell precursors in the bone marrow, and a markedly reduced number of reticulocytes in the peripheral blood (ie, reticulocytes &lt;1.0 percent and an absolute reticulocyte count &lt;10,000 per microL). (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Anemia'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/1/17433?source=see_link&amp;anchor=H17#H17\">",
"     \"Acquired pure red cell aplasia\", section on 'Presentation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Impaired erythropoiesis can be associated with a variety of infections. Most cases in children follow infection with human parvovirus B19, which specifically invades proliferating erythroid progenitors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/11/42170/abstract/43-45\">",
"     43-45",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/54/22377?source=see_link&amp;anchor=H10#H10\">",
"     \"Clinical manifestations and pathogenesis of human parvovirus B19 infection\", section on 'Hematologic manifestations'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/1/31767?source=see_link&amp;anchor=H5#H5\">",
"     \"Treatment and prevention of parvovirus B19 infection\", section on 'Transient aplastic crisis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In one report, aplastic crisis occurred in 118 of 177 B19-infected patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/11/42170/abstract/44\">",
"     44",
"    </a>",
"    ]. Over 60 percent of the children at risk showed serologic evidence of B19 infection by age 15; the high incidence of protective antibodies following infection makes parvovirus an uncommon cause of aplasia in SCD after this age.",
"   </p>",
"   <p>",
"    Other reported causes of transient aplasia are infections by Streptococcus pneumoniae, salmonella, streptococci, and Epstein-Barr virus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/11/42170/abstract/46,47\">",
"     46,47",
"    </a>",
"    ]. Affected patients require acute transfusion therapy. Reticulocytes typically reappear within 2 to 14 days [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/11/42170/abstract/45\">",
"     45",
"    </a>",
"    ]. Recurrent aplasia from parvovirus is rare, presumably due to persistent immunity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/11/42170/abstract/43,44\">",
"     43,44",
"    </a>",
"    ]. However, recurrence due to other causes is not uncommon.",
"   </p>",
"   <p>",
"    Parvovirus B19 infection also may be associated with other manifestations of SCD. One study examined the risks attendant to B19 infection in a population of children with SCD in which cumulative B19 infection rates were 26, 47, and 73 percent at 5, 10, and 20 years of age, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/11/42170/abstract/37\">",
"     37",
"    </a>",
"    ]. When compared with 4262 acute events in children not acutely infected with B19, the 76 events in acutely B19-infected children were associated with significantly higher risks for acute splenic sequestration (relative risk [RR] 11.4), painful episodes (RR 1.9), and fever (RR 3.2).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Hyperhemolytic crisis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hyperhemolytic crisis refers to the sudden exacerbation of anemia with reticulocytosis. This complication is rare, its cause is unknown, and some experts doubt its existence. Most such cases probably reflect occult splenic sequestration or aplastic crisis detected during a period of resolving reticulocytosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/11/42170/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, some episodes have been documented in multiply-transfused patients, consistent with a delayed transfusion reaction in which the patient's own cells (\"bystander hemolysis\"), as well as the transfused cells, were being destroyed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/11/42170/abstract/49-51\">",
"     49-51",
"    </a>",
"    ], although the cause of this destruction is unclear [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/11/42170/abstract/52-56\">",
"     52-56",
"    </a>",
"    ]. A number of anecdotal reports have noted response of this potentially fatal complication to treatment with IV immunoglobulin (eg, 0.4",
"    <span class=\"nowrap\">",
"     g/kg",
"    </span>",
"    per day for five days) plus corticosteroids (eg, intravenous",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?30/25/31129?source=see_link\">",
"     methylprednisolone",
"    </a>",
"    500",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    for two days) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/11/42170/abstract/51,52,57,58\">",
"     51,52,57,58",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"     Rituximab",
"    </a>",
"    has been used in hemolytic transfusion reactions with some success in sickle cell anemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/11/42170/abstract/59\">",
"     59",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/56/37766?source=see_link&amp;anchor=H5#H5\">",
"     \"Transfusion-associated immune and non immune-mediated hemolysis\", section on 'Hyperhemolytic crisis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition, accelerated hemolysis has been associated with acute sickle events including acute chest syndrome and painful crises. Other causes include drug exposure, infections, and occasionally associated enzyme deficiencies. In one report, seven of eight children with hyperhemolysis had associated glucose-6-phosphate dehydrogenase deficiency [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/11/42170/abstract/60,61\">",
"     60,61",
"    </a>",
"    ], an inherited disorder found in 10 to 15 percent of African-Americans, which is usually quite mild. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/62/13289?source=see_link&amp;anchor=H7#H7\">",
"     \"Genetics and pathophysiology of glucose-6-phosphate dehydrogenase deficiency\", section on 'G6PD A- variant'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     MAJOR CLINICAL MANIFESTATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Acute painful episodes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Episodes of acute pain, previously called sickle cell crisis, are the most common type of vasoocclusive event. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/63/14330?source=see_link\">",
"     \"Vasoocclusion in sickle cell disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Acute pain is the first symptom of disease in more than 25 percent of patients and is the most frequent symptom after the age of two years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/11/42170/abstract/7\">",
"     7",
"    </a>",
"    ]. Acute pain is also the complication for which patients with sickle cell disease commonly seek medical attention [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/11/42170/abstract/62,63\">",
"     62,63",
"    </a>",
"    ], although some of these episodes are short-lived and are managed at home [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/11/42170/abstract/64,65\">",
"     64,65",
"    </a>",
"    ]. The frequency of pain peaks between the ages of 19 and 39; more frequent pain is associated with a higher mortality rate in patients over age 19 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/11/42170/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is considerable variability in the severity and frequency of acute painful episodes experienced by patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/11/42170/abstract/65,66\">",
"     65,66",
"    </a>",
"    ]. In one large study, one-third of patients rarely had pain, one-third were hospitalized for pain approximately two to six times per year, and one-third had more than six pain-related hospitalizations per year [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/11/42170/abstract/67\">",
"     67",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Similar results were noted in a prospective evaluation of 3578 patients (ranging from newborns to age 66) by the Cooperative Study of Sickle Cell Disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/11/42170/abstract/6\">",
"     6",
"    </a>",
"    ]. Over a five-year period, the mean number of pain episodes per year was 0.8 in SCD, 1.0 in sickle cell-beta (0) thalassemia, and 0.4 in HbSC disease and sickle cell-beta (+) thalassemia. Among the patients with SCD, 40 percent had no painful episodes, while 1 percent had 3 to 10 episodes per year. Among patients with SCD over age 20, those with high rates of pain episodes tend to die earlier [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/11/42170/abstract/6,68\">",
"     6,68",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Pain frequency in this report correlated with high hemoglobin levels [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/11/42170/abstract/6\">",
"     6",
"    </a>",
"    ]. A similar observation has been made in another study in which a hemoglobin concentration &gt;8.5",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    was a major risk factor [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/11/42170/abstract/69\">",
"     69",
"    </a>",
"    ]. Low fetal hemoglobin levels also appear to be a risk factor [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/11/42170/abstract/6\">",
"     6",
"    </a>",
"    ]",
"   </p>",
"   <p>",
"    Most pain frequency studies have focused on emergency department or hospital visits. However, the increasing use of comprehensive long-term diary studies describe a different spectrum of painful events. One group studied pain by using a daily assessment diary in adults with sickle cell disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/11/42170/abstract/65\">",
"     65",
"    </a>",
"    ]. Pain was reported in 55 percent of analyzed patient days, while 29 percent of patients reported pain almost daily. In this study, a painful event without utilization of hospital care was the norm rather than the exception. A similar discrepancy between home-managed pain and hospital treatment has been observed in pediatric patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/11/42170/abstract/64\">",
"     64",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Pain may be precipitated by events such as weather conditions (eg, high wind speed, low humidity, atmospheric pollutants) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/11/42170/abstract/70-72\">",
"     70-72",
"    </a>",
"    ], dehydration, infection, stress, menses, alcohol consumption, nocturnal hypoxemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/11/42170/abstract/73,74\">",
"     73,74",
"    </a>",
"    ], and rarely obstructive sleep apnea [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/11/42170/abstract/75\">",
"     75",
"    </a>",
"    ]. However, the majority of painful episodes have no identifiable cause. The episodes can affect any area of the body, with the back, chest, extremities, and abdomen being most commonly affected; the pain severity can range from trivial to excruciating. Approximately one-half of episodes are accompanied by objective clinical signs such as fever, swelling, tenderness, tachypnea, hypertension, nausea, and vomiting. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/4/18506?source=see_link\">",
"     \"Bone and joint complications in sickle cell disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/30/16874?source=see_link&amp;anchor=H36#H36\">",
"     \"Differential diagnosis of abdominal pain in adults\", section on 'Sickle cell disease'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There are often premonitory symptoms and, in most instances, the episode lasts for two to seven days [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/11/42170/abstract/76\">",
"     76",
"    </a>",
"    ]. Frequent pain may generate feelings of despair, depression, and apathy that interfere with daily life and promote an existence that revolves around pain. A comprehensive approach to pain with an understanding of each patient&rsquo;s management plan is indicated. Many variables affect therapy such as opioid clearance, hyperalgesia, and pseudoaddiction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/11/42170/abstract/77\">",
"     77",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/45/17114?source=see_link\">",
"     \"Acute pain management in adults with sickle cell disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Laboratory studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no test to diagnose a vaso-occlusive event. Standard laboratory tests cannot be used to distinguish pain crisis from the baseline condition. The peripheral blood smear typically reveals that 5 to 50 percent of the red cells are irreversibly sickled cells (",
"    <a class=\"graphic graphic_picture graphicRef64449 \" href=\"mobipreview.htm?1/42/1703\">",
"     picture 1",
"    </a>",
"    ), although the presence of sickled forms on the peripheral smear is not diagnostic of an acute pain episode.",
"   </p>",
"   <p>",
"    The most promising laboratory indicators of acute vaso-occlusion are changes in the density distribution of sickle cell subpopulations and the rheologic properties of the blood [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/11/42170/abstract/78-80\">",
"     78-80",
"    </a>",
"    ]. There is often an increase in the fraction of dense cells and a decrease in the maximum deformability of sickle cells one to three days prior to the onset of pain; this is followed by a decrease in the number of dense cells, and an increase in red cell deformability to values higher than those seen in the steady state [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/11/42170/abstract/79\">",
"     79",
"    </a>",
"    ]. These observations suggest that the first phase of the crisis may be characterized by preferential trapping of deformable cells in the microcirculation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/11/42170/abstract/79\">",
"     79",
"    </a>",
"    ]; these deformable cells may be more likely to adhere to vascular endothelium [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/11/42170/abstract/78\">",
"     78",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The evolution of pain is also associated with changes in the levels of acute phase reactants (eg, C-reactive protein, fibrinogen) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/11/42170/abstract/80,81\">",
"     80,81",
"    </a>",
"    ], serum lactate dehydrogenase [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/11/42170/abstract/82\">",
"     82",
"    </a>",
"    ], interleukin-1, tumor necrosis factor, and serum viscosity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/11/42170/abstract/83\">",
"     83",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Neurologic complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Cooperative Study of Sickle Cell Disease found that 24 percent of individuals with sickle cell anemia experienced a clinical overt stroke by age 45. In childhood, 25 percent of children with sickle cell anemia have silent ischemic lesions that may impair neurocognitive function and predict for progressive disease. Transcranial Doppler Screening (TCD) of children detects increased blood flow in the Circle of Willis which strongly predicts stroke risk. These findings have resulted in all children with sickle cell anemia being screened for ischemic injury. Patients with elevated flow on TCD screening are placed on permanent transfusion therapy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/11/31930?source=see_link\">",
"     \"Cerebrovascular complications of sickle cell disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    As patients with sickle cell anemia age, they are also at risk for neurocognitive decline and intracranial hemorrhage. These findings have led to increased surveillance of adult patients for ischemic brain injury. One study evaluated neurocognitive function in neurologically asymptomatic adults with sickle cell anemia. Compared with healthy controls, neurologically intact adults with sickle cell anemia had poorer cognitive performance, which appears to correlate with age and hemoglobin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/11/42170/abstract/84\">",
"     84",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Chronic transfusion therapy is the mainstay therapy for patients with overt central nervous system injury as well as those with abnormal TCD screening.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/16/16648?source=see_link\">",
"     Hydroxyurea",
"    </a>",
"    has been evaluated as an alternative option in selected patients. The &ldquo;SWiTCH&rdquo; trial randomly assigned stable patients with a history of a stroke to receive either transfusion or hydroxyurea. The study was stopped early because of the increased rate of stroke in the hydroxyurea treatment group [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/11/42170/abstract/85\">",
"     85",
"    </a>",
"    ]. This subject is discussed in depth separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/11/31930?source=see_link&amp;anchor=H3#H3\">",
"     \"Cerebrovascular complications of sickle cell disease\", section on 'Cerebral infarction'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Bone marrow transplantation is often considered in those children with these complications and sibling matches [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/11/42170/abstract/84\">",
"     84",
"    </a>",
"    ]. The success of sibling-matched transplantation for children with sickle cell disease has led to trials evaluating unrelated, matched cord blood transplantation in sickle cell patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/11/42170/abstract/86\">",
"     86",
"    </a>",
"    ]. These experimental trials are ongoing. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/3/30775?source=see_link\">",
"     \"Hematopoietic cell transplantation in sickle cell disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Epilepsy in individuals with sickle cell disease is two to three times more common than in non-sickle populations and is associated with increased all-cause mortality. This was shown in an examination of all records of the 543 persons in the Jamaica sickle cell cohort, in which the five-year cumulative incidence of febrile convulsions was 2.2 percent and the incidence rate of epilepsy was 100 per 100,000 person-years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/11/42170/abstract/87\">",
"     87",
"    </a>",
"    ]. Male gender (OR 4.0; 95% CI 1.03-20) and dactylitis in childhood (OR 17; 95% CI 4.8-63) were associated with an increased risk of developing epilepsy. The hazard ratios for all-cause mortality were 3.6, 2.3, and 3.4 for those with acute symptomatic seizures, a single seizure, or epilepsy, respectively. That both acute symptomatic seizures and stroke occurred during the same period of life (ie, before the 11",
"    <sup>",
"     th",
"    </sup>",
"    birthday) suggests a shared pathologic process.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Multiorgan failure",
"    </span>",
"    &nbsp;&mdash;&nbsp;The potentially fatal acute multiorgan failure syndrome is most often seen during severe pain episodes in patients with SCD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/11/42170/abstract/88\">",
"     88",
"    </a>",
"    ]. The pathogenesis of this syndrome in SCD is uncertain but may be reversed by prompt and aggressive exchange transfusion therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/11/42170/abstract/88,89\">",
"     88,89",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/10/24744?source=see_link\">",
"     \"Sepsis and the systemic inflammatory response syndrome: Definitions, epidemiology, and prognosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Psychosocial issues",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most patients with sickle cell disease are well adjusted [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/11/42170/abstract/90\">",
"     90",
"    </a>",
"    ]. However, there are issues involving low self esteem, social isolation, poor family relationships, and withdrawal from normal daily living [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/11/42170/abstract/90-92\">",
"     90-92",
"    </a>",
"    ]. Specific problem areas may include inappropriate pain coping strategies, reduced quality of life, anxiety, depression, and neurocognitive impairment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/11/42170/abstract/8,84,93,94\">",
"     8,84,93,94",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Well-adjusted patients have active coping strategies, family support, and support from the extended family unit [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/11/42170/abstract/95-97\">",
"     95-97",
"    </a>",
"    ], although in one study children with three or more prior painful events had increased odds of a poor outcome postdischarge, including a negative impact on their caregivers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/11/42170/abstract/98\">",
"     98",
"    </a>",
"    ]. The development of active coping mechanisms should be encouraged.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Growth and development",
"    </span>",
"    &nbsp;&mdash;&nbsp;Growth failure and delayed puberty are common in children with SCD. Most have detectable growth retardation that affects weight more than height by the age of two years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/11/42170/abstract/99\">",
"     99",
"    </a>",
"    ]. Normal height is often achieved by adulthood but weight remains lower than that of controls. Neurodevelopment and skeletal maturation are also delayed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/11/42170/abstract/100,101\">",
"     100,101",
"    </a>",
"    ]. Boys and girls have retarded sexual maturation and delayed menarche [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/11/42170/abstract/99,102,103\">",
"     99,102,103",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/57/22424?source=see_link\">",
"     \"Diagnosis and treatment of delayed puberty\"",
"    </a>",
"    .) In a report from the Jamaican Cohort Study, for example, extreme growth retardation, defined as absence of the adolescent growth spurt and prepubertal sexual development (Tanner stage 1 or 2) at age 16, was noted in 8 of 52 boys (15 percent) with SCD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/11/42170/abstract/104\">",
"     104",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These effects on growth and development are more prominent in patients with SCD and sickle cell-beta (0) thalassemia than in HbSC disease or sickle cell-beta (+) thalassemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/11/42170/abstract/99\">",
"     99",
"    </a>",
"    ]. The pathogenesis is uncertain although primary hypogonadism [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/11/42170/abstract/102,104,105\">",
"     102,104,105",
"    </a>",
"    ], hypopituitarism [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/11/42170/abstract/106\">",
"     106",
"    </a>",
"    ], and hypothalamic insufficiency [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/11/42170/abstract/107\">",
"     107",
"    </a>",
"    ] have been described.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12679833\">",
"    <span class=\"h2\">",
"     Reduced or absent splenic function",
"    </span>",
"    &nbsp;&mdash;&nbsp;Reduced (hyposplenism) or absent (functional asplenia) splenic function is commonly seen in subjects with SCD, due to repeated episodes of splenic infarction secondary to sickling of red cells within the spleen. As is discussed below, children with SCD are vulnerable to life-threatening infection early in life due to the inability of the spleen to filter microorganisms from the blood stream. (See",
"    <a class=\"local\" href=\"#H20\">",
"     'Infection'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Biomarkers of splenic function were studied using baseline data from the BABY HUG Trial to determine the onset and extent of reduced to absent splenic function in 193 infants with SCD (mean age 12.9 months, range 8.1 to 18 months) not selected for clinical severity. Results included the following [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/11/42170/abstract/108\">",
"     108",
"    </a>",
"    ] (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/34/34346?source=see_link&amp;anchor=H5#H5\">",
"     \"Approach to the adult patient with splenomegaly and other splenic disorders\", section on 'Hyposplenism and asplenia'",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Results of a",
"      <sup>",
"       99m",
"      </sup>",
"      Tc sulfur colloid scan indicated normal, decreased, or absent splenic colloid uptake in 12, 73, and 15 percent of the infants, respectively. Splenic function was decreased or absent in 75, 86, and 91 percent of those &le;9, 9.1 to 12, and &ge;12.1 months of age, respectively.",
"     </li>",
"     <li>",
"      Quantitative measurement of Howell-Jolly bodies (HJB) and membrane vacuoles (PIT counts) in circulating red cells correlated well with each other as well as with results of the colloid scans. Results suggested that PIT counts &le;1.2 percent predict for normal splenic function, while PIT counts &ge;4.5 percent predict for absent function. For Howell-Jolly bodies, &le;55",
"      <span class=\"nowrap\">",
"       HJB/10",
"       <sup>",
"        6",
"       </sup>",
"      </span>",
"      red cells predicts normal and &ge;665",
"      <span class=\"nowrap\">",
"       HJB/10",
"       <sup>",
"        6",
"       </sup>",
"      </span>",
"      red cells predicts absent splenic function.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The high rate of splenic dysfunction documented by one year of age in this study mandates that preventive strategies for minimizing risk of infection be adhered to assiduously. (See",
"    <a class=\"local\" href=\"#H20\">",
"     'Infection'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infection is a major cause of morbidity and mortality in patients with SCD. Affected children are vulnerable to life-threatening infection as early as four months of age because of splenic dysfunction caused by sickling of the red cells within the spleen and the inability of the spleen to filter microorganisms from the blood stream. Splenic dysfunction is followed eventually by splenic infarction, usually by two to four years of age. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/34/34346?source=see_link&amp;anchor=H5#H5\">",
"     \"Approach to the adult patient with splenomegaly and other splenic disorders\", section on 'Hyposplenism and asplenia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In the absence of normal splenic function, the patient is susceptible to overwhelming infection by encapsulated organisms, especially Streptococcus pneumoniae and Haemophilus influenzae. Dysfunctional IgG and IgM antibody responses, defects in alternative pathway fixation of complement, and opsonophagocytic dysfunction may also play a role in the predisposition to invasive infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/11/42170/abstract/109,110\">",
"     109,110",
"    </a>",
"    ]. Viral infections such as H1N1 and parvovirus can appear to be more virulent in sickle cell disease, possibly by serving as a catalyst to sickling and associated inflammatory reactions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/11/42170/abstract/111-113\">",
"     111-113",
"    </a>",
"    ]. Worldwide, malaria is a common cause of morbidity and mortality in children with sickle cell disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/11/42170/abstract/9\">",
"     9",
"    </a>",
"    ]. &nbsp;(See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/42/9895?source=see_link\">",
"     \"Clinical features and management of sepsis in the asplenic patient\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Bacteremia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bacteremia in children with SCD is most commonly caused by S. pneumoniae [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/11/42170/abstract/114-117\">",
"     114-117",
"    </a>",
"    ]. Bacteremia typically presents with leukocytosis, a left shift in the differential count, aplastic or hypoproliferative crisis due to associated bone marrow suppression, sometimes disseminated intravascular coagulation, and is associated with a mortality rate of 20 to 50 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/11/42170/abstract/118\">",
"     118",
"    </a>",
"    ]. The risk of recurrent S. pneumoniae sepsis and death is increased in patients who have had previous sepsis. A discussion of the most common bacterial infections seen in children with SCD can be found elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/1/39961?source=see_link&amp;anchor=H4#H4\">",
"     \"Management of fever in sickle cell disease\", section on 'Empiric antibiotic therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Bacteremia occurs less often in adults, although often with devastating results [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/11/42170/abstract/119-121\">",
"     119-121",
"    </a>",
"    ]. In one study, the most common community-acquired bacteria were E. coli, S. aureus, S. pneumoniae, and Salmonella, while the most common hospital-acquired bacterium was S. aureus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/11/42170/abstract/121\">",
"     121",
"    </a>",
"    ]. Bacteremia was associated with severe immunosuppression, the presence of indwelling venous catheters, and a high frequency of associated bone-joint infections.",
"   </p>",
"   <p>",
"    Bacteremia may be associated with episodes of acute chest syndrome. It is most likely to occur in infants (14 versus 1.8 percent in patients over 10 years of age in one series) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/11/42170/abstract/122\">",
"     122",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26155837\">",
"    <span class=\"h4\">",
"     S. pneumoniae",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prior to the use of prophylactic penicillin and pneumococcal vaccination, infants with SCD had 4 to 10 episodes per 100 patient years of bacteremia due to S. pneumoniae [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/11/42170/abstract/114,118\">",
"     114,118",
"    </a>",
"    ]. As described in the next section, pneumococcal bacteremia is associated with a high risk of meningitis unless antibiotics are rapidly administered. Introduction of the pneumococcal conjugate vaccine has led to a significant reduction of over 90 percent in the incidence of pneumococcal infection in children under the age of five years, although infection with pneumococcal serotypes not included in these vaccines, and infection in those not vaccinated has continued to occur [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/11/42170/abstract/118,123\">",
"     118,123",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/0/39946?source=see_link&amp;anchor=H3#H3\">",
"     \"Overview of the management of sickle cell disease\", section on 'Infection control and prophylaxis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    How SCD specifically predisposes to invasive pneumococcal infection is not well understood. Intact pneumococci use phosphorylcholine to tether to the platelet activating factor (PAF) receptor, thereby inserting the bacteria into the PAF receptor uptake pathway and promoting cell entry [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/11/42170/abstract/124\">",
"     124",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/38/23143?source=see_link&amp;anchor=H6#H6\">",
"     \"Microbiology and pathogenesis of Streptococcus pneumoniae\", section on 'Invasion'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A possible predisposing mechanism in SCD is the upregulation of PAF receptors on chronically activated endothelial cells. The following observations in a SCD mouse model are consistent with this hypothesis: higher rates of infection and mortality after exposure to pneumococci compared with wild-type mice; increased expression of PAF receptors on endothelium and pulmonary epithelium; and protection from mortality by genetic deletion or pharmacologic blockade of PAF receptors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/11/42170/abstract/125\">",
"     125",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26155854\">",
"    <span class=\"h4\">",
"     H. influenzae type b",
"    </span>",
"    &nbsp;&mdash;&nbsp;Haemophilus influenzae type b has been the second most common organism responsible for bacteremia in children with SCD, accounting for 10 to 25 percent of episodes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/11/42170/abstract/126,127\">",
"     126,127",
"    </a>",
"    ]. H. influenzae affects older children and is usually less fulminant than pneumococcal bacteremia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/11/42170/abstract/118,128\">",
"     118,128",
"    </a>",
"    ]. The incidence of invasive H. influenzae type b infection has declined markedly after introduction of the H. influenzae type b vaccine, both by direct protection of the patient and by decreased carriage of the organism in the general population.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Meningitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Meningitis in SCD is primarily a problem of infants and young children. It is most frequently caused by S. pneumoniae and occurs in the setting of bacteremia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/11/42170/abstract/129\">",
"     129",
"    </a>",
"    ]. In older studies, the incidence of meningitis among bacteremic patients was as high as 50 percent, a value that has been markedly reduced by the rapid administration of antibiotics [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/11/42170/abstract/115,130\">",
"     115,130",
"    </a>",
"    ]. H. influenzae type b is now a less common cause of meningitis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/8/28810?source=see_link&amp;anchor=H2#H2\">",
"     \"Clinical features and diagnosis of acute bacterial meningitis in children older than one month of age\", section on 'Epidemiology'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Bacterial pneumonia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Causes of bacterial pneumonia in patients with SCD include Mycoplasma pneumoniae, Chlamydia pneumoniae (which together account for about 20 percent of cases), and Legionella [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/11/42170/abstract/131\">",
"     131",
"    </a>",
"    ]. Respiratory viruses are also common causes of pulmonary infection, while S. pneumoniae and H. influenza type b are uncommon [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/11/42170/abstract/131\">",
"     131",
"    </a>",
"    ]. Patients may present with any combination of dyspnea, cough, chest pain, fever, tachypnea, and leukocytosis, and may develop the acute chest syndrome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/11/42170/abstract/131\">",
"     131",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/28/27082?source=see_link\">",
"     \"Pulmonary complications of sickle cell disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/26/16810?source=see_link\">",
"     \"The acute chest syndrome in children and adolescents with sickle cell disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Osteomyelitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is an increased incidence of osteomyelitis in patients with sickle cell anemia resulting from infection of infarcted bone. This subject is reviewed in detail separately, but will be briefly reviewed here. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/4/18506?source=see_link&amp;anchor=H12#H12\">",
"     \"Bone and joint complications in sickle cell disease\", section on 'Osteomyelitis and septic arthritis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The most common offending organisms are Salmonella species. Staphylococcus aureus, the most common etiologic agent in patients without sickle cell anemia, accounts for less than 25 percent of cases. Articular infection is less common and is often due to S. pneumoniae.",
"   </p>",
"   <p>",
"    Osteomyelitis usually affects long bones, often at multiple sites. It may be difficult to distinguish osteomyelitis from vaso-occlusive events involving bone. Bone imaging studies may be helpful and cultures are essential.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Cerebrovascular events",
"    </span>",
"    &nbsp;&mdash;&nbsp;The issues related to cerebrovascular disease in patients with SCD and its variants are discussed in detail elsewhere and will be only briefly reviewed here. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/11/31930?source=see_link\">",
"     \"Cerebrovascular complications of sickle cell disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Neurologic complications, including transient ischemic attacks, infarctive stroke, intracerebral hemorrhage, spinal cord infarction or compression, vestibular dysfunction, and sensory hearing loss, occur in 25 percent of patients with sickle cell anemia. Cognitive impairment may occur as a consequence of vascular disease",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    silent cerebral infarcts.",
"   </p>",
"   <p>",
"    The risk of a cerebrovascular accident (CVA) varies with the genotype:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The likelihood of having a first CVA by age 20, 30, and 45 years was 11, 15, and 24 percent, respectively, for SCD compared with 2, 4, and 10 percent for HbSC disease (",
"      <a class=\"graphic graphic_figure graphicRef61397 \" href=\"mobipreview.htm?40/31/41469\">",
"       figure 1",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/11/42170/abstract/5\">",
"       5",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Imaging studies have identified silent infarcts in 10 to 20 percent of patients with SCD compared with 3 percent in HbSC disease [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/11/42170/abstract/132\">",
"       132",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    On multivariate analysis, the following major risk factors were identified for infarctive stroke [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/11/42170/abstract/5\">",
"     5",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Prior TIA &mdash; relative risk [RR] 56",
"     </li>",
"     <li>",
"      Low steady state hemoglobin &mdash; RR 1.9 per 1",
"      <span class=\"nowrap\">",
"       g/dL",
"      </span>",
"      decrease",
"     </li>",
"     <li>",
"      Rate of acute chest syndrome &mdash; RR 2.4 per event per year",
"     </li>",
"     <li>",
"      Episode of acute chest syndrome within the previous two weeks &mdash; RR 7.0",
"     </li>",
"     <li>",
"      Elevated systolic blood pressure &mdash; RR 1.3 per 10 mmHg increase",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Only two major risk factors were identified for intracerebral hemorrhage:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Low steady state hemoglobin &mdash; RR 1.6 per 1",
"      <span class=\"nowrap\">",
"       g/dL",
"      </span>",
"      decrease",
"     </li>",
"     <li>",
"      Increased steady state leukocyte count &mdash; RR 1.9 per",
"      <span class=\"nowrap\">",
"       5000/&micro;L",
"      </span>",
"      increase",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The major issue in relation to infarctive stroke is prevention. Transcranial Doppler can identify children at risk; among such children, institution of a prophylactic chronic transfusion program with a goal HbS of less than 30 percent of total hemoglobin reduces the risk of stroke by 92 percent (",
"    <a class=\"graphic graphic_figure graphicRef57656 \" href=\"mobipreview.htm?4/40/4750\">",
"     figure 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/11/42170/abstract/133\">",
"     133",
"    </a>",
"    ]. Transfusion therapy also markedly reduces the incidence of recurrent stroke. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/11/31930?source=see_link\">",
"     \"Cerebrovascular complications of sickle cell disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Bone complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;The skeletal system is frequently involved in sickle cell disease due accelerated hematopoiesis",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    bone infarction. The extended hematopoietic marrow resulting from the chronic hemolysis can lead to chronic tower skull, bossing of the forehead, and fish-mouth deformity of vertebrae. These effects cause widening of the medullary space, thinning of the trabeculae and cortices and osteoporosis. Sickle cell patients have a high rate of vitamin D deficiency and osteoporosis, which may increase the bone pathology [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/11/42170/abstract/134\">",
"     134",
"    </a>",
"    ]. This subject is discussed in detail separately, but will be briefly reviewed here. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/4/18506?source=see_link\">",
"     \"Bone and joint complications in sickle cell disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Bone complications in sickle cell disease include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Bone infarction and necrosis &mdash; Excruciating pain due to bone infarction, the hand-foot syndrome or dactylitis, is the most common initial symptoms of sickle cell disease, occurring in 40 percent of patients overall and 50 percent of children who became symptomatic before age two. It is important to distinguish this syndrome, which resolves spontaneously, from osteomyelitis using nuclear medicine scintigraphy or magnetic resonance imaging (MRI).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Osteonecrosis (also called avascular, ischemic, or aseptic necrosis) results from infarction of bone trabeculae and marrow cells and occurs in all sickle cell disease genotypes. Osteonecrosis occurs with equal frequency in the femoral and humeral heads and a similar relationship to genotype is seen at both sites. The femoral heads more commonly undergo progressive joint destruction as a result of chronic weight bearing. The changes are best detected by MRI. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/4/18506?source=see_link&amp;anchor=H16#H16\">",
"     \"Bone and joint complications in sickle cell disease\", section on 'Osteonecrosis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/43/28346?source=see_link\">",
"     \"Osteonecrosis (avascular necrosis of bone)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Bone marrow infarction &mdash; Bone marrow infarction in sickle cell disorders causes reticulocytopenia, exacerbation of anemia, a leukoerythroblastic blood picture, and occasional pancytopenia. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/23/13689?source=see_link&amp;anchor=H6#H6\">",
"     \"Evaluation of bone marrow aspirate smears\", section on 'Bone marrow necrosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pulmonary fat embolism is a complication of bone marrow infarction, which may be associated with fat globules in the sputum and refractile bodies visible in the optic fundi. Fat embolism is a life-threatening event that may require exchange transfusion,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      , and corticosteroids. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?26/28/27082?source=see_link&amp;anchor=H12#H12\">",
"       \"Pulmonary complications of sickle cell disease\", section on 'Fat and bone marrow embolism'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?25/21/25942?source=see_link\">",
"       \"Fat embolism syndrome\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Orbital compression syndrome &mdash; Vaso-occlusion of the periorbital marrow space with subperiosteal hemorrhage produce a syndrome consisting of headache, fever, and palpebral edema. This syndrome primarily occurs in patients with SCD. Compression of the optic nerve may occur, requiring consideration of surgical decompression. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?18/4/18506?source=see_link&amp;anchor=H20#H20\">",
"       \"Bone and joint complications in sickle cell disease\", section on 'Orbital bone infarction and orbital compression syndrome'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?6/47/6906?source=see_link&amp;anchor=H24#H24\">",
"       \"Congenital anomalies and acquired abnormalities of the optic nerve\", section on 'Compression'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Cardiac complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cardiac complications are a common, often unrecognized, cause of morbidity and mortality in sickle cell disease, and are a major cause of death in adult patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/11/42170/abstract/135-137\">",
"     135-137",
"    </a>",
"    ]. There is no specific cardiomyopathy in sickle cell disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/11/42170/abstract/138\">",
"     138",
"    </a>",
"    ]. There are, however, two important cardiac effects: an increased cardiac output and acute myocardial infarction. The chronic anemia of SCD",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    asleep and waking oxygen desaturation results in a compensatory increase in cardiac output that leads to chronic chamber enlargement and cardiomegaly even in young children [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/11/42170/abstract/139-143\">",
"     139-143",
"    </a>",
"    ]. In older patients, right heart, as well as left heart, failure may develop. The electrocardiogram shows evidence of left ventricular hypertrophy, and less often first-degree block and nonspecific ST-T wave changes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/11/42170/abstract/144\">",
"     144",
"    </a>",
"    ]. Arrhythmias appear to be an important component of death in older patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/11/42170/abstract/135\">",
"     135",
"    </a>",
"    ]. Patients may have a higher rate of prolonged QT intervals secondary to their disease or medications, ie,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/57/36761?source=see_link\">",
"     methadone",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/11/42170/abstract/145,146\">",
"     145,146",
"    </a>",
"    ]. Left sided diastolic dysfunction is increasingly being identified in patients with pulmonary hypertension and early cor pulmonale [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/11/42170/abstract/147\">",
"     147",
"    </a>",
"    ]. Hemosiderosis-induced cardiomyopathy has been observed in older sickle cell patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/11/42170/abstract/148,149\">",
"     148,149",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Exercise capacity of sickle cell patients is often diminished, but heart failure is uncommon and restriction of activity is seldom necessary [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/11/42170/abstract/150,151\">",
"     150,151",
"    </a>",
"    ]. However, an age-dependent loss of cardiac reserve may predispose to heart failure in adulthood following fluid overload, transfusion, reduced oxygen carrying capacity, or hypertension [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/11/42170/abstract/140,152\">",
"     140,152",
"    </a>",
"    ]. Exercise performance can be improved by transfusion therapy to lower the HbS percentage [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/11/42170/abstract/153\">",
"     153",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h3\">",
"     Myocardial infarction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute myocardial infarction in the absence of epicardial coronary artery disease has been described in patients with SCD, and is often misdiagnosed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/11/42170/abstract/154-156\">",
"     154-156",
"    </a>",
"    ]. In one autopsy series, 7 of 72 consecutive patients with SCD (9.7 percent) had myocardial infarction; gross obstructive and atherosclerotic lesions were absent in all seven patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/11/42170/abstract/155\">",
"     155",
"    </a>",
"    ]. Infarction in this setting may reflect increased oxygen demand exceeding limited oxygen-carrying capacity or abnormal myocardial microvasculature.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Dermatologic complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vasoocclusion in the skin produces leg ulcers and myofascial syndromes in patients with sickle cell disorders.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h3\">",
"     Leg ulcers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Leg ulcers are a frequent complication in SCD, causing significant physical disability and a negative psychologic and social impact, occurring usually after the age of 10 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/11/42170/abstract/157,158\">",
"     157,158",
"    </a>",
"    ]. They are most common in SCD, less frequent in sickle cell-beta (0) thalassemia and sickle cell-alpha thalassemia (10, 5.7, and 2.4 per hundred patient-years, respectively), and nonexistent in HbSC disease and sickle cell-beta (+) thalassemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/11/42170/abstract/158\">",
"     158",
"    </a>",
"    ]. The risk is highest in tropical regions, and is increased in males and in those with a low hematocrit and increased evidence for hemolysis; HbF appears to be protective [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/11/42170/abstract/158-161\">",
"     158-161",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/32/39434?source=see_link&amp;anchor=H20#H20\">",
"     \"Clinical variability in sickle cell anemia\", section on 'Leg ulcers'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In a study of 225 subjects from the Jamaican Cohort Study, chronic leg ulcers occurred in 53 subjects (24 percent), with a median age of initial ulceration of 17 years (range: 13 to 24) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/11/42170/abstract/162\">",
"     162",
"    </a>",
"    ]. The mode of onset was traumatic, spontaneous, or unknown in 60, 28, and 12 percent, respectively. On multivariate analysis, risk factors included venous incompetence, low socioeconomic status, and increased levels of LDH.",
"   </p>",
"   <p>",
"    Most leg ulcers occur near the medial or lateral malleolus and are frequently bilateral [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/11/42170/abstract/158,159\">",
"     158,159",
"    </a>",
"    ]. They may begin spontaneously or occur after trauma, and may become infected, most commonly by S. aureus, Pseudomonas, streptococci, or Bacteroides [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/11/42170/abstract/163\">",
"     163",
"    </a>",
"    ]. Systemic infection, osteomyelitis, and tetanus are rare complications [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/11/42170/abstract/159\">",
"     159",
"    </a>",
"    ]. The ulcers are resistant to healing, tend to be recurrent in well over one-half of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/11/42170/abstract/164\">",
"     164",
"    </a>",
"    ], and may be associated with venous incompetence [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/11/42170/abstract/165\">",
"     165",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18480916\">",
"    <span class=\"h4\">",
"     Management",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prevention is the best treatment with well-fitting shoes or sneakers and aggressive treatment of early signs of skin injury. Management of leg ulcers in patients with SCD begins with gentle debridement to remove nonviable, superficial tissue from more vital areas. Wet to dry dressings and Duoderm hydrocolloid dressings facilitate devitalization. Once debridement is complete, zinc oxide-impregnated Unna's boots are used to promote healing. Bed rest speeds healing by improving tissue perfusion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/11/42170/abstract/166,167\">",
"     166,167",
"    </a>",
"    ]. Other modalities that may be required include topical antibiotics [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/11/42170/abstract/168\">",
"     168",
"    </a>",
"    ] and elastic wraps or leg elevation to control edema, which can retard healing. Extensive lesions may require skin grafting and the use of soft tissue flaps [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/11/42170/abstract/169\">",
"     169",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Use of oral zinc supplementation (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/57/17300?source=see_link\">",
"     zinc sulfate",
"    </a>",
"    200 mg po three times per day) has been suggested, although definitive evidence for its efficacy is not available [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/11/42170/abstract/170\">",
"     170",
"    </a>",
"    ]. A six-month course of transfusion therapy may accelerate healing [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/11/42170/abstract/171\">",
"     171",
"    </a>",
"    ]. Several other modalities have been advocated:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A phase II trial studied the effectiveness of arginine butyrate in 26 subjects with SCD and chronic lower extremity ulcers refractory to standard care for at least six months. Subjects were randomly assigned to receive either standard local care (SLC, 12 subjects) or SLC plus arginine butyrate (SLC+AB, 14 subjects). AB was delivered by intravenous infusion at a total daily dose of 500",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      infused over a period of 6 to 8 hours through a long vascular catheter or port device and given five days per week for 12 weeks [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/11/42170/abstract/172\">",
"       172",
"      </a>",
"      ]. After three months, proportions of ulcers which healed were 24 and 78 percent in the SLC and SLC+AB arms respectively.",
"     </li>",
"     <li>",
"      Apligraf&reg;, an artificial wound membrane, may accelerate healing. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?31/41/32410?source=see_link&amp;anchor=H28#H28\">",
"       \"Medical management of lower extremity chronic venous disease\", section on 'Ulcer care'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Local or topical low-dose GM-CSF has anecdotally been beneficial [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/11/42170/abstract/173,174\">",
"       173,174",
"      </a>",
"      ]. However, parenteral dosing has been reported to cause sickle events.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/16/40200?source=see_link\">",
"       Bosentan",
"      </a>",
"      has been utilized in refractory ulcers [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/11/42170/abstract/175\">",
"       175",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Local topical opioids appear to accelerate healing in sickle cell disease and in the animal model [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/11/42170/abstract/176,177\">",
"       176,177",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h2\">",
"     Hepatobiliary complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are multiple causes of hepatic dysfunction in patients with SCD (\"sickle cell hepatopathy\"). These include, but are not limited to, the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Acute hepatic ischemia",
"     </li>",
"     <li>",
"      Benign cholestasis",
"     </li>",
"     <li>",
"      Hepatic sequestration crisis",
"     </li>",
"     <li>",
"      Transfusional iron overload",
"     </li>",
"     <li>",
"      Acute and chronic cholelithiasis secondary to pigmented gallstones",
"     </li>",
"     <li>",
"      Acute and chronic liver disease secondary to hepatitis C virus infection (HCV) complicating blood transfusion",
"     </li>",
"     <li>",
"      Drug toxicity (eg,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/19/2360?source=see_link\">",
"       deferasirox",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/16/16648?source=see_link\">",
"       hydroxyurea",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/49/2842?source=see_link\">",
"     \"Hepatic manifestations of sickle cell disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h2\">",
"     Pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pregnancy is associated with both fetal and maternal complications, which are more common with SCD compared with sickle cell trait or HbSC disease.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Fetal complications are related to compromised placental blood flow and include spontaneous abortion, intrauterine growth restriction, fetal death in utero, and low birthweight.",
"     </li>",
"     <li>",
"      Maternal complications occur in as many as one-half of pregnancies, including acute chest syndrome, bacteriuria, urinary tract infection, pyelonephritis, endometritis, preeclampsia, thromboembolic events, and the use of cesarean section.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    As a result of these complications, close maternal-fetal surveillance is warranted. This subject is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/62/20458?source=see_link\">",
"     \"Pregnancy in women with sickle cell disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h2\">",
"     Priapism",
"    </span>",
"    &nbsp;&mdash;&nbsp;Priapism is a common, serious, and often underdiagnosed problem that leads to impotence. This complication of SCD and its management are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/30/23017?source=see_link\">",
"     \"Diagnosis and management of priapism in sickle cell disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h2\">",
"     Pulmonary complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pulmonary arterial circulation, which has low oxygen tension and low pressure in a slow-flow system, is ideally suited to facilitate the polymerization of sickle hemoglobin, causing both acute and chronic pulmonary manifestations that collectively are the most common cause of death in SCD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/11/42170/abstract/178-180\">",
"     178-180",
"    </a>",
"    ]. The pulmonary manifestations of SCD are reviewed in detail separately, but will be briefly summarized here. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/28/27082?source=see_link\">",
"     \"Pulmonary complications of sickle cell disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/26/16810?source=see_link\">",
"     \"The acute chest syndrome in children and adolescents with sickle cell disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Evaluation of the pulmonary status in patients with sickle cell disease may reveal a variety of chronic manifestations including restrictive and obstructive lung disease, hypoxemia, and pulmonary hypertension singly or in combination. Undetected, acute worsening of pulmonary arterial hypertension during acute sickle cell events has been associated with acute cor-pulmonale and sudden death [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/11/42170/abstract/181,182\">",
"     181,182",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    CT scanning may reveal chronic interstitial fibrosis. These abnormalities are more common in, but not restricted to, those with a past history of multiple episodes of acute chest syndrome. Pulmonary hypertension usually occurs in adults and carries a poor prognosis.",
"   </p>",
"   <p>",
"    Other pulmonary manifestations of SCD have been described. Airway hyperreactivity occurs in nearly two-thirds of children with sickle cell disease not diagnosed as having asthma and as many as one-third of children have sleep-related upper airway obstruction. Recurrent episodes of hypoxemia with sleep apnea may be a risk factor for vaso-occlusive events.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h3\">",
"     Oxygen saturation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Baseline oxygen saturation (SaO2) measurements by pulse oximetry are below normal in patients with SCD. This was illustrated in the following studies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a prospective cohort study of 130 children from the Cooperative Study for Sickle Cell Disease (CSSCD), mean and median daytime SaO2 were 94 and 95 percent, respectively [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/11/42170/abstract/183\">",
"       183",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Similar results (95 to 96 percent) were seen in three other studies of mean daytime SaO2 [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/11/42170/abstract/184-186\">",
"       184-186",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In contrast to nocturnal hypoxemia, daytime SaO2 does not appear to independently predict subsequent pain or acute chest episodes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/11/42170/abstract/183\">",
"     183",
"    </a>",
"    ]. In addition, there are currently no data correlating daytime SaO2 with nighttime SaO2, which generally is lower than daytime values [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/11/42170/abstract/183\">",
"     183",
"    </a>",
"    ]. Nevertheless, SaO2 values below baseline measurements for individual patients with SCD, either at rest or following exercise, are useful in detecting and monitoring for the presence of pulmonary complications.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37\">",
"    <span class=\"h3\">",
"     Acute chest syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;The acute pulmonary complications of SCD, which have been referred to as the acute chest syndrome (ACS), include pneumonia, infarction due to in situ thrombosis, and embolic phenomena due to fat embolism and bone marrow infarction. The acute chest syndrome is the most common form of acute pulmonary disease in SCD, occurring in 30 to 50 percent of patients. It is the second most common cause of hospitalization in SCD and the leading cause of death. Acute complications of ACS include acute multiorgan failure with neurologic",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    renal events. Long-term complications include pulmonary hypertension and chronic lung disease.",
"   </p>",
"   <p>",
"    Acute chest syndrome (ACS) has been defined as the new appearance of an infiltrate with pulmonary symptoms in a patient with sickle cell anemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/11/42170/abstract/111,187\">",
"     111,187",
"    </a>",
"    ]. Patients often have fever, chest pain, and cough, although many present with a fever, mild hypoxia, and an initially negative chest x-ray. A fall in hemoglobin and platelet count and rise in phospholipase A2 may precede radiographic changes.",
"   </p>",
"   <p>",
"    The etiology of ACS is multi-factorial, including pulmonary infarction, infection (S. pneumoniae, mycoplasma, chlamydia, and common viral pathogens), and pulmonary fat embolism. Infection is a more common cause in children than in adults. ACS often follows a vaso-occlusive event and may be prevented by incentive spirometry, optimal analgesic control, and transfusion.",
"   </p>",
"   <p>",
"    Therapy may require oxygen, antibiotics, and transfusion therapy. Undetected bronchoreactive lung disease is common and therefore, treatment with bronchodilators is often selectively used. Corticosteroids may result in rapid improvement but have been associated with frequent rebound readmissions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/11/42170/abstract/188\">",
"     188",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/16/16648?source=see_link\">",
"     Hydroxyurea",
"    </a>",
"    significantly reduces the frequency of ACS. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/28/27082?source=see_link\">",
"     \"Pulmonary complications of sickle cell disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/26/16810?source=see_link\">",
"     \"The acute chest syndrome in children and adolescents with sickle cell disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38\">",
"    <span class=\"h2\">",
"     Renal complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Renal involvement is common in sickle cell disease, leading to renal failure in up 18 percent of patients. Asymptomatic albuminuria is often a precursor of progressive renal disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/11/42170/abstract/189,190\">",
"     189,190",
"    </a>",
"    ]. New predictors of renal injury have been identified. Urinary kidney injury molecule, N-acetylb-D-glucosaminidase (NAG), and cystatin C correlate with proteinuria and kidney disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/11/42170/abstract/189\">",
"     189",
"    </a>",
"    ]. The primary event appears to be occlusion of the vasa recta capillaries in the renal medulla. The normal medullary environment plays an important role in this process, because it has both a low oxygen tension and high osmolality (osmotically dehydrating the red cells, thereby increasing the concentration of HbS) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/11/42170/abstract/191\">",
"     191",
"    </a>",
"    ]. The lesions are most marked in patients with SCD, but are less severe with heterozygous sickle cell trait (HbAS) or HbSC disease.",
"   </p>",
"   <p>",
"    Increased in vitro sickling has been noted following intravenous iodinated contrast material used for imaging studies, but may be less when second-generation low- and iso-osmolar contrast agents are employed. This was shown in a study of 132 imaging studies in 79 patients, most of whom had HbSS disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/11/42170/abstract/192\">",
"     192",
"    </a>",
"    ]. Contrast-induced nephropathy occurred in 1.5 percent, at a rate similar to the general population, resolving in all cases. Prehydration was associated with a significantly decreased incidence of adverse events.",
"   </p>",
"   <p>",
"    The renal manifestations of sickle cell disease are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/3/6202?source=see_link\">",
"     \"Renal manifestations of sickle cell disease\"",
"    </a>",
"    .) They include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Enuresis secondary to hyposthenuria",
"     </li>",
"     <li>",
"      Painless hematuria due to papillary infarcts",
"     </li>",
"     <li>",
"      Proteinuria and hypertension",
"     </li>",
"     <li>",
"      Renal infarction, papillary necrosis, and renal colic",
"     </li>",
"     <li>",
"      Nephrogenic diabetes insipidus that can lead to polyuria",
"     </li>",
"     <li>",
"      Focal segmental glomerulosclerosis that can lead to end-stage renal disease; dialysis is well tolerated and increasing numbers of patients are being treated with renal transplantation",
"     </li>",
"     <li>",
"      Renal medullary carcinoma is a malignancy found almost exclusively in black patients with HbSC disease or sickle cell trait.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H39\">",
"    <span class=\"h2\">",
"     Retinopathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sickle cell disease in the eye primarily affects the retina, with manifestations such as proliferative retinopathy, retinal artery occlusion, and retinal detachment and hemorrhage [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/11/42170/abstract/193,194\">",
"     193,194",
"    </a>",
"    ]. The vaso-occlusions may begin in childhood. Lesions are first observed in the periphery, resulting in a nonperfused and presumably ischemic peripheral retina. New blood vessels develop at the border of perfused and nonperfused retina. The elaborate preretinal neovascular structures that form during proliferative sickle cell retinopathy are called \"sea fans\" because of their resemblance to a marine invertebrate. Postmortem studies suggest that autoinfarction occurs at the preretinal capillary and that sea fans tend to develop at the site of arteriovenous crossings [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/11/42170/abstract/195\">",
"     195",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These fragile blood vessels can hemorrhage into the vitreous and produce traction retinal detachments, the major cause of blindness in sickle cell subjects. The stimuli for sea fan formation are unknown. Autocrine production of angiogenic factors such as basic fibroblast growth factor and vascular endothelial growth factor may play an important role [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/11/42170/abstract/196\">",
"     196",
"    </a>",
"    ]. Superficial and deep retinal hemorrhages have a characteristic appearance:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Superficial hemorrhages have a pink \"salmon patch\" appearance that resolves into an iridescent \"schisis cavity\".",
"     </li>",
"     <li>",
"      Deeper retinal hemorrhages have a black \"sunburst\" appearance, which is the most common abnormality [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/11/42170/abstract/197\">",
"       197",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H40\">",
"    <span class=\"h3\">",
"     Proliferative sickle retinopathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incidence of proliferative sickle retinopathy (PSR) varies with the type of disease. In two reports of over 500 patients from England, PSR occurred in 11 percent with SCD and 37 percent with HbSC disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/11/42170/abstract/193,198\">",
"     193,198",
"    </a>",
"    ]. In the latter condition, the disease usually occurred between the ages of 20 and 30 and 68 percent of those over age 45 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/11/42170/abstract/198\">",
"     198",
"    </a>",
"    ]. Other studies have confirmed that the risk of proliferative retinopathy is higher in HbSC disease than it is in HbSS disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/11/42170/abstract/199,200\">",
"     199,200",
"    </a>",
"    ]. Although rare, retinopathy and serious ocular complications can occur in patients with HbC trait [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/11/42170/abstract/201\">",
"     201",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Risk factors in males with both disorders are higher hematocrits and a low HbF level [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/11/42170/abstract/193,198\">",
"     193,198",
"    </a>",
"    ]. The greater frequency among patients with HbSC disease suggests that retinal vessels are more susceptible to occlusion by more viscous blood than by more rigid individual cells.",
"   </p>",
"   <p>",
"    Loss of visual acuity in untreated patients with PSR ranges from 5 to 10 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/11/42170/abstract/199,202\">",
"     199,202",
"    </a>",
"    ]. One report, for example, followed 120 patients with SCD disease and 220 with HbSC disease for a mean of 6.9 years; loss of visual acuity occurred in 10 percent of untreated eyes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/11/42170/abstract/197\">",
"     197",
"    </a>",
"    ]. The incidence of visual loss was 31 per 1000 eye-years of observation among eyes with PSR compared with 1.4 per 1000 among eyes with nonproliferative disease. Similar findings were noted in another report of 97 patients over age 18 with HbSC disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/11/42170/abstract/199\">",
"     199",
"    </a>",
"    ]. PSR occurred in 50 percent; vitreous hemorrhage in 18 percent; retinal detachment in 8 percent; and blindness in one eye in 6 percent.",
"   </p>",
"   <p>",
"    Prophylactic photocoagulation may have a role in the treatment of PSR in selected patients. However, no controlled studies have established that the long-term outcome is improved compared with the natural history of the disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/11/42170/abstract/203\">",
"     203",
"    </a>",
"    ]. There is a greater predilection for spontaneous regression, involution, or autoinfarction of the neovascular tissue in sickle retinopathy as opposed to the neovascularization in other retinal vascular diseases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/11/42170/abstract/200\">",
"     200",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H41\">",
"    <span class=\"h1\">",
"     ADDITIONAL INFORMATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Centers for Disease Control and Prevention has a website that provides additional information concerning sickle cell trait and sickle cell disease. It is available at:",
"    <a class=\"external\" href=\"file://www.cdc.gov/ncbddd/sicklecell/index.html\">",
"     www.cdc.gov/ncbddd/sicklecell/index.html",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/11/42170/abstract/204\">",
"     204",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?4/8/4227?source=see_link\">",
"       \"Patient information: Sickle cell anemia (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24957881\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vasoocclusive phenomena (acute painful episodes) and increased red blood cell destruction (hemolysis) are the clinical hallmarks of sickle cell disease (SCD). These phenomena result in recurrent painful episodes (previously called sickle cell crisis), a life-long transfusion requirement, and a variety of serious organ system complications that can lead to life-long disabilities",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    early death. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'General overview'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Clinical manifestations",
"      </strong>",
"      &mdash; The major clinical manifestations of SCD include painful episodes, symptomatic anemia, susceptibility to infection, stroke, cardiopulmonary complications, renal involvement, leg ulcers, and recurrent priapism in males. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Major clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <strong>",
"       Laboratory findings",
"      </strong>",
"      &mdash; SCD is associated with a mild to moderate anemia, reticulocytosis of 3 to 15 percent, unconjugated hyperbilirubinemia, elevated serum lactate dehydrogenase, and low serum haptoglobin. The peripheral blood smear reveals sickled red cells, polychromasia due to increased reticulocytes, and Howell-Jolly bodies reflecting hyposplenia secondary to repeated splenic infarctions (",
"      <a class=\"graphic graphic_picture graphicRef64449 \" href=\"mobipreview.htm?1/42/1703\">",
"       picture 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Laboratory findings'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?41/54/42856?source=see_link\">",
"       \"Diagnosis of sickle cell syndromes\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Management",
"      </strong>",
"      &mdash; Management of the complications of SCD is discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?39/0/39946?source=see_link\">",
"       \"Overview of the management of sickle cell disease\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42170/abstract/1\">",
"      Bunn HF. Pathogenesis and treatment of sickle cell disease. N Engl J Med 1997; 337:762.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42170/abstract/2\">",
"      Akinsheye I, Alsultan A, Solovieff N, et al. Fetal hemoglobin in sickle cell anemia. Blood 2011; 118:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42170/abstract/3\">",
"      Kaul DK, Fabry ME, Costantini F, et al. In vivo demonstration of red cell-endothelial interaction, sickling and altered microvascular response to oxygen in the sickle transgenic mouse. J Clin Invest 1995; 96:2845.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42170/abstract/4\">",
"      Rees DC, Williams TN, Gladwin MT. Sickle-cell disease. Lancet 2010; 376:2018.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42170/abstract/5\">",
"      Ohene-Frempong K, Weiner SJ, Sleeper LA, et al. Cerebrovascular accidents in sickle cell disease: rates and risk factors. Blood 1998; 91:288.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42170/abstract/6\">",
"      Platt OS, Thorington BD, Brambilla DJ, et al. Pain in sickle cell disease. Rates and risk factors. N Engl J Med 1991; 325:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42170/abstract/7\">",
"      Bainbridge R, Higgs DR, Maude GH, Serjeant GR. Clinical presentation of homozygous sickle cell disease. J Pediatr 1985; 106:881.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42170/abstract/8\">",
"      Dampier C, LeBeau P, Rhee S, et al. Health-related quality of life in adults with sickle cell disease (SCD): a report from the comprehensive sickle cell centers clinical trial consortium. Am J Hematol 2011; 86:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42170/abstract/9\">",
"      McAuley CF, Webb C, Makani J, et al. High mortality from Plasmodium falciparum malaria in children living with sickle cell anemia on the coast of Kenya. Blood 2010; 116:1663.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42170/abstract/10\">",
"      Makani J, Cox SE, Soka D, et al. Mortality in sickle cell anemia in Africa: a prospective cohort study in Tanzania. PLoS One 2011; 6:e14699.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42170/abstract/11\">",
"      Yanni E, Grosse SD, Yang Q, Olney RS. Trends in pediatric sickle cell disease-related mortality in the United States, 1983-2002. J Pediatr 2009; 154:541.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42170/abstract/12\">",
"      Quinn CT, Rogers ZR, Buchanan GR. Survival of children with sickle cell disease. Blood 2004; 103:4023.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42170/abstract/13\">",
"      Quinn CT, Rogers ZR, McCavit TL, Buchanan GR. Improved survival of children and adolescents with sickle cell disease. Blood 2010; 115:3447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42170/abstract/14\">",
"      Machado RF, Hildesheim M, Mendelsohn L, et al. NT-pro brain natriuretic peptide levels and the risk of death in the cooperative study of sickle cell disease. Br J Haematol 2011; 154:512.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42170/abstract/15\">",
"      Miller ST, Sleeper LA, Pegelow CH, et al. Prediction of adverse outcomes in children with sickle cell disease. N Engl J Med 2000; 342:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42170/abstract/16\">",
"      Quinn CT, Shull EP, Ahmad N, et al. Prognostic significance of early vaso-occlusive complications in children with sickle cell anemia. Blood 2007; 109:40.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42170/abstract/17\">",
"      Quinn CT, Lee NJ, Shull EP, et al. Prediction of adverse outcomes in children with sickle cell anemia: a study of the Dallas Newborn Cohort. Blood 2008; 111:544.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42170/abstract/18\">",
"      Dover GJ, Boyer SH, Charache S, Heintzelman K. Individual variation in the production and survival of F cells in sickle-cell disease. N Engl J Med 1978; 299:1428.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42170/abstract/19\">",
"      Nagel RL, Ranney HM. Genetic epidemiology of structural mutations of the beta-globin gene. Semin Hematol 1990; 27:342.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42170/abstract/20\">",
"      Oner C, Dimovski AJ, Altay C, et al. Sequence variations in the 5' hypersensitive site-2 of the locus control region of beta S chromosomes are associated with different levels of fetal globin in hemoglobin S homozygotes. Blood 1992; 79:813.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42170/abstract/21\">",
"      Diop S, Thiam D, Cisse M, et al. New results in clinical severity of homozygous sickle cell anemia, in Dakar, Senegal. Hematol Cell Ther 1999; 41:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42170/abstract/22\">",
"      Wilber A, Nienhuis AW, Persons DA. Transcriptional regulation of fetal to adult hemoglobin switching: new therapeutic opportunities. Blood 2011; 117:3945.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42170/abstract/23\">",
"      West MS, Wethers D, Smith J, Steinberg M. Laboratory profile of sickle cell disease: a cross-sectional analysis. The Cooperative Study of Sickle Cell Disease. J Clin Epidemiol 1992; 45:893.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42170/abstract/24\">",
"      Tassel C, Arnaud C, Kulpa M, et al. Leukocytosis is a risk factor for lung function deterioration in children with sickle cell disease. Respir Med 2011; 105:788.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42170/abstract/25\">",
"      Embury SH, Dozy AM, Miller J, et al. Concurrent sickle-cell anemia and alpha-thalassemia: effect on severity of anemia. N Engl J Med 1982; 306:270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42170/abstract/26\">",
"      McCurdy PR. 32-DFP and 51-Cr for measurement of red cell life span in abnormal hemoglobin syndromes. Blood 1969; 33:214.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42170/abstract/27\">",
"      Sherwood JB, Goldwasser E, Chilcote R, et al. Sickle cell anemia patients have low erythropoietin levels for their degree of anemia. Blood 1986; 67:46.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42170/abstract/28\">",
"      Saraf S, Farooqui M, Infusino G, et al. Standard clinical practice underestimates the role and significance of erythropoietin deficiency in sickle cell disease. Br J Haematol 2011; 153:386.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42170/abstract/29\">",
"      Singh A, Eckardt KU, Zimmermann A, et al. Increased plasma viscosity as a reason for inappropriate erythropoietin formation. J Clin Invest 1993; 91:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42170/abstract/30\">",
"      JONSSON U, ROATH OS, KIRKPATRICK CI. Nutritional megaloblastic anemia associated with sickle cell states. Blood 1959; 14:535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42170/abstract/31\">",
"      Lopez R, Shimizu N, Cooperman JM. Recurrent folic acid deficiency in sickle cell disease. Am J Dis Child 1973; 125:544.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42170/abstract/32\">",
"      Lanzkowsky P. Iron deficiency anemia. Pediatr Ann 1974; 3:6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42170/abstract/33\">",
"      Vichinsky E, Kleman K, Embury S, Lubin B. The diagnosis of iron deficiency anemia in sickle cell disease. Blood 1981; 58:963.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42170/abstract/34\">",
"      Topley JM, Rogers DW, Stevens MC, Serjeant GR. Acute splenic sequestration and hypersplenism in the first five years in homozygous sickle cell disease. Arch Dis Child 1981; 56:765.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42170/abstract/35\">",
"      Emond AM, Collis R, Darvill D, et al. Acute splenic sequestration in homozygous sickle cell disease: natural history and management. J Pediatr 1985; 107:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42170/abstract/36\">",
"      Orringer EP, Fowler VG Jr, Owens CM, et al. Case report: splenic infarction and acute splenic sequestration in adults with hemoglobin SC disease. Am J Med Sci 1991; 302:374.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42170/abstract/37\">",
"      Smith-Whitley K, Zhao H, Hodinka RL, et al. Epidemiology of human parvovirus B19 in children with sickle cell disease. Blood 2004; 103:422.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42170/abstract/38\">",
"      Pappo A, Buchanan GR. Acute splenic sequestration in a 2-month-old infant with sickle cell anemia. Pediatrics 1989; 84:578.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42170/abstract/39\">",
"      Airede AI. Acute splenic sequestration in a five-week-old infant with sickle cell disease. J Pediatr 1992; 120:160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42170/abstract/40\">",
"      Lane PA, Rogers ZR, Woods GM, et al. Fatal pneumococcal septicemia in hemoglobin SC disease. J Pediatr 1994; 124:859.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42170/abstract/41\">",
"      Piccin A, Smith OP, Murphy C, et al. Splenectomy in sickle cell anaemia: a cause of further crises? Br J Haematol 2009; 145:144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42170/abstract/42\">",
"      Wright JG, Hambleton IR, Thomas PW, et al. Postsplenectomy course in homozygous sickle cell disease. J Pediatr 1999; 134:304.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42170/abstract/43\">",
"      Rao SP, Miller ST, Cohen BJ. Transient aplastic crisis in patients with sickle cell disease. B19 parvovirus studies during a 7-year period. Am J Dis Child 1992; 146:1328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42170/abstract/44\">",
"      Serjeant BE, Hambleton IR, Kerr S, et al. Haematological response to parvovirus B19 infection in homozygous sickle-cell disease. Lancet 2001; 358:1779.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42170/abstract/45\">",
"      Saarinen UM, Chorba TL, Tattersall P, et al. Human parvovirus B19-induced epidemic acute red cell aplasia in patients with hereditary hemolytic anemia. Blood 1986; 67:1411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42170/abstract/46\">",
"      CHARNEY E, MILLER G. RETICULOCYTOPENIA IN SICKLE CELL DISEASE. APLASTIC EPISODES IN THE COURSE OF SICKLE CELL DISEASE IN CHILDREN. Am J Dis Child 1964; 107:450.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42170/abstract/47\">",
"      CHERNOFF AI, JOSEPHSON AM. Acute erythroblastopenia in sickle-cell anemia and infectious mononucleosis. AMA Am J Dis Child 1951; 82:310.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42170/abstract/48\">",
"      Petz LD, Calhoun L, Shulman IA, et al. The sickle cell hemolytic transfusion reaction syndrome. Transfusion 1997; 37:382.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42170/abstract/49\">",
"      Talano JA, Hillery CA, Gottschall JL, et al. Delayed hemolytic transfusion reaction/hyperhemolysis syndrome in children with sickle cell disease. Pediatrics 2003; 111:e661.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42170/abstract/50\">",
"      King KE, Shirey RS, Lankiewicz MW, et al. Delayed hemolytic transfusion reactions in sickle cell disease: simultaneous destruction of recipients' red cells. Transfusion 1997; 37:376.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42170/abstract/51\">",
"      Cullis JO, Win N, Dudley JM, Kaye T. Post-transfusion hyperhaemolysis in a patient with sickle cell disease: use of steroids and intravenous immunoglobulin to prevent further red cell destruction. Vox Sang 1995; 69:355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42170/abstract/52\">",
"      Win N, New H, Lee E, de la Fuente J. Hyperhemolysis syndrome in sickle cell disease: case report (recurrent episode) and literature review. Transfusion 2008; 48:1231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42170/abstract/53\">",
"      Chadebech P, Habibi A, Nzouakou R, et al. Delayed hemolytic transfusion reaction in sickle cell disease patients: evidence of an emerging syndrome with suicidal red blood cell death. Transfusion 2009; 49:1785.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42170/abstract/54\">",
"      Zimring JC, Spitalnik SL. To RBC or not to RBC: the role of suicidal death in hemolytic transfusion reactions. Transfusion 2009; 49:1776.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42170/abstract/55\">",
"      de Montalembert M, Dumont MD, Heilbronner C, et al. Delayed hemolytic transfusion reaction in children with sickle cell disease. Haematologica 2011; 96:801.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42170/abstract/56\">",
"      Yazdanbakhsh K, Ware RE, Noizat-Pirenne F. Red blood cell alloimmunization in sickle cell disease: pathophysiology, risk factors, and transfusion management. Blood 2012; 120:528.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42170/abstract/57\">",
"      Mota MA, Sakashita AM, Hammerschlak N, et al. Post-transfusion hyperhemolysis after haemolytic transfusion reaction in a patient with severe anemia: case report (abstract). Vox Sang 2006; 91:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42170/abstract/58\">",
"      Win N, Sinha S, Lee E, Mills W. Treatment with intravenous immunoglobulin and steroids may correct severe anemia in hyperhemolytic transfusion reactions: case report and literature review. Transfus Med Rev 2010; 24:64.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42170/abstract/59\">",
"      Bachmeyer C, Maury J, Parrot A, et al. Rituximab as an effective treatment of hyperhemolysis syndrome in sickle cell anemia. Am J Hematol 2010; 85:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42170/abstract/60\">",
"      Ballas SK, Marcolina MJ. Hyperhemolysis during the evolution of uncomplicated acute painful episodes in patients with sickle cell anemia. Transfusion 2006; 46:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42170/abstract/61\">",
"      Smits HL, Oski FA, Brody JI. The hemolytic crisis of sickle cell disease: the role of glucose-6-phosphate dehydrogenase deficiency. J Pediatr 1969; 74:544.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42170/abstract/62\">",
"      Brozovi M, Anionwu E. Sickle cell disease in Britain. J Clin Pathol 1984; 37:1321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42170/abstract/63\">",
"      Brozovi M, Davies SC, Brownell AI. Acute admissions of patients with sickle cell disease who live in Britain. Br Med J (Clin Res Ed) 1987; 294:1206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42170/abstract/64\">",
"      Dampier C, Setty BN, Eggleston B, et al. Vaso-occlusion in children with sickle cell disease: clinical characteristics and biologic correlates. J Pediatr Hematol Oncol 2004; 26:785.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42170/abstract/65\">",
"      Smith WR, Penberthy LT, Bovbjerg VE, et al. Daily assessment of pain in adults with sickle cell disease. Ann Intern Med 2008; 148:94.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42170/abstract/66\">",
"      Alexander N, Higgs D, Dover G, Serjeant GR. Are there clinical phenotypes of homozygous sickle cell disease? Br J Haematol 2004; 126:606.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42170/abstract/67\">",
"      Powars DR. Natural history of sickle cell disease--the first ten years. Semin Hematol 1975; 12:267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42170/abstract/68\">",
"      Houston-Yu P, Rana SR, Beyer B, Castro O. Frequent and prolonged hospitalizations: a risk factor for early mortality in sickle cell disease patients. Am J Hematol 2003; 72:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42170/abstract/69\">",
"      Baum KF, Dunn DT, Maude GH, Serjeant GR. The painful crisis of homozygous sickle cell disease. A study of the risk factors. Arch Intern Med 1987; 147:1231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42170/abstract/70\">",
"      Jones S, Duncan ER, Thomas N, et al. Windy weather and low humidity are associated with an increased number of hospital admissions for acute pain and sickle cell disease in an urban environment with a maritime temperate climate. Br J Haematol 2005; 131:530.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42170/abstract/71\">",
"      Yallop D, Duncan ER, Norris E, et al. The associations between air quality and the number of hospital admissions for acute pain and sickle-cell disease in an urban environment. Br J Haematol 2007; 136:844.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42170/abstract/72\">",
"      Nolan VG, Zhang Y, Lash T, et al. Association between wind speed and the occurrence of sickle cell acute painful episodes: results of a case-crossover study. Br J Haematol 2008; 143:433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42170/abstract/73\">",
"      Hargrave DR, Wade A, Evans JP, et al. Nocturnal oxygen saturation and painful sickle cell crises in children. Blood 2003; 101:846.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42170/abstract/74\">",
"      Setty BN, Stuart MJ, Dampier C, et al. Hypoxaemia in sickle cell disease: biomarker modulation and relevance to pathophysiology. Lancet 2003; 362:1450.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42170/abstract/75\">",
"      Sidman JD, Fry TL. Exacerbation of sickle cell disease by obstructive sleep apnea. Arch Otolaryngol Head Neck Surg 1988; 114:916.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42170/abstract/76\">",
"      Jacob E, Beyer JE, Miaskowski C, et al. Are there phases to the vaso-occlusive painful episode in sickle cell disease? J Pain Symptom Manage 2005; 29:392.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42170/abstract/77\">",
"      Darbari DS, Neely M, van den Anker J, Rana S. Increased clearance of morphine in sickle cell disease: implications for pain management. J Pain 2011; 12:531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42170/abstract/78\">",
"      Ballas SK, Larner J, Smith ED, et al. Rheologic predictors of the severity of the painful sickle cell crisis. Blood 1988; 72:1216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42170/abstract/79\">",
"      Ballas SK, Smith ED. Red blood cell changes during the evolution of the sickle cell painful crisis. Blood 1992; 79:2154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42170/abstract/80\">",
"      Akinola NO, Stevens SM, Franklin IM, et al. Rheological changes in the prodromal and established phases of sickle cell vaso-occlusive crisis. Br J Haematol 1992; 81:598.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42170/abstract/81\">",
"      Akinola NO, Stevens SM, Franklin IM, et al. Subclinical ischaemic episodes during the steady state of sickle cell anaemia. J Clin Pathol 1992; 45:902.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42170/abstract/82\">",
"      Neely CL, Wajima T, Kraus AP, et al. Lactic acid dehydrogenase activity and plasma hemoglobin elevations in sickle cell disease. Am J Clin Pathol 1969; 52:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42170/abstract/83\">",
"      Richardson SG, Matthews KB, Stuart J, et al. Serial changes in coagulation and viscosity during sickle-cell crisis. Br J Haematol 1979; 41:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42170/abstract/84\">",
"      Vichinsky EP, Neumayr LD, Gold JI, et al. Neuropsychological dysfunction and neuroimaging abnormalities in neurologically intact adults with sickle cell anemia. JAMA 2010; 303:1823.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42170/abstract/85\">",
"      Ware RE, Helms RW. Stroke with transfusions changing to hydroxyurea (SWiTCH): a phase 3 randomized clinical trial for treatment of children with sickle cell anemia, previous stroke, and iron overload. Blood (ASH Annual Meeting Abstracts) 2010; 116:844.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42170/abstract/86\">",
"      Ruggeri A, Eapen M, Scaravadou A, et al. Umbilical cord blood transplantation for children with thalassemia and sickle cell disease. Biol Blood Marrow Transplant 2011; 17:1375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42170/abstract/87\">",
"      Ali SB, Reid M, Fraser R, et al. Seizures in the Jamaica cohort study of sickle cell disease. Br J Haematol 2010; 151:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42170/abstract/88\">",
"      Hassell KL, Eckman JR, Lane PA. Acute multiorgan failure syndrome: a potentially catastrophic complication of severe sickle cell pain episodes. Am J Med 1994; 96:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42170/abstract/89\">",
"      Green M, Hall RJ, Huntsman RG, et al. Sickle cell crisis treated by exchange transfusion. Treatment of two patients with heterozygous sickle cell syndrome. JAMA 1975; 231:948.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42170/abstract/90\">",
"      Kumar S, Powars D, Allen J, Haywood LJ. Anxiety, self-concept, and personal and social adjustments in children with sickle cell anemia. J Pediatr 1976; 88:859.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42170/abstract/91\">",
"      Conyard S, Krishnamurthy M, Dosik H. Psychosocial aspects of sickle-cell anemia in adolescents. Health Soc Work 1980; 5:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42170/abstract/92\">",
"      Barrett DH, Wisotzek IE, Abel GG, et al. Assessment of psychosocial functioning of patients with sickle cell disease. South Med J 1988; 81:745.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42170/abstract/93\">",
"      Anie KA. Psychological complications in sickle cell disease. Br J Haematol 2005; 129:723.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42170/abstract/94\">",
"      Panepinto JA, O'Mahar KM, DeBaun MR, et al. Health-related quality of life in children with sickle cell disease: child and parent perception. Br J Haematol 2005; 130:437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42170/abstract/95\">",
"      Gil KM, Abrams MR, Phillips G, Williams DA. Sickle cell disease pain: 2. Predicting health care use and activity level at 9-month follow-up. J Consult Clin Psychol 1992; 60:267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42170/abstract/96\">",
"      Thompson RJ Jr, Gil KM, Abrams MR, Phillips G. Stress, coping, and psychological adjustment of adults with sickle cell disease. J Consult Clin Psychol 1992; 60:433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42170/abstract/97\">",
"      Dilworth-Anderson P. The importance of grandparents in extended-kin caregiving to black children with sickle cell disease. J Health Soc Policy 1994; 5:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42170/abstract/98\">",
"      Brandow AM, Brousseau DC, Panepinto JA. Postdischarge pain, functional limitations and impact on caregivers of children with sickle cell disease treated for painful events. Br J Haematol 2009; 144:782.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42170/abstract/99\">",
"      Platt OS, Rosenstock W, Espeland MA. Influence of sickle hemoglobinopathies on growth and development. N Engl J Med 1984; 311:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42170/abstract/100\">",
"      Hogan AM, Kirkham FJ, Prengler M, et al. An exploratory study of physiological correlates of neurodevelopmental delay in infants with sickle cell anaemia. Br J Haematol 2006; 132:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42170/abstract/101\">",
"      Stevens MC, Maude GH, Cupidore L, et al. Prepubertal growth and skeletal maturation in children with sickle cell disease. Pediatrics 1986; 78:124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42170/abstract/102\">",
"      Olambiwonnu NO, Penny R, Frasier SD. Sexual maturation in subjects with sickle cell anemia: studies of serum gonadotropin concentration, height, weight, and skeletal age. J Pediatr 1975; 87:459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42170/abstract/103\">",
"      Alleyne SI, Rauseo RD, Serjeant GR. Sexual development and fertility of Jamaican female patients with homozygous sickle cell disease. Arch Intern Med 1981; 141:1295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42170/abstract/104\">",
"      Singhal A, Gabay L, Serjeant GR. Testosterone deficiency and extreme retardation of puberty in homozygous sickle-cell disease. West Indian Med J 1995; 44:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42170/abstract/105\">",
"      Abbasi AA, Prasad AS, Ortega J, et al. Gonadal function abnormalities in sickle cell anemia. Studies in adult male patients. Ann Intern Med 1976; 85:601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42170/abstract/106\">",
"      Dada OA, Nduka EU. Endocrine function and haemoglobinopathies: relation between the sickle cell gene and circulating plasma levels of testosterone, luteinising hormone (LH) and follicle stimulating hormone (FSH) in adult males. Clin Chim Acta 1980; 105:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42170/abstract/107\">",
"      Landefeld CS, Schambelan M, Kaplan SL, Embury SH. Clomiphene-responsive hypogonadism in sickle cell anemia. Ann Intern Med 1983; 99:480.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42170/abstract/108\">",
"      Rogers ZR, Wang WC, Luo Z, et al. Biomarkers of splenic function in infants with sickle cell anemia: baseline data from the BABY HUG Trial. Blood 2011; 117:2614.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42170/abstract/109\">",
"      Bjornson AB, Lobel JS. Direct evidence that decreased serum opsonization of Streptococcus pneumoniae via the alternative complement pathway in sickle cell disease is related to antibody deficiency. J Clin Invest 1987; 79:388.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42170/abstract/110\">",
"      Overturf GD. Infections and immunizations of children with sickle cell disease. Adv Pediatr Infect Dis 1999; 14:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42170/abstract/111\">",
"      Vichinsky EP, Neumayr LD, Earles AN, et al. Causes and outcomes of the acute chest syndrome in sickle cell disease. National Acute Chest Syndrome Study Group. N Engl J Med 2000; 342:1855.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42170/abstract/112\">",
"      Jacobs JE, Quirolo K, Vichinsky E. Novel influenza A (H1N1) viral infection in pediatric patients with sickle-cell disease. Pediatr Blood Cancer 2011; 56:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42170/abstract/113\">",
"      Strouse JJ, Reller ME, Bundy DG, et al. Severe pandemic H1N1 and seasonal influenza in children and young adults with sickle cell disease. Blood 2010; 116:3431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42170/abstract/114\">",
"      Wong WY, Powars DR, Chan L, et al. Polysaccharide encapsulated bacterial infection in sickle cell anemia: a thirty year epidemiologic experience. Am J Hematol 1992; 39:176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42170/abstract/115\">",
"      Overturf GD, Powars D, Baraff LJ. Bacterial meningitis and septicemia in sickle cell disease. Am J Dis Child 1977; 131:784.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42170/abstract/116\">",
"      Williams TN, Uyoga S, Macharia A, et al. Bacteraemia in Kenyan children with sickle-cell anaemia: a retrospective cohort and case-control study. Lancet 2009; 374:1364.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42170/abstract/117\">",
"      Hankins J, Ware RE. Sickle-cell disease: an ounce of prevention, a pound of cure. Lancet 2009; 374:1308.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42170/abstract/118\">",
"      Halasa NB, Shankar SM, Talbot TR, et al. Incidence of invasive pneumococcal disease among individuals with sickle cell disease before and after the introduction of the pneumococcal conjugate vaccine. Clin Infect Dis 2007; 44:1428.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42170/abstract/119\">",
"      Greene JR, Polk OD, Castro O. Fulminant pneumococcal sepsis in an adult with sickle-cell anemia. N Engl J Med 1984; 311:674.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42170/abstract/120\">",
"      Olopoenia L, Frederick W, Greaves W, et al. Pneumococcal sepsis and meningitis in adults with sickle cell disease. South Med J 1990; 83:1002.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42170/abstract/121\">",
"      Zarrouk V, Habibi A, Zahar JR, et al. Bloodstream infection in adults with sickle cell disease: association with venous catheters, Staphylococcus aureus, and bone-joint infections. Medicine (Baltimore) 2006; 85:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42170/abstract/122\">",
"      Vichinsky EP, Styles LA, Colangelo LH, et al. Acute chest syndrome in sickle cell disease: clinical presentation and course. Cooperative Study of Sickle Cell Disease. Blood 1997; 89:1787.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42170/abstract/123\">",
"      McCavit TL, Quinn CT, Techasaensiri C, Rogers ZR. Increase in invasive Streptococcus pneumoniae infections in children with sickle cell disease since pneumococcal conjugate vaccine licensure. J Pediatr 2011; 158:505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42170/abstract/124\">",
"      Cundell DR, Gerard NP, Gerard C, et al. Streptococcus pneumoniae anchor to activated human cells by the receptor for platelet-activating factor. Nature 1995; 377:435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42170/abstract/125\">",
"      Miller ML, Gao G, Pestina T, et al. Hypersusceptibility to invasive pneumococcal infection in experimental sickle cell disease involves platelet-activating factor receptor. J Infect Dis 2007; 195:581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42170/abstract/126\">",
"      Vichinsky E, Hurst D, Earles A, et al. Newborn screening for sickle cell disease: effect on mortality. Pediatrics 1988; 81:749.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42170/abstract/127\">",
"      Ward J, Smith AL. Hemophilus influenzae bacteremia in children with sickle cell disease. J Pediatr 1976; 88:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42170/abstract/128\">",
"      Powars D, Overturf G, Turner E. Is there an increased risk of Haemophilus influenzae septicemia in children with sickle cell anemia? Pediatrics 1983; 71:927.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42170/abstract/129\">",
"      Barrett-Connor E. Bacterial infection and sickle cell anemia. An analysis of 250 infections in 166 patients and a review of the literature. Medicine (Baltimore) 1971; 50:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42170/abstract/130\">",
"      Robinson MG, Watson RJ. Pneumococcal meningitis in sickle-cell anemia. N Engl J Med 1966; 274:1006.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42170/abstract/131\">",
"      Poncz M, Kane E, Gill FM. Acute chest syndrome in sickle cell disease: etiology and clinical correlates. J Pediatr 1985; 107:861.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42170/abstract/132\">",
"      Moser FG, Miller ST, Bello JA, et al. The spectrum of brain MR abnormalities in sickle-cell disease: a report from the Cooperative Study of Sickle Cell Disease. AJNR Am J Neuroradiol 1996; 17:965.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42170/abstract/133\">",
"      Adams RJ, McKie VC, Hsu L, et al. Prevention of a first stroke by transfusions in children with sickle cell anemia and abnormal results on transcranial Doppler ultrasonography. N Engl J Med 1998; 339:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42170/abstract/134\">",
"      Lal A, Fung EB, Pakbaz Z, et al. Bone mineral density in children with sickle cell anemia. Pediatr Blood Cancer 2006; 47:901.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42170/abstract/135\">",
"      Fitzhugh CD, Lauder N, Jonassaint JC, et al. Cardiopulmonary complications leading to premature deaths in adult patients with sickle cell disease. Am J Hematol 2010; 85:36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42170/abstract/136\">",
"      Gladwin MT, Sachdev V. Cardiovascular abnormalities in sickle cell disease. J Am Coll Cardiol 2012; 59:1123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42170/abstract/137\">",
"      Voskaridou E, Christoulas D, Terpos E. Sickle-cell disease and the heart: review of the current literature. Br J Haematol 2012; 157:664.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42170/abstract/138\">",
"      Covitz W, Espeland M, Gallagher D, et al. The heart in sickle cell anemia. The Cooperative Study of Sickle Cell Disease (CSSCD). Chest 1995; 108:1214.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42170/abstract/139\">",
"      Varat MA, Adolph RJ, Fowler NO. Cardiovascular effects of anemia. Am Heart J 1972; 83:415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42170/abstract/140\">",
"      Gerry JL, Bulkley BH, Hutchins GM. Clinicopathologic analysis of cardiac dysfunction in 52 patients with sickle cell anemia. Am J Cardiol 1978; 42:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42170/abstract/141\">",
"      Zilberman MV, Du W, Das S, Sarnaik SA. Evaluation of left ventricular diastolic function in pediatric sickle cell disease patients. Am J Hematol 2007; 82:433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42170/abstract/142\">",
"      Johnson MC, Kirkham FJ, Redline S, et al. Left ventricular hypertrophy and diastolic dysfunction in children with sickle cell disease are related to asleep and waking oxygen desaturation. Blood 2010; 116:16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42170/abstract/143\">",
"      Eddine AC, Alvarez O, Lipshultz SE, et al. Ventricular structure and function in children with sickle cell disease using conventional and tissue Doppler echocardiography. Am J Cardiol 2012; 109:1358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42170/abstract/144\">",
"      Ng ML, Liebman J, Anslovar J, Gross S. Cardiovascular findings in children with sickle cell anemia. Dis Chest 1967; 52:788.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42170/abstract/145\">",
"      Mueller BU, Martin KJ, Dreyer W, et al. Prolonged QT interval in pediatric sickle cell disease. Pediatr Blood Cancer 2006; 47:831.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42170/abstract/146\">",
"      Liem RI, Young LT, Thompson AA. Prolonged QTc interval in children and young adults with sickle cell disease at steady state. Pediatr Blood Cancer 2009; 52:842.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42170/abstract/147\">",
"      Klings ES, Wyszynski DF, Nolan VG, Steinberg MH. Abnormal pulmonary function in adults with sickle cell anemia. Am J Respir Crit Care Med 2006; 173:1264.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42170/abstract/148\">",
"      Westwood MA, Shah F, Anderson LJ, et al. Myocardial tissue characterization and the role of chronic anemia in sickle cell cardiomyopathy. J Magn Reson Imaging 2007; 26:564.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42170/abstract/149\">",
"      Aessopos A, Farmakis D, Trompoukis C, et al. Cardiac involvement in sickle beta-thalassemia. Ann Hematol 2009; 88:557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42170/abstract/150\">",
"      Balfour IC, Covitz W, Arensman FW, et al. Left ventricular filling in sickle cell anemia. Am J Cardiol 1988; 61:395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42170/abstract/151\">",
"      Karayalcin G, Rosner F, Kim KY, et al. Sickle cell anemia- clinical manifestations in 100 patients and review of the literature. Am J Med Sci 1975; 269:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42170/abstract/152\">",
"      Val-Mejias J, Lee WK, Weisse AB, Regan TJ. Left ventricular performance during and after sickle cell crisis. Am Heart J 1979; 97:585.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42170/abstract/153\">",
"      Miller DM, Winslow RM, Klein HG, et al. Improved exercise performance after exchange transfusion in subjects with sickle cell anemia. Blood 1980; 56:1127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42170/abstract/154\">",
"      Martin CR, Cobb C, Tatter D, et al. Acute myocardial infarction in sickle cell anemia. Arch Intern Med 1983; 143:830.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42170/abstract/155\">",
"      Martin CR, Johnson CS, Cobb C, et al. Myocardial infarction in sickle cell disease. J Natl Med Assoc 1996; 88:428.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42170/abstract/156\">",
"      Pannu R, Zhang J, Andraws R, et al. Acute myocardial infarction in sickle cell disease: a systematic review. Crit Pathw Cardiol 2008; 7:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42170/abstract/157\">",
"      Eckman JR. Leg ulcers in sickle cell disease. Hematol Oncol Clin North Am 1996; 10:1333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42170/abstract/158\">",
"      Koshy M, Entsuah R, Koranda A, et al. Leg ulcers in patients with sickle cell disease. Blood 1989; 74:1403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42170/abstract/159\">",
"      Serjeant GR. Leg ulceration in sickle cell anemia. Arch Intern Med 1974; 133:690.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42170/abstract/160\">",
"      Kato GJ, McGowan V, Machado RF, et al. Lactate dehydrogenase as a biomarker of hemolysis-associated nitric oxide resistance, priapism, leg ulceration, pulmonary hypertension, and death in patients with sickle cell disease. Blood 2006; 107:2279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42170/abstract/161\">",
"      Nolan VG, Adewoye A, Baldwin C, et al. Sickle cell leg ulcers: associations with haemolysis and SNPs in Klotho, TEK and genes of the TGF-beta/BMP pathway. Br J Haematol 2006; 133:570.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42170/abstract/162\">",
"      Cumming V, King L, Fraser R, et al. Venous incompetence, poverty and lactate dehydrogenase in Jamaica are important predictors of leg ulceration in sickle cell anaemia. Br J Haematol 2008; 142:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42170/abstract/163\">",
"      Sehgal SC, Arunkumar BK. Microbial flora and its significance in pathology of sickle cell disease leg ulcers. Infection 1992; 20:86.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42170/abstract/164\">",
"      Ankra-Badu GA. Sickle cell leg ulcers in Ghana. East Afr Med J 1992; 69:366.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42170/abstract/165\">",
"      Clare A, FitzHenley M, Harris J, et al. Chronic leg ulceration in homozygous sickle cell disease: the role of venous incompetence. Br J Haematol 2002; 119:567.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42170/abstract/166\">",
"      Keidan AJ, Stuart J. Rheological effects of bed rest in sickle cell disease. J Clin Pathol 1987; 40:1187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42170/abstract/167\">",
"      Mohan JS, Marshall JM, Reid HL, et al. Postural vasoconstriction and leg ulceration in homozygous sickle cell disease. Clin Sci (Lond) 1997; 92:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42170/abstract/168\">",
"      Baum KF, MacFarlane DE, Maude GH, Serjeant GR. Topical antibiotics in chronic sickle cell leg ulcers. Trans R Soc Trop Med Hyg 1987; 81:847.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42170/abstract/169\">",
"      Weinzweig N, Schuler J, Vitello J. Simultaneous reconstruction of extensive soft-tissue defects of both lower limbs with free hemiflaps harvested from the omentum. Plast Reconstr Surg 1997; 99:757.",
"     </a>",
"    </li>",
"    <li>",
"     Leg ulcers. In: The management of sickle cell disease, 4th ed, National Institutes of Health publication 02-2117, June 2002. p.139.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42170/abstract/171\">",
"      Wun T, Hassell K. Best practices for transfusion for patients with sickle cell disease. Hematology Reports 2009; 1:e22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42170/abstract/172\">",
"      McMahon L, Tamary H, Askin M, et al. A randomized phase II trial of Arginine Butyrate with standard local therapy in refractory sickle cell leg ulcers. Br J Haematol 2010; 151:516.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42170/abstract/173\">",
"      M&eacute;ry L, Girot R, Aractingi S. Topical effectiveness of molgramostim (GM-CSF) in sickle cell leg ulcers. Dermatology 2004; 208:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42170/abstract/174\">",
"      Alikhan MA, Carter G, Mehta P. Topical GM-CSF hastens healing of leg ulcers in sickle cell disease. Am J Hematol 2004; 76:192.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42170/abstract/175\">",
"      Lionnet F, Bachmeyer C, Stankovic K, et al. Efficacy of the endothelin receptor blocker bosentan for refractory sickle cell leg ulcers. Br J Haematol 2008; 142:991.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42170/abstract/176\">",
"      Ballas SK. Treatment of painful sickle cell leg ulcers with topical opioids. Blood 2002; 99:1096.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42170/abstract/177\">",
"      Anuforo J, Nguyen J, Luk K, et al. Association of non-healing wounds, pain and neurochemical alterations in sickle cell disease. Blood (ASH Annual Meeting Abstracts) 2010; 116:842.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42170/abstract/178\">",
"      Platt OS, Brambilla DJ, Rosse WF, et al. Mortality in sickle cell disease. Life expectancy and risk factors for early death. N Engl J Med 1994; 330:1639.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42170/abstract/179\">",
"      Gray A, Anionwu EN, Davies SC, Brozovic M. Patterns of mortality in sickle cell disease in the United Kingdom. J Clin Pathol 1991; 44:459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42170/abstract/180\">",
"      Powars D, Weidman JA, Odom-Maryon T, et al. Sickle cell chronic lung disease: prior morbidity and the risk of pulmonary failure. Medicine (Baltimore) 1988; 67:66.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42170/abstract/181\">",
"      Mekontso Dessap A, Leon R, Habibi A, et al. Pulmonary hypertension and cor pulmonale during severe acute chest syndrome in sickle cell disease. Am J Respir Crit Care Med 2008; 177:646.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42170/abstract/182\">",
"      Alam S, Mehari A, Kato GJ, et al. Study of clinical characteristics of sickle cell disease patients developing cor-pulmonale during acute hospitalization. Am J Respir Crit Care Med 2011; 183:A5945.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42170/abstract/183\">",
"      Uong EC, Boyd JH, DeBaun MR. Daytime pulse oximeter measurements do not predict incidence of pain and acute chest syndrome episodes in sickle cell anemia. J Pediatr 2006; 149:707.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42170/abstract/184\">",
"      Rackoff WR, Kunkel N, Silber JH, et al. Pulse oximetry and factors associated with hemoglobin oxygen desaturation in children with sickle cell disease. Blood 1993; 81:3422.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42170/abstract/185\">",
"      Quinn CT, Ahmad N. Clinical correlates of steady-state oxyhaemoglobin desaturation in children who have sickle cell disease. Br J Haematol 2005; 131:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42170/abstract/186\">",
"      Campbell A, Minniti CP, Nouraie M, et al. Prospective evaluation of haemoglobin oxygen saturation at rest and after exercise in paediatric sickle cell disease patients. Br J Haematol 2009; 147:352.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42170/abstract/187\">",
"      Gladwin MT, Vichinsky E. Pulmonary complications of sickle cell disease. N Engl J Med 2008; 359:2254.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42170/abstract/188\">",
"      Paul RN, Castro OL, Aggarwal A, Oneal PA. Acute chest syndrome: sickle cell disease. Eur J Haematol 2011; 87:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42170/abstract/189\">",
"      Sundaram N, Bennett M, Wilhelm J, et al. Biomarkers for early detection of sickle nephropathy. Am J Hematol 2011; 86:559.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42170/abstract/190\">",
"      McPherson Yee M, Jabbar SF, Osunkwo I, et al. Chronic kidney disease and albuminuria in children with sickle cell disease. Clin J Am Soc Nephrol 2011; 6:2628.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42170/abstract/191\">",
"      Pham PT, Pham PC, Wilkinson AH, Lew SQ. Renal abnormalities in sickle cell disease. Kidney Int 2000; 57:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42170/abstract/192\">",
"      Campbell KL, Hud LM, Adams S, et al. Safety of iodinated intravenous contrast medium administration in sickle cell disease. Am J Med 2012; 125:100.e11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42170/abstract/193\">",
"      Hayes RJ, Condon PI, Serjeant GR. Haematological factors associated with proliferative retinopathy in homozygous sickle cell disease. Br J Ophthalmol 1981; 65:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42170/abstract/194\">",
"      Nagpal KC, Goldberg MF, Rabb MF. Ocular manifestations of sickle hemoglobinopathies. Surv Ophthalmol 1977; 21:391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42170/abstract/195\">",
"      McLeod DS, Merges C, Fukushima A, et al. Histopathologic features of neovascularization in sickle cell retinopathy. Am J Ophthalmol 1997; 124:455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42170/abstract/196\">",
"      Cao J, Mathews MK, McLeod DS, et al. Angiogenic factors in human proliferative sickle cell retinopathy. Br J Ophthalmol 1999; 83:838.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42170/abstract/197\">",
"      Friberg TR, Young CM, Milner PF. Incidence of ocular abnormalities in patients with sickle hemoglobinopathies. Ann Ophthalmol 1986; 18:150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42170/abstract/198\">",
"      Hayes RJ, Condon PI, Serjeant GR. Haematological factors associated with proliferative retinopathy in sickle cell-haemoglobin C disease. Br J Ophthalmol 1981; 65:712.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42170/abstract/199\">",
"      van Meurs JC. Ocular findings in sickle cell patients on Cura&ccedil;ao. Int Ophthalmol 1991; 15:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42170/abstract/200\">",
"      Downes SM, Hambleton IR, Chuang EL, et al. Incidence and natural history of proliferative sickle cell retinopathy: observations from a cohort study. Ophthalmology 2005; 112:1869.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42170/abstract/201\">",
"      Hingorani M, Bentley CR, Jackson H, et al. Retinopathy in haemoglobin C trait. Eye (Lond) 1996; 10 ( Pt 3):338.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42170/abstract/202\">",
"      Moriarty BJ, Acheson RW, Condon PI, Serjeant GR. Patterns of visual loss in untreated sickle cell retinopathy. Eye (Lond) 1988; 2 ( Pt 3):330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/11/42170/abstract/203\">",
"      Clarkson JG. The ocular manifestations of sickle-cell disease: a prevalence and natural history study. Trans Am Ophthalmol Soc 1992; 90:481.",
"     </a>",
"    </li>",
"    <li>",
"     www.cdc.gov/ncbddd/sicklecell/index.html (Accessed on October 03, 2011).",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7119 Version 23.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-89.218.100.194-EFEE8658EB-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_11_42170=[""].join("\n");
var outline_f41_11_42170=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H24957881\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      GENERAL OVERVIEW",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Survival and prognosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Early predictors of morbidity and mortality",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      LABORATORY FINDINGS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      CBC and routine laboratory testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Hemoglobin electrophoresis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Anemia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Acute severe anemia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Splenic sequestration crisis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Aplastic crisis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Hyperhemolytic crisis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      MAJOR CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Acute painful episodes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Laboratory studies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Neurologic complications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Multiorgan failure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Psychosocial issues",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Growth and development",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12679833\">",
"      Reduced or absent splenic function",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Infection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Bacteremia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H26155837\">",
"      S. pneumoniae",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H26155854\">",
"      H. influenzae type b",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Meningitis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Bacterial pneumonia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Osteomyelitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Cerebrovascular events",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Bone complications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Cardiac complications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      - Myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Dermatologic complications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      - Leg ulcers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H18480916\">",
"      Management",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      Hepatobiliary complications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      Pregnancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      Priapism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      Pulmonary complications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      - Oxygen saturation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H37\">",
"      - Acute chest syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H38\">",
"      Renal complications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H39\">",
"      Retinopathy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H40\">",
"      - Proliferative sickle retinopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H41\">",
"      ADDITIONAL INFORMATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24957881\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/7119\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/7119|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?43/18/44335\" title=\"diagnostic image 1\">",
"      Sickle cell scanning EM",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/7119|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?40/31/41469\" title=\"figure 1\">",
"      CVA in sickle cell disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?4/40/4750\" title=\"figure 2\">",
"      Prevent first CVA sickle cell",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/7119|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?1/42/1703\" title=\"picture 1\">",
"      Sickle cell anemia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/1/17433?source=related_link\">",
"      Acquired pure red cell aplasia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/45/17114?source=related_link\">",
"      Acute pain management in adults with sickle cell disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/46/29418?source=related_link\">",
"      Approach to the adult patient with anemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/34/34346?source=related_link\">",
"      Approach to the adult patient with splenomegaly and other splenic disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/3/18489?source=related_link\">",
"      Approach to the diagnosis of hemolytic anemia in the adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/4/18506?source=related_link\">",
"      Bone and joint complications in sickle cell disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/39/26234?source=related_link\">",
"      Causes and diagnosis of anemia due to iron deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/11/31930?source=related_link\">",
"      Cerebrovascular complications of sickle cell disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/8/28810?source=related_link\">",
"      Clinical features and diagnosis of acute bacterial meningitis in children older than one month of age",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/42/9895?source=related_link\">",
"      Clinical features and management of sepsis in the asplenic patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/54/22377?source=related_link\">",
"      Clinical manifestations and pathogenesis of human parvovirus B19 infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/32/39434?source=related_link\">",
"      Clinical variability in sickle cell anemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/47/6906?source=related_link\">",
"      Congenital anomalies and acquired abnormalities of the optic nerve",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/30/23017?source=related_link\">",
"      Diagnosis and management of priapism in sickle cell disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/57/22424?source=related_link\">",
"      Diagnosis and treatment of delayed puberty",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/54/42856?source=related_link\">",
"      Diagnosis of sickle cell syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/30/16874?source=related_link\">",
"      Differential diagnosis of abdominal pain in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/23/13689?source=related_link\">",
"      Evaluation of bone marrow aspirate smears",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/21/25942?source=related_link\">",
"      Fat embolism syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/62/13289?source=related_link\">",
"      Genetics and pathophysiology of glucose-6-phosphate dehydrogenase deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/3/30775?source=related_link\">",
"      Hematopoietic cell transplantation in sickle cell disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/49/2842?source=related_link\">",
"      Hepatic manifestations of sickle cell disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/1/39961?source=related_link\">",
"      Management of fever in sickle cell disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/41/32410?source=related_link\">",
"      Medical management of lower extremity chronic venous disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/38/23143?source=related_link\">",
"      Microbiology and pathogenesis of Streptococcus pneumoniae",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/43/28346?source=related_link\">",
"      Osteonecrosis (avascular necrosis of bone)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/0/39946?source=related_link\">",
"      Overview of the management of sickle cell disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?4/8/4227?source=related_link\">",
"      Patient information: Sickle cell anemia (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/62/20458?source=related_link\">",
"      Pregnancy in women with sickle cell disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/28/27082?source=related_link\">",
"      Pulmonary complications of sickle cell disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/30/36326?source=related_link\">",
"      Red blood cell survival: Normal values and measurement",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/3/6202?source=related_link\">",
"      Renal manifestations of sickle cell disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/10/24744?source=related_link\">",
"      Sepsis and the systemic inflammatory response syndrome: Definitions, epidemiology, and prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/25/30104?source=related_link\">",
"      Sickle hemoglobin polymer: Structure and functional properties",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/33/34330?source=related_link\">",
"      Specific therapies for sickle cell disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/29/23001?source=related_link\">",
"      Structure and function of normal human hemoglobins",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/26/16810?source=related_link\">",
"      The acute chest syndrome in children and adolescents with sickle cell disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/56/37766?source=related_link\">",
"      Transfusion-associated immune and non immune-mediated hemolysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/1/31767?source=related_link\">",
"      Treatment and prevention of parvovirus B19 infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/5/5209?source=related_link\">",
"      Variant sickle cell syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/63/14330?source=related_link\">",
"      Vasoocclusion in sickle cell disease",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f41_11_42171="Criteria for initiation of antibiotics for UTI";
var content_f41_11_42171=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F61419&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F61419&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Minimum criteria for the initiation of antibiotics for urinary tract infection in long-term care residents",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        With indwelling catheter",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        At least one of the following:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Fever (&gt;37.9&deg;C [100&deg;F] or 1.5&deg;C [2.4&deg;F] above baseline)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        New CVA tenderness",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Rigors",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        New onset delirium",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Without indwelling catheter:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Acute dysuria",
"        <strong>",
"         OR",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fever (&gt;37.9&deg;C [100&deg;F] or 1.5&deg;C [2.4&deg;F] above baseline)",
"        <strong>",
"         AND",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        At least one of the following:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        New or worsening urgency",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Frequency",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Suprapubic pain",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Gross hematuria",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        CVA tenderness",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Urinary incontinence",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Source: Loeb M, Bentley DW, Bradley S, et al. Development of minimum criteria for the initiation of antibiotics in residents of long-term-care facilities: results of a consensus conference. Infect Control Hosp Epidemiol 2001; 22:120.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_11_42171=[""].join("\n");
var outline_f41_11_42171=null;
var title_f41_11_42172="Chemical quality standards";
var content_f41_11_42172=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F71221&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F71221&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Chemical quality standards for water used in hemodialysis applications in the United States",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Contaminant",
"       </td>",
"       <td class=\"subtitle1\">",
"        Maximum concentration (mg/L)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Substances normally included in dialysate",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Calcium",
"       </td>",
"       <td>",
"        2 (0.1 mEq/L)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Magnesium",
"       </td>",
"       <td>",
"        4 (0.3 mEq/L)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Potassium",
"       </td>",
"       <td>",
"        8 (0.2 mEq/L)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Sodium",
"       </td>",
"       <td>",
"        70 (3.0 mEq/L)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Substances regulated by the Safe Water Drinking Act",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Antimony",
"       </td>",
"       <td>",
"        0.006",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Arsenic",
"       </td>",
"       <td>",
"        0.005",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Barium",
"       </td>",
"       <td>",
"        0.10",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Beryllium",
"       </td>",
"       <td>",
"        0.0004",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Cadmium",
"       </td>",
"       <td>",
"        0.001",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Chromium",
"       </td>",
"       <td>",
"        0.014",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Mercury",
"       </td>",
"       <td>",
"        0.0002",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Selenium",
"       </td>",
"       <td>",
"        0.09",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Silver",
"       </td>",
"       <td>",
"        0.005",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Thallium",
"       </td>",
"       <td>",
"        0.002",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Substances known to be toxic in hemodialysis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Aluminum",
"       </td>",
"       <td>",
"        0.01",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Total chlorine*",
"       </td>",
"       <td>",
"        0.10",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Copper",
"       </td>",
"       <td>",
"        0.10",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Fluoride",
"       </td>",
"       <td>",
"        0.20",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Lead",
"       </td>",
"       <td>",
"        0.005",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Nitrate (as N)",
"       </td>",
"       <td>",
"        2.0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Sulfate",
"       </td>",
"       <td>",
"        100",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Zinc",
"       </td>",
"       <td>",
"        0.10",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * A maximum allowable level for total chlorine of 0.10 mg/L replaces the separate maximum allowable levels for free chlorine and chloramine included in versions of the AAMI water quality standard published before 2011.",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Association for the Advancement of Medical Instrumentation. Water for Hemodialysis and Related Therapies, ANSI/AAMI/ISO 13959:2009, Association for the Advancement of Medical Instrumentation, Arlington, VA 2011.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_11_42172=[""].join("\n");
var outline_f41_11_42172=null;
var title_f41_11_42173="Inverse psoriasis";
var content_f41_11_42173=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F79274&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F79274&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Inverse psoriasis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 217px; height: 145px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCACRANkDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD5dtotxzjmtuzgPy+1VbGPgcf/AF62rKNuMqR/SuWpK5dOPVk8ECgcVZUHg9CKmjhGOeac0RUEnp29652dMY3Ks43R5BrLFuyXJIyQRWw8Jf1xVO4mWGXa3Jx+VHodVKLvZInhlZVAzk+ta1pOo9Olc1DKTKZMjpyK0YZVkiPGCT+VHIdqo23OpjnXy8qc461aivd5V04PfBrnLa5cDYAoBGAc1o2M8flt5q7ZcdfX3qHBmyo2V2a8iea/mEbz2pIPMEUqqDgc46HmqkN26tEu0N0JP9KuQNLPdsXbaSACo9MnAqWrESVkU79sfvIznYvzkdj2rc0u422x5IKk/jWVPErxXCoQoOc+5p2jORbr5h4DkEenvSsQuzOgUCRiG644NWYgTEDuG7PBqpFztYHkDHuams5PkKcEqcVLLLoQg8tx+VPGN23Ax2+tVxIpALg4zjBqRXJB5HHOPSkUStkJ0+tV5Ap69P0FPE3GfQdz2qq0isrlPuZ4pAO2D+Dbjt6VXlGMA5I6HmhpQp+XGB2qrJPubrnmmkDZHIQGbknHQjtUe4SD6UyWRgCeuDUYkUnGMZppEtk74AwGPTpVSU5XpzUhbHaonkGMZ5qkYykQOxCgA9+lZf8AZtr/AM+8f/fIq5I+wHpuqHf7t+darQ55PU4WxjJIGAAK2ooSAD2x+dVrGMDBI71swwgqueRWkmcEIi28Y25wfxqy8eRgjjFTRAKuGGDipFAfjOOKzZ0QRlMNoweB7VzmqoVnzztxXX3dqcbuM4rAv4TNGeBmnF63O7Dvllcx4mAHXNWUkcbMLuHrmo4bYMcN1Hepooi2Cei1vozvktTTjlwEYDHQHmr4cLEo6luc9azYLfdMW3sUxkgmrkeQ4JXgcjNQ0NdjXt8CMOYw/PTOMVfQiNWaaTYnUL3IHvWPDcFGXzAPkPHoafLI8vAclTzs5xismgltY0pZPtCBIMmMn+EdvelsVMZeM/dBzmsNbtok2E7C2Rgd60bCVlJddwjIGVY557UnHQlU03odHayIGjcdVBB5wKuRHe7EDa3UZ4zWTBLsUnZg4wQO4qfz45I/mYoAc471mRUjY09+VBU9D83HSmvLtPy4NZk11tJAQcjG4dx+dQibc6q0hbuFB+XGe9KxES5POViILkY6kDPHPFNguRtwiDB5wTVTUopvvrhhgEY7VXs5MQAvnknBotoacvu3LbzFmG7jnOKdLMoA2Hk9qpXBIkBX5gOMVD5wPJ/DFNIzloWzNhiGwAaY0yA/QVTkk+93PaovM3E85osZORbaU9CepqItwWbrnFRSvyGz07UiuArA9KpGEmRSuMtn8Kq+eabdNyfas7zB61qkc8paklpAVPT61q2wBB4psEBA+7VyKH5+nNDM4IXymyDwR2qZdkaEucA+gq3DEFQseVHtUkdsJm3Hr6DtWbZ0wiZ0kRZdyn5cdM1iSQFZHOBtOcc11NxbGNu+COB71mTwgx/L1IwRmhM6qcTlhEmXaM555xTxCM5AJI9KtrZrE7DPXnipYjtfHBzxz1rVS7HoqFyGJBkBkq9Dbq/zMxUAY49aZ8kmAxK464PWtSxiVQTlg2OCaq9yXCy0M1LF5bjuQMHBPb3p80PltsjB644Na8kWTmLeGJIbB7deKcbZthGQ69fw9/yosTDsznpbQLumkBDJyCOcCrtncbNu5xKoO4YwM/WpbuB2IQPmNh8wJxxVB7VlfdASAp5z3/Ck9TTlOjF1FKx3hQxXOVzj9KiW7gP7uLk9B6muaupLu0bzBI20jGwevakhmkDl2baSMMyjOPYVnyIxmmjpPN3ACUlT2GMjIpsEwR/3xGW4XK/4VFZzRNgJ8uWxuPQj1q5IrOWjYfumXO8DkmhLozO7SsWFkO3c2CwxmhY1IzIAD6VVsx5KYlztONu4nP0NWbu5XcFjPmYxk54rOwlsVbw7VYH+EYrN8wHIDH5eMVLdzhjtJIYnj3qrMp2ssYBwAeeKtIzmxksoycnnHGKBLtGOlV2yrcjHfikeQl89x60+U52y6JQzYB49aaznYSevQVSikKvgEYqRpM9afKZSkVr6T5Tg84rG88+v6Vd1OQBWAPtWD9oHpWsY3MHJI9JgiOPlb3NW4YivJU59qkt4RxgEAdauxRliByPWsmzanAkt48gAjjrxVyK1A+ZeD61PbRZU9CfarSKQTk8VmzaK6IzLiAMvzAkjmsi8tic5+7ndkDmuocKwPIyp59qz5rcMdvJJGetRc6qehxF4jJNtAG0+nNVHQKw8nJHfnpW5qtqYljb5VfPJbvVK3tll5cgtjp1rWEtD0oL3dCtbxK1wSOM4HNa726soVgfU571UuYXtnUgHy+vSr9v88RL7uP4c8gU+Ydu4y2kZWeNeg+7z2qzbTlNu4BSMbd3Oaowo7yuYm2leMGllmdYwsqAhuwGOa1izGdO+xNLavJKZNq84KjdjOT6VBN+6YbtpG7pnmm2UgZ4jnnIG3uMH8qfIgcZ3bgVOM8EEdzTauEGZl4kefldlYk5U9AKilt1iUrbhmOfvnhTW7BaxPaGVOSoOcnoc4/rWRdyS2oYjaVzzHjmoFJXJ7KR4WKMdrIv1BzVqDVJJJgGICrjHGMisK2E927K7qiN1CZI47ZqZ7WGNxGAyynkEHgigzklLodKl1HcSMAeD69KjuEieJkB2sOm08Z96xreSS3JR8A9wwwTTpb088bWxzkYPt7VKWolAdqKbyrQLkxvt2nuMdaghdyD7cYxziozdymTlcquQBmrkSk7HIA9TmqZjVSSsyKYZRiVB9CKz5yTlTwwrUuwAhEZCnuPWsu6+fGeMjsKSOGWhWSXD8kVYMmBg421WKjaWGDUE0jbAOlMxepS1WbAcA/lXPed9a072QsrHPOKxsn/JremrI5Kz1PoO1hXHfLH860kgGccDt9aLaJQytjJX9avJGTggHrnmuWx6cVqNih28r1FShMHLemamSPJ3Hg1KwBADAE/SpZqkUgijkrhj39qqlADjHB6HFaUkeUPy/SmSxnG1eGzyKhqx0Rlc4rX0klRYzGR07VnpG0ZQpzkcjHBrudSsA6bjlRXN3lrLAWWPkKucjtzRGVtDvo1YyjyozDcGddswyMgfMOT7UtvKQrbF+ZD90jmql7IQQ2394rZYjp+X41JYSPJG0uWVmOSfStbFW1siW4IkdAR5b9nIxRDcmbMcoyxGOePxq80QayO4AgDjPBFZF9FIHIjQkjkNxTTIbZKWVX8uWMiI4DY+Y+n9BUrLGyM6/NsUqOcE1Vjd5EKyS7GB4U4pxc4X7pP8RQ4P0q1IztrcuxRQraxhHZZIuQBxnjnjp3rD1oy+YT8mCTjC8lsc5rWe4RwrFPkHVc9M9qy9RAR1ntmyDldhbIwRimhSuZ9o9wpPlzMoZTuUrxgcfy71o2HmbsTRqQcqCh4z9aveGEs3k2tGsmVOQ4zjjp7H/Parmq2EWnsqRYCSMQoD7h0zQxRS7mQ5laRmyX2kmQ8cNnGePWoGmy/zjjv7U9ZxBcsJHySdrZGfxxVyKW3cmNxw/GccVDVgvbUpwRB4w65/DtzVvbuAZeP4SKG2WpKoQUY9hVuH7gBKnjOaV9TkrO7KDKVjG3kA/wAVU7hjjaRwPWtQxbRlumc1nXcZLA9ycCqTOKRnSDn5Tx6GqNyyltx7dq0GGODVG5CFue9M5+ph3qj5+eaya1rsFXbuKysV0R2OWqrs+oYUG7hR061fijyM9O9RwIvGSPpV9IwVwv0IrlsesmMji4CnqelOdAQARk8VNGm8kHj0pzqV6r81S0XcpMADk+2KYQDuPTvnFWP4ypA9vwqPDLIQQNp6+1RIuJTvGMhUL93NZ2pwo1u4287fTpWsYtrMTnGAOvA/zmq11ArRnb1KnPtUM3ptI821WHFxhc9Oo+h/wq3p6ER8YK7QCo7dv6ip57f/AE5gT93JAP0/z+dQnNsT5eDG4BGOMH1/OtU7o74yJ7dHmd4gR8uWG49R/nNV76PZEGyVkg6oOdw9vyNR3kkhujPbkhcZIJ/kO3WppXhubeNiA0gHI75x+tNGerKBVLmbfkbTnHU7gP69aiFmYWYHcc8gg8EfnUlxaSRIstmzsmMsuOh9RSxzMYnPR1zhGHDdMkenWqErXszNvpPI+6HAxhgOje9QmeOaAReWFbgqw7+1aMslvKpWdQvPAIzVFtOW3BbmSIdV/iU+3rVJmbT6DbBmgmBjfGQAygjnr1/MituKd7y2FtIEwh+VOgx7HrWVHDEcOsgaFiAHA5HrV77HPEjND++2/fCkEgdc+9JsFZakMenKJpAV2TA/LkndToIQ0TozYlUj5voOuKQy7wueXA4ZThgf8arebIuEDAuDncBz+P50XuHQe08kUhinXdtPLbcg+9aVgytGHJ4xn6VmTTyOp3R5OCAR61f09WNuoLfL02kdKTOerboWmPzqd25TziqtwgK469was4KcEcdqNgIww5FTc45GJPD1Iz+NZ1ynUFc4PWuiuI8rjnGKyLiMAN27VaOaZy97HgHAIrL8kf3jXSX8OdxwMYrK8j3P5VvB6HPON2fUCRhgc9R61bhwO4/GmQgHByOnarAjBYY6c/jWB6Nhdu4jBGM806X5eccZ5pyhQOex60Mu7d3FJlLQrPCpJx1zwB17Uzbkk47/AP1v61LICuTngHH1ppXA56Z/rUMtMqldxcZ+Xgj/AD+FZtzOsSbZOhyASM4/GtGVjGcgZAGSKzb+UGIInLSfLnqBnqay2NIs5+SNmvzKYThckdwxA9vSufvnSWeTYwAwG8vH3T3x7cV1217QLCy/KAdjdeM9K5y+s2W5hkACnBBU8E47H/GnGVmdVOfcyhJPAxYclQPmb1HpSCSNZxuLgliw29UPUHA7UpmZ9qMrL5b5Gcfrmpw2IP3jIVYAMF5YrxjHHB4rZM3i7lT7W5dghBYsRsHU57j29utRBllxHzHMpzx09KivVVEBd5FZhwcYJFU7xWBjZMuASyyk8/Q/57VVrmU076l61hNxI4lb95GcADjnsR35FaWmyxeb9lmUGXqOOfwFYpmVfLuXyJlwGdTlWX/H29jVstJcIssRBO4fMo5U98H/AD0pNDgvMnu7eA3W2ExoG4O08Ej/AB/nS20EsSFoWyy8bW6mq5cyMEnXZKi5+UfeHr7/AEq/HJA9splH7wE4IPX/AANJorljLczNStQsf2i2yXHLpnGPeqnzSIJGIDA4HvWpfEzsvl5Doeff6iqUg/0ZztK9iP7pprRC5XDYivZPLhA4BJwa0NFlMwKnhh39f84rnLtpQ2Ml1I6DtWxpDrCcE7W9wRj9Kco6GVdR5bs6FxvyW/Cq5ba5QnP49atrP50a+Uu4Ywdo/qaguIg5XcdhHIwKhHmzsynMxbqSVxWdNktnp61qupLZwP8AGs64UAkVaOeSMi6j+8TxWb5f+eK2LpAORVDy1/2qtGVrn0vHHtJYc4qdAQAM9vWol+U8Hv3qZFJTOc7sVJ3LzHx/dyQCM45FRzZVSEPNPUYxk9eR+JqMfKDk4PJ4FSy0iFzuBByT1xUUhbBHTjr1xU7LjJXuvINQsyhfmGc1ncbsVbmNQvQn3bmqaRAysTkqvygeh/yf0rRYZUlyOeMelZ0b446PknGO9RIcTP1a3klj+TKyIdwz04rFu0+0JkFuVJx2HTP/ANauqnVnVty57jPrXN3RkguQylk2NtckZGO39Ki5rfQ4+7jlhuSI2JSQYYk4LDPf6f4VcW5aGKOIFmQkFAjd/StLW7OVF89QjqDnK/4Vi20zwzCV49sTjsMk+4HPvxWibNIVHHXoPaGSXEc7KJOy9SBz3/KpZY4opFRlEgxht3JYe2KkTYquZUYM/ovBX0z/AFoXyZdrG1JweD93gfQGnzm6rRe5y9+Pss2xmZbdjtLHoD26flmrumK1pIglcqxGQp6ex/pWrqFjmLOxTG/8IAI/L+dUNOeWREgmiEnluVCk9s+vWq57o5nVUXoPkk+0IzKjKeSQOTken+e9JabpHUoF+cfL2zW9badBcK/2f93gZGV5BHUURaaRLgfMepVuDjPI/rS5zZVtblQWqO2GUqT90DnBHYHuParUulCWARpgkdeevsa2Y4V8qJXjypwQ4PJ+tQnTmSYybpiBwAf8aLtkSrs5H+wd10qopwTyRyBjrxWguhIoC7naQkfeONv4YrppLXdAPIBEg6lv4f60nkOgySCWOTn1qlJnNUqOe5zZ0ryxujcqw4wQMH9KY1uclWJD/XNdFNEDHkjCj0qhPCoGR+tFzBrQzZoiEC7sn6VnSjBOT061qSkrx1rNlQGRienfFUjCRl3C8EjFU/Kb+8v5VrXCDBwOapeU/wDdFaIwba2Pogna2TjpU0eTznr2FNwu3kcU9DtUZyOnTtUdT0FsK6n5wOp4FIG5G7qacpLNjPHao5Cw7EuBUspCfL5mAf4agkUc88cdDVhVyynGe1MkTcpI60mtAuUpFIUqeeKzY0LPzkELgHPeteRD5ZwM1QPyyAjjjBHp/nFZtDTKbSOq5xlh97jj/wCtVK8BFyruqmKT5HI6+1alySv3ADuPQmsyQbkIJGMksp7j/GoaKTuZM6+S0kTMv2ZhmP8A2fb+VUbSOCF2jkV87v3ZOSRxW5NEGh+RMlfmwfQ1jmRpJQrEB1XHA5wPWkiiRUdo3jtom4OGZuPyptpZwoglTcSTlkY4D9c49/rWvGjStG8Z2Jt2yKOCaqmzjW5XyASj7gDnow5/lQEUTQ2VvcRMbcnB6qMfyrEvNJ2XjmNNm7kY9fT9K2wjWkq3Ef3HbDYPf3/z2q3cxLIA33lB3dP5GhCfmYsDF9kc3Ew5EnTd+NTv5kU5DHDg5yR1Hp9adc2ktxE7lg7Bifl4zg8Ee9R2kfnNmVgRjr/eB4qkjSCTW5rQKWBIK7X7EVOYlQBWYsg53Dt9ay2aeJRgkq3Q98//AK61LeSQxMG6e1UiZQ0uEyHnaRtI7VVMZGQcdc1ZljkzlOO7Zqu+Sx3YyOx61aMXEglAGcke4rNuFHPB9K0pE79T1waoT4H3SBz0pozZkXK4BBGcdBWbOPmYgfWtm4C7j696zrhQct26VSMZIzJscnkmq3PtVmZcOB0BFVPI9qtGDPoWP/VN9RUy/db6UUUmdwqfcH1/oaSTt+H8hRRS6FCj/Vj8f5VG3b6UUVLJRB/C341mzf67/gX9DRRWUioEU3U/Wsm9/wBYPqf60UUpFx3Jbf8A49f+2Q/kK5n/AJikn0ooqUWdHb/6uH/dH8jRD/x/r/vn/wBF0UUiRB/yC5P+u/8A7PTbH/j3f6n+dFFAMfZ/db6f/E1lap/rovr/AFFFFUho0rj/AI9P+Af1FW7D/XT/AO6tFFWgZaf7q/739Kx737klFFV0M+oxu30FZN198UUURI6lJvvn6VSl6/jRRVmEtynP/B9D/Ss+iirjsc8tz//Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Inverse psoriasis of the axilla (armpit) is characterized by erythema without visible scaling.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of James C Shaw, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_11_42173=[""].join("\n");
var outline_f41_11_42173=null;
var title_f41_11_42174="Contents: Critical care neurology";
var content_f41_11_42174=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"mobipreview.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"mobipreview.htm?8/24/8590\">",
"       Pulmonary, Critical Care, and Sleep Medicine",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Critical care neurology",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"mobipreview.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Critical care neurology",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <strong>",
"         Cardiovascular disease",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?16/57/17305\">",
"           Antihypertensive therapy to prevent recurrent stroke or transient ischemic attack",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?26/20/26952\">",
"           Cardiac complications of stroke",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?18/26/18853\">",
"           Drug treatment of hypertensive emergencies",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?40/27/41398\">",
"           Malignant hypertension and hypertensive encephalopathy in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?3/47/3834\">",
"           Neurologic complications of cardiac surgery",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?2/7/2168\">",
"           Prevention of neurologic complications of cardiac surgery",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?28/28/29130\">",
"           Spontaneous intracerebral hemorrhage: Pathogenesis, clinical features, and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?31/56/32650\">",
"           Spontaneous intracerebral hemorrhage: Prognosis and treatment",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?9/54/10087\">",
"           Stroke-related pulmonary complications and abnormal respiratory patterns",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?18/11/18614\">",
"           Treatment of specific hypertensive emergencies",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Encephalopathy",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?36/1/36889\">",
"           Acute toxic-metabolic encephalopathy in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?38/10/39081\">",
"           Diagnosis of delirium and confusional states",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?18/56/19337\">",
"           Hypoxic-ischemic brain injury: Evaluation and prognosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?9/53/10074\">",
"           Osmotic demyelination syndrome and overly rapid correction of hyponatremia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?18/34/18986\">",
"           Overview of the treatment of hyponatremia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?27/33/28185\">",
"           Prevention and treatment of delirium and confusional states",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Miscellaneous",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?37/48/38664\">",
"           Air embolism",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?38/55/39801\">",
"           Eclampsia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?32/39/33402\">",
"           Evaluation and management of elevated intracranial pressure in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?25/21/25942\">",
"           Fat embolism syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?43/32/44552\">",
"           Infections of central nervous system shunts and other devices",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?19/61/20441\">",
"           Management of moderate and severe alcohol withdrawal syndromes",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?10/8/10377\">",
"           Suicidal ideation and behavior in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?42/44/43720\">",
"           Use of neuromuscular blocking medications in critically ill patients",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Neuromuscular disease",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?5/22/5481\">",
"           Clinical features and diagnosis of Guillain-Barr syndrome in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?39/6/40038\">",
"           Pathogenesis of Guillain-Barr syndrome in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?40/36/41543\">",
"           Practical aspects of nocturnal noninvasive ventilation in neuromuscular and chest wall disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?41/28/42439\">",
"           Respiratory complications of spinal cord injury",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?34/20/35142\">",
"           Respiratory muscle weakness due to neuromuscular disease: Clinical manifestations and evaluation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?0/16/265\">",
"           Treatment and prognosis of Guillain-Barr syndrome in adults",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Respiratory failure",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?24/43/25271\">",
"           Neurogenic pulmonary edema",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?40/36/41543\">",
"           Practical aspects of nocturnal noninvasive ventilation in neuromuscular and chest wall disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?41/28/42439\">",
"           Respiratory complications of spinal cord injury",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?34/20/35142\">",
"           Respiratory muscle weakness due to neuromuscular disease: Clinical manifestations and evaluation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?9/54/10087\">",
"           Stroke-related pulmonary complications and abnormal respiratory patterns",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Seizures",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?38/55/39801\">",
"           Eclampsia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?25/9/25753\">",
"           Evaluation of the first seizure in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?19/61/20441\">",
"           Management of moderate and severe alcohol withdrawal syndromes",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?42/61/43994\">",
"           Pharmacology of antiepileptic drugs",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?19/11/19642\">",
"           Status epilepticus in adults",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Stroke",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?16/57/17305\">",
"           Antihypertensive therapy to prevent recurrent stroke or transient ischemic attack",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?26/20/26952\">",
"           Cardiac complications of stroke",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?39/17/40216\">",
"           Clinical diagnosis of stroke subtypes",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?8/63/9208\">",
"           Etiology and classification of stroke",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?37/39/38522\">",
"           Etiology, clinical manifestations, and diagnosis of aneurysmal subarachnoid hemorrhage",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?32/29/33242\">",
"           Initial assessment and management of acute stroke",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?6/26/6570\">",
"           Intravenous fibrinolytic (thrombolytic) therapy in acute ischemic stroke: Therapeutic use",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?27/47/28410\">",
"           Overview of the evaluation of stroke",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?40/8/41098\">",
"           Reperfusion therapy for acute ischemic stroke",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?28/28/29130\">",
"           Spontaneous intracerebral hemorrhage: Pathogenesis, clinical features, and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?31/56/32650\">",
"           Spontaneous intracerebral hemorrhage: Prognosis and treatment",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?9/54/10087\">",
"           Stroke-related pulmonary complications and abnormal respiratory patterns",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?36/54/37738\">",
"           Treatment of aneurysmal subarachnoid hemorrhage",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?24/40/25225\">",
"           Unruptured intracranial aneurysms",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0605-95.154.198.148-71BCF8DC3D-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f41_11_42174=[""].join("\n");
var outline_f41_11_42174=null;
var title_f41_11_42175="Pruritic papular eruption";
var content_f41_11_42175=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F82671&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F82671&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Pruritic papular eruption, anterior trunk and arm",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 252px; height: 432px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Pruritic papular eruption is an intensely pruritic skin rash seen commonly in people infected with HIV in sub-Saharan Africa.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Resneck JS, Van Beek M, Furmanski L, et al. Etiology of pruritic papular eruption with HIV Infection in Uganda. JAMA 2004; 292:2614. Copyright &copy; 2004 American Medical Association. All rights reserved.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_11_42175=[""].join("\n");
var outline_f41_11_42175=null;
